Pathology In Depth

Library › Soft tissue tumors: WHO 2026 classification, grading and staging, adipocytic, fibroblastic, fibrohistiocytic, vascular, myogenic, nerve sheath and uncertain-differentiation tumors, and small round cell sarcomas

Soft tissue tumors: WHO 2026 classification, grading and staging, adipocytic, fibroblastic, fibrohistiocytic, vascular, myogenic, nerve sheath and uncertain-differentiation tumors, and small round cell sarcomas

Last reviewed 2026-11-17 by a board-certified pathologist. 213 references.

Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing

Definition and scope. Soft tissue tumors are classified by the WHO Classification of Tumours of Soft Tissue and Bone, 6th edition (STB6, 2026), which replaced the 5th edition (STB5, 2020) (Hornick et al. 2026; Sbaraglia et al. 2021). Sarcomas are graded by the French Federation of Cancer Centers Sarcoma Group (FNCLCC) system and staged by the AJCC 8th edition, which the CAP Soft Tissue 4.2.0.0 protocols apply (CAP 2024a). Sarcomas have an incidence of about 5 per 100,000, comprise about 70 subtypes, and carry a published diagnostic inaccuracy rate of 20%–30% (Sbaraglia et al. 2021).

Related page: The WHO Reporting System for Soft Tissue Cytopathology and the Approach to Soft Tissue FNA (WHO reporting system for soft tissue cytopathology) Related page: Molecular and Ancillary Testing of Soft Tissue FNA Material (fusion table and FISH on cytology specimens) Related page: Round Cell, Spindle Cell and Pleomorphic Sarcomas on FNA (round, spindle and pleomorphic sarcomas on FNA) Related page: Adipocytic Tumors: Lipoma and Variants, Lipoblastoma, Hibernoma and Liposarcomas (lipomatous tumors and liposarcomas) Related page: Reactive Pseudosarcomas, Benign Fibroblastic and Myofibroblastic Tumors, Fibromatoses and Tenosynovial Giant Cell Tumor (pseudosarcomas, fibromas, fibromatoses and tenosynovial giant cell tumor) Related page: Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma (solitary fibrous tumor, inflammatory myofibroblastic tumor, fibrosarcomas and undifferentiated pleomorphic sarcoma) Related page: Vascular Anomalies and Vascular Tumors, Perivascular Tumors, and Smooth Muscle Tumors of Deep Soft Tissue (vascular, perivascular and smooth muscle tumors) Related page: Rhabdomyoma, Rhabdomyosarcoma and Risk Stratification, Ewing Sarcoma and Other Small Round Cell Sarcomas (rhabdomyosarcoma, Ewing sarcoma and other round cell sarcomas) Related page: Peripheral Nerve Sheath Tumors: Schwannoma, Neurofibroma and ANNUBP, Perineurioma, Granular Cell Tumor and MPNST (schwannoma, neurofibroma and MPNST) Related page: Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others (synovial sarcoma, epithelioid sarcoma and other tumors of uncertain differentiation) Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (gastrointestinal stromal tumor and its CAP protocol) Related page: Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen (follicular dendritic cell sarcoma, Rosai–Dorfman disease and Erdheim–Chester disease)

WHO 2026 (STB6) framework: tumor type, subtype and morphological pattern

  • Terminology. A tumor type (entity) differs from other tumor types in multiple clinical, anatomic, histopathological or molecular parameters. A subtype differs from the main tumor type in at least one dimension, preferably with a different treatment or outcome. A morphological pattern, a term that replaces "variant", is a morphology important for recognition that carries no different clinical behavior (Hornick et al. 2026).
  • Scope of the volume. STB6 adds 19 new entities. Organ-restricted entities such as biphenotypic sinonasal sarcoma and uterine sarcomas are classified in other WHO volumes, and gastrointestinal stromal tumor is the exception that remains in STB6 (Hornick et al. 2026).
  • Diagnostic criteria. "Essential" criteria are mostly morphologic with basic immunohistochemistry. Molecularly defined tumors, such as sarcomas with BCOR alterations, require molecular confirmation as an essential criterion. "Desirable" criteria add molecular tests and surrogate immunohistochemical markers. Each type and subtype carries an ICD-O-4 morphology code (Hornick et al. 2026).

Behavior categories. Soft tissue tumors are divided into 4 categories: benign, intermediate (locally aggressive), intermediate (rarely metastasizing) and malignant (CAP 2024a). Desmoid fibromatosis is the model of the locally aggressive category and plexiform fibrohistiocytic tumor of the rarely metastasizing category (Sbaraglia et al. 2021). The CAP histologic type list includes only intermediate and malignant tumors (CAP 2024a).

Chapter-level changes in STB6 with the STB5 rule

Chapter or framework element STB6 (2026) Previous rule (STB5, 2020) Source
Vascular tumors One chapter for vascular tumors of soft tissue and bone, with bone and soft tissue differences marked within each section Separate vascular sections in the soft tissue and bone chapters Hornick et al. 2026
Hematolymphoid tumors One chapter for hematopoietic and dendritic cell neoplasms arising in nonmucosal extranodal soft tissue or primarily in bone: plasmacytoma, DLBCL NOS involving bone, Langerhans cell histiocytosis, Erdheim–Chester disease, follicular dendritic cell sarcoma and Rosai–Dorfman disease Not combined into one chapter Hornick et al. 2026
Fibrohistiocytic chapter Renamed "fibrohistiocytic and synovial tumors" "Fibrohistiocytic tumors" Hornick et al. 2026
Round cell sarcoma chapter Renamed "undifferentiated spindle and small round cell sarcomas": Ewing sarcoma, NFATC2-rearranged sarcoma, sarcomas with BCOR alterations and CIC-rearranged sarcoma "Undifferentiated small round cell sarcomas of bone and soft tissue", with round cell sarcoma with EWSR1–non-ETS fusions as one category Hornick et al. 2026; Sbaraglia et al. 2021
Undifferentiated soft tissue sarcoma Umbrella term no longer recommended Umbrella for undifferentiated pleomorphic, spindle cell and round cell sarcoma Hornick et al. 2026
Gastrointestinal stromal tumor SDH-deficient GIST is a separate category SDH-deficient GIST discussed within the GIST entity Hornick et al. 2026; Sbaraglia et al. 2021

Entity-level changes in STB6 with the STB5 rule

Chapter STB6 change Previous rule (STB5) Source
Adipocytic (Adipocytic Tumors: Lipoma and Variants, Lipoblastoma, Hibernoma and Liposarcomas) New: lipoblastoma-like tumor Absent from STB5 Hornick et al. 2026
Adipocytic (Adipocytic Tumors: Lipoma and Variants, Lipoblastoma, Hibernoma and Liposarcomas) Atypical spindle cell and atypical pleomorphic lipomatous tumors are separate subtypes One entity, atypical spindle cell/pleomorphic lipomatous tumor Hornick et al. 2026; Sbaraglia et al. 2021
Adipocytic (Adipocytic Tumors: Lipoma and Variants, Lipoblastoma, Hibernoma and Liposarcomas) Nonlipogenic tumors of the WDLPS/DDLPS spectrum: ≤4 mitoses/10 HPF = cellular well-differentiated liposarcoma; ≥5/10 HPF = dedifferentiated liposarcoma; "low-grade dedifferentiated liposarcoma" not recommended WHO 2020 recognized low-grade dedifferentiation; ≥5 mitoses/10 HPF was used as a criterion that was not universally accepted Hornick et al. 2026; Savarese et al. 2026
Adipocytic (Adipocytic Tumors: Lipoma and Variants, Lipoblastoma, Hibernoma and Liposarcomas) Higher-grade myxoid liposarcoma: cellular round cell areas >5% of the tumor, usually with diminished myxoid matrix Before STB6, reviews separated low-grade (≤5% round cells) from high-grade (>5%) myxoid liposarcoma Hornick et al. 2026; Dwianingsih et al. 2025
Fibroblastic and myofibroblastic (Reactive Pseudosarcomas, Benign Fibroblastic and Myofibroblastic Tumors, Fibromatoses and Tenosynovial Giant Cell Tumor) New: PRRX1-rearranged fibroblastic tumor and nodular necrotizing fibroblastic tumor; calcifying fibrous tumor restored Calcifying fibrous tumor inadvertently omitted Hornick et al. 2026
Fibroblastic and myofibroblastic (Reactive Pseudosarcomas, Benign Fibroblastic and Myofibroblastic Tumors, Fibromatoses and Tenosynovial Giant Cell Tumor) Renamed: SMAD3-rearranged fibroblastic tumor and superficial CD34-positive pleomorphic fibroblastic tumor EWSR1::SMAD3-positive fibroblastic tumor; superficial CD34-positive fibroblastic tumor Hornick et al. 2026
Fibroblastic and myofibroblastic (Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma) Adult fibrosarcoma removed Fibrosarcoma NOS listed as malignant Hornick et al. 2026; Sbaraglia et al. 2021
Fibroblastic and myofibroblastic (Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma) Undifferentiated pleomorphic sarcoma moved here; still a diagnosis of exclusion Tumor of uncertain differentiation Hornick et al. 2026
Fibrohistiocytic and synovial (Reactive Pseudosarcomas, Benign Fibroblastic and Myofibroblastic Tumors, Fibromatoses and Tenosynovial Giant Cell Tumor) New: chondroid synoviocytic neoplasm and keratin-positive giant cell-rich tumor; deep fibrous histiocytoma removed Deep benign fibrous histiocytoma listed as benign Hornick et al. 2026; Sbaraglia et al. 2021
Pericytic (Vascular Anomalies and Vascular Tumors, Perivascular Tumors, and Smooth Muscle Tumors of Deep Soft Tissue) New: SRF-rearranged myoid neoplasm Part of the "atypical cellular variant" of myofibroma Hornick et al. 2026
Smooth and skeletal muscle (Rhabdomyoma, Rhabdomyosarcoma and Risk Stratification, Ewing Sarcoma and Other Small Round Cell Sarcomas) Inflammatory rhabdomyoblastic tumor; spindle cell/sclerosing RMS split into fusion-associated spindle cell RMS, MYOD1-mutant spindle cell/sclerosing RMS and TFCP2-rearranged RMS (bone chapter); ectomesenchymoma removed as an entity (now embryonal rhabdomyosarcoma with divergent neuroectodermal differentiation) Inflammatory leiomyosarcoma; one spindle cell/sclerosing RMS entity; ectomesenchymoma Hornick et al. 2026
Peripheral nerve sheath (Peripheral Nerve Sheath Tumors: Schwannoma, Neurofibroma and ANNUBP, Perineurioma, Granular Cell Tumor and MPNST) Epithelioid MPNST is a separate entity Subtype of MPNST Hornick et al. 2026
Uncertain differentiation (Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others) New: OGT-rearranged mesenchymal neoplasm, acral fibrochondromyxoid tumor, GLI1-altered mesenchymal tumors, superficial FET-ETS family neurocristic tumor, pseudoendocrine sarcoma, NUT-rearranged sarcoma, FET-CREB family epithelioid mesenchymal tumor and PATZ1-rearranged sarcoma; atypical fibroxanthoma and ectopic hamartomatous thymoma no longer included NTRK-rearranged spindle cell neoplasm as an emerging entity Hornick et al. 2026; Sbaraglia et al. 2021
Uncertain differentiation (Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others) Kinase-altered spindle cell neoplasms NTRK-rearranged spindle cell neoplasm Hornick et al. 2026
Vascular (Vascular Anomalies and Vascular Tumors, Perivascular Tumors, and Smooth Muscle Tumors of Deep Soft Tissue) Vascular anomaly and lymphatic malformation terminology aligned with ISSVA; spindle cell hemangioma restored; YAP1::TFE3 hemangioendothelioma separated Hemangioma and lymphangioma names; EHE with CAMTA1- and TFE3-related molecular variants Hornick et al. 2026; Sbaraglia et al. 2021
Undifferentiated round cell (Rhabdomyoma, Rhabdomyosarcoma and Risk Stratification, Ewing Sarcoma and Other Small Round Cell Sarcomas) NFATC2-rearranged sarcoma in this chapter; PATZ1-rearranged sarcoma moved to tumors of uncertain differentiation Round cell sarcoma with EWSR1–non-ETS fusions Hornick et al. 2026

Diagnostic approach to soft tissue tumors by morphologic pattern and line of differentiation

Diagnosis integrates morphology, immunohistochemistry and molecular genetics, and many fusion-defined tumors have surrogate immunohistochemical markers (Anderson and Jo 2021). Tumors are first sorted by pattern. Pleomorphic tumors are classified only after carcinoma, melanoma and lymphoma are excluded (Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma).

Pattern Main soft tissue considerations First-line markers Source
Spindle cell, monomorphic Synovial sarcoma, solitary fibrous tumor, MPNST, desmoid fibromatosis, low-grade fibromyxoid sarcoma, kinase-fusion tumors SS18-SSX, STAT6, H3K27me3, nuclear β-catenin, MUC4, pan-TRK; focal CD34 or S100 without SOX10 in kinase-fusion tumors Anderson and Jo 2021; Carlson and Fletcher 2007; CAP 2024a
Epithelioid Epithelioid sarcoma, epithelioid MPNST, extrarenal rhabdoid tumor, EHE, alveolar soft part sarcoma, PEComa, clear cell sarcoma SMARCB1 (INI1) loss, CAMTA1, TFE3 Anderson and Jo 2021; CAP 2024a
Round cell Ewing sarcoma, CIC-rearranged sarcoma, sarcoma with BCOR alteration, alveolar rhabdomyosarcoma, DSRCT, poorly differentiated synovial sarcoma, small cell osteosarcoma, mesenchymal chondrosarcoma NKX2.2, WT1 (C-terminus), ETV4, BCOR, CCNB3, PAX3/7-FOXO1, SS18-SSX Sbaraglia et al. 2021; Anderson and Jo 2021
Pleomorphic Dedifferentiated and pleomorphic liposarcoma, myxofibrosarcoma, pleomorphic leiomyosarcoma and rhabdomyosarcoma, MPNST, carcinoma, melanoma, undifferentiated pleomorphic sarcoma MDM2 and CDK4 with MDM2 FISH; H3K27me3 Rottmann et al. 2023; Anderson and Jo 2021
Myxoid Myxoid liposarcoma, myxofibrosarcoma, low-grade fibromyxoid sarcoma, extraskeletal myxoid chondrosarcoma DDIT3, MUC4 Anderson and Jo 2021; Doyle et al. 2011

Undifferentiated pleomorphic sarcoma and myxofibrosarcoma are pleomorphic tumors without a corresponding nonpleomorphic form, and pleomorphic variants occur in rhabdomyosarcoma, leiomyosarcoma and liposarcoma (Rottmann et al. 2023).

FNCLCC histologic grading of soft tissue sarcomas

  • FNCLCC versus NCI. Both are 3-grade systems. FNCLCC grade predicted metastasis and tumor mortality slightly better than NCI grade (Guillou et al. 1997), and the NCI system also requires quantification of cellularity and pleomorphism for some subtypes (CAP 2024a).
  • Rules of use. Histologic typing precedes grading. FNCLCC grading is useful in more than 90% of adult sarcomas but is not used for tumors of intermediate malignancy or for some sarcomas such as dedifferentiated liposarcoma (Coindre 2006).
  • AJCC use of grade. The AJCC 8th edition adopted the FNCLCC 3-tier system, but stage grouping uses grade 1 and grades 2–3 (effectively low and high grade) (CAP 2024a).
FNCLCC parameter Score 1 Score 2 Score 3 Source
Differentiation Sarcoma closely resembling normal adult mesenchymal tissue, hard to separate from its benign counterpart (well-differentiated liposarcoma, well-differentiated leiomyosarcoma) Sarcoma of certain histologic type (myxoid liposarcoma, myxofibrosarcoma) Embryonal and undifferentiated sarcomas, synovial sarcoma and sarcomas of uncertain type CAP 2024a
Mitotic count per 10 HPF (1 HPF = 0.1734 mm²) 0–9 10–19 >19 CAP 2024a
Mitotic count per 1 mm² 0–5 6–11 >11 CAP 2024a
Tumor necrosis <50% (score 1); no necrosis scores 0 ≥50% No score 3 CAP 2024a

Total score 2–3 = grade 1. Total score 4–5 = grade 2. Total score 6–8 = grade 3 (CAP 2024a).

Histologic type Differentiation score Source
Atypical lipomatous tumor/well-differentiated liposarcoma; well-differentiated leiomyosarcoma 1 CAP 2024a
Myxoid liposarcoma; conventional leiomyosarcoma; myxofibrosarcoma 2 CAP 2024a
High-grade myxoid (round cell) liposarcoma; pleomorphic and dedifferentiated liposarcoma; pleomorphic rhabdomyosarcoma; poorly differentiated/pleomorphic leiomyosarcoma; biphasic, monophasic and poorly differentiated synovial sarcoma; mesenchymal chondrosarcoma; extraskeletal osteosarcoma; extraskeletal Ewing sarcoma; malignant rhabdoid tumor; undifferentiated pleomorphic sarcoma; undifferentiated sarcoma NOS 3 CAP 2024a

Mitotic counting. Mitoses are counted in the most mitotically active area away from necrosis, in 10 consecutive high-power fields (40× objective) or in 1 mm². On whole-slide images 1 mm² is measured directly. A count close to a cut-off is repeated. The original HPF measured 0.1734 mm², and modern wide-field 40× objectives cover more area. The count is corrected by multiplying the 10-HPF count by 0.1734 divided by the local field area, or the count is expressed per mm² (CAP 2024a).

40× field diameter (mm) Field area (mm²) Approximate fields per 1 mm² Source
0.40–0.41 0.126–0.132 8 CAP 2024a
0.42–0.44 0.138–0.152 7 CAP 2024a
0.45–0.48 0.159–0.181 6 CAP 2024a
0.49–0.53 0.188–0.221 5 CAP 2024a
0.54–0.60 0.229–0.283 4 CAP 2024a
0.61–0.69 0.292–0.374 3 CAP 2024a

Field diameter equals the objective field number divided by the objective magnification (CAP 2024a).

Tumor necrosis. Necrosis is evaluated grossly and validated on histologic sections (CAP 2024a).

Sarcomas for which FNCLCC grade is not assigned or not informative

Tumor Grading rule Source
Desmoplastic small round cell tumor, alveolar rhabdomyosarcoma, intimal sarcoma High grade by definition CAP 2024a
Alveolar soft part sarcoma, clear cell sarcoma, epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, low-grade fibromyxoid sarcoma, sclerosing epithelioid fibrosarcoma Not assigned an FNCLCC grade; may metastasize late CAP 2024a
Angiosarcoma Not graded; all are clinically high grade because deceptively bland tumors behave poorly CAP 2024a
MPNST Prognostic value of FNCLCC grade unclear CAP 2024a
Solitary fibrous tumor Risk stratification replaces grade CAP 2024a; Demicco et al. 2017

The CAP differentiation table assigns dedifferentiated liposarcoma a score of 3 (CAP 2024a), whereas Coindre recommends that it not be graded (Coindre 2006).

Grading on core biopsies and after neoadjuvant therapy

  • Core needle biopsy. Current grading is not suitable for core needle biopsies (Coindre 2006). Separation into low and high grade is encouraged on needle biopsies. Multiple cores of high-grade sarcoma can be regarded as high grade because later downgrading is remote, and limited cores of low-grade sarcoma carry a risk of upgrading (CAP 2024a).
  • Histologic type alone. Some types, such as Ewing sarcoma and pleomorphic liposarcoma, establish high grade by type (CAP 2024a).
  • Treated tumors. Necrosis, fibrosis and therapy-induced pleomorphism can prevent classification of a treated tumor, and the grade of the pretreatment specimen takes precedence (CAP 2024a).

AJCC 8th edition staging of soft tissue sarcoma by anatomic site

The AJCC 8th edition stages soft tissue sarcomas separately for the trunk and extremities, retroperitoneum, head and neck, and abdominal and thoracic visceral organs, and orbital sarcomas have their own system (CAP 2024a; Tanaka and Ozaki 2019). The AJCC Version 9 protocol list (2021–2026) contains no soft tissue protocol, and all 8th edition disease sites remain current until replaced (AJCC 2026).

The site and pT tables follow the CAP Soft Tissue Resection 4.2.0.0 case summary and Note B (CAP 2024a).

Site Included sites Source
Trunk and extremities Extremities and trunk, including breast CAP 2024a
Retroperitoneum About 10% of soft tissue sarcomas; sarcomas of the peritoneal, pleural or mediastinal cavities not arising from a specific organ may be staged like retroperitoneal sarcomas CAP 2024a
Head and neck Neck, oral cavity, upper aerodigestive tract including larynx, pharynx, nasal cavity and paranasal sinuses, infratemporal fossa and masticator space, major salivary glands, thyroid and parathyroid, cervical esophagus and trachea, and peripheral and cranial nerves CAP 2024a
Abdominal and thoracic visceral organs Hollow viscera (esophagus, stomach, small intestine, colon, rectum) and solid viscera (liver, kidneys, lungs, heart) CAP 2024a
Orbit Primary orbital sarcomas CAP 2024a
pT Trunk and extremities; retroperitoneum Head and neck Source
pT1 ≤5 cm ≤2 cm CAP 2024a
pT2 >5 cm and ≤10 cm >2 cm to ≤4 cm CAP 2024a
pT3 >10 cm and ≤15 cm >4 cm CAP 2024a
pT4 >15 cm pT4a: orbital invasion, skull base or dural invasion, invasion of central compartment viscera, facial skeleton or pterygoid muscles; pT4b: brain parenchymal invasion, carotid artery encasement, prevertebral muscle invasion or central nervous system involvement by perineural spread CAP 2024a
pT Abdominal and thoracic visceral organs Orbit Source
pT1 Organ confined ≤2 cm CAP 2024a
pT2 Extension beyond organ: pT2a invades serosa or visceral peritoneum; pT2b extends beyond serosa (mesentery) >2 cm without invasion of bony walls or globe CAP 2024a
pT3 Invades another organ, including diaphragm, abdominal wall or pelvic side wall Any size with invasion of bony walls CAP 2024a
pT4 Multifocal: pT4a 2 sites; pT4b 3–5 sites; pT4c >5 sites Any size with invasion of globe or periorbital structures (eyelid, conjunctiva, temporal fossa, nasal cavity, paranasal sinuses or central nervous system) CAP 2024a
  • Regional nodes and metastasis. pN0 is no regional lymph node metastasis and pN1 is regional lymph node metastasis. When no nodes are resected, pN is not assigned, and pNX is not used. Patients without nodes proven positive are designated N0. pM1 is distant metastasis, and pMX and pM0 are not case summary options (CAP 2024a).
  • Nodal involvement. Regional node metastasis is uncommon in adult sarcomas, except in epithelioid sarcoma, clear cell sarcoma and, rarely, alveolar rhabdomyosarcoma, and nodes are not searched exhaustively (CAP 2024a).
  • Stage groups. Sarcomas of the trunk and extremities and of the retroperitoneum share 6 stage groups (IA, IB, II, IIIA, IIIB and IV) (Guedes et al. 2021; Yamagata et al. 2024). Any T N1 M0 trunk and extremity sarcoma is stage IV, grouped with distant metastasis, whereas N1 M0 sarcoma of the retroperitoneum remains stage IIIB (Guedes et al. 2021; Yamagata et al. 2024; Tanaka and Ozaki 2019; Cates 2018). The CAP 4.2.0.0 explanatory note gives stage IIIB for N1 M0 sarcoma of the trunk and extremities, which disagrees with the AJCC 8th edition stage table (CAP 2024a; Guedes et al. 2021).
  • Size measurement. When the excised tumor cannot be measured accurately, radiologic size may assign pT. Size is a continuous variable and the centimeter cut-offs are arbitrary divisions (CAP 2024a).
  • Descriptors. The "m" suffix records multiple primary tumors in one site, the "y" prefix classification during or after neoadjuvant therapy, and the "r" prefix a recurrence after a documented disease-free interval (CAP 2024a).

AJCC 8th edition prognostic stage groups for sarcoma of the trunk and extremities (Guedes et al. 2021):

Stage T N M Grade Source
IA T1 N0 M0 G1, GX Guedes et al. 2021
IB T2, T3, T4 N0 M0 G1, GX Guedes et al. 2021
II T1 N0 M0 G2, G3 Guedes et al. 2021
IIIA T2 N0 M0 G2, G3 Guedes et al. 2021
IIIB T3, T4 N0 M0 G2, G3 Guedes et al. 2021
IV Any T N1 M0 Any G Guedes et al. 2021
IV Any T Any N M1 Any G Guedes et al. 2021

AJCC 8th edition prognostic stage groups for sarcoma of the retroperitoneum (Yamagata et al. 2024):

Stage T N M Grade Source
IA T1 N0 M0 G1, GX Yamagata et al. 2024
IB T2, T3, T4 N0 M0 G1, GX Yamagata et al. 2024
II T1 N0 M0 G2, G3 Yamagata et al. 2024
IIIA T2 N0 M0 G2, G3 Yamagata et al. 2024
IIIB T3, T4 N0 M0 G2, G3 Yamagata et al. 2024
IIIB Any T N1 M0 Any G Yamagata et al. 2024
IV Any T Any N M1 Any G Yamagata et al. 2024
Element AJCC 8th edition Previous rule (AJCC 7th edition) Source
Organization Separate systems for trunk and extremity, retroperitoneum, head and neck and visceral sites One soft tissue system Tanaka and Ozaki 2019
Size categories (trunk, extremity, retroperitoneum) 4 categories: ≤5, >5–10, >10–15 and >15 cm 2 size categories with superficial or deep subcategories; the 8th edition added 2 T categories and dropped depth Tanaka and Ozaki 2019; Cates 2018
Depth Not used Superficial lesions lacked involvement of the superficial investing fascia; retroperitoneal and visceral lesions were deep CAP 2024a; Tanaka and Ozaki 2019
N1 M0, trunk and extremity Stage IV, grouped with distant metastasis Stage III: the 7th edition moved N1 M0 out of stage IV and had a single stage III (groups IA, IB, IIA, IIB, III and IV); the 8th edition returned trunk and extremity N1 M0 to stage IV Guedes et al. 2021; Fan et al. 2024; Cates 2018

Sarcomas staged and not staged by the CAP protocol

The CAP protocol limits pTNM staging to malignant tumors for which it is clinically relevant: dedifferentiated, myxoid, pleomorphic and myxoid pleomorphic liposarcoma; fibrosarcomatous DFSP; myxofibrosarcoma; low-grade fibromyxoid sarcoma; sclerosing epithelioid fibrosarcoma; epithelioid hemangioendothelioma (with exceptions); leiomyosarcoma; rhabdomyosarcoma (with exceptions); ectomesenchymoma (CAP list based on the WHO 5th edition); extraskeletal osteosarcoma; mesenchymal chondrosarcoma; malignant tyrosine kinase fusion sarcoma; synovial sarcoma; epithelioid sarcoma; alveolar soft part sarcoma; clear cell sarcoma; extraskeletal myxoid chondrosarcoma; undifferentiated sarcoma; Ewing sarcoma; round cell sarcoma with EWSR1–non-ETS fusions; CIC-rearranged sarcoma; and sarcoma with BCOR alterations (CAP 2024a).

Reason staging is not applied Examples Source
Risk stratification systems used Solitary fibrous tumor, GIST, ossifying fibromyxoid tumor, glomus tumor CAP 2024a
Multifocal tumors Epithelioid hemangioendothelioma of the abdominal and thoracic cavities CAP 2024a
Behavior unlike other sarcomas Kaposi sarcoma, angiosarcoma, head and neck embryonal and alveolar rhabdomyosarcoma, infantile fibrosarcoma, dural and brain sarcoma, desmoplastic small round cell tumor, PEComa, retroperitoneal leiomyosarcoma CAP 2024a
Locally aggressive tumors with no or extremely low metastatic risk Desmoid tumor, DFSP, kaposiform hemangioendothelioma, atypical fibroxanthoma, angiomatoid fibrous histiocytoma, pleomorphic hyalinizing angiectatic tumor, atypical lipomatous tumor, inflammatory myofibroblastic tumor, low-grade myofibroblastic sarcoma, myxoinflammatory fibroblastic sarcoma CAP 2024a
Insufficient evidence Emerging and rare entities CAP 2024a

CAP Soft Tissue 4.2.0.0 protocols and the ICCR datasets

Scope. The CAP Soft Tissue Resection 4.2.0.0 protocol (posted June 2024) applies to soft tissue sarcomas for which pTNM staging is clinically relevant. It is not required for accreditation for biopsies, resections without residual tumor after neoadjuvant therapy, cytology specimens, or locally recurring tumors with no or extremely low metastatic risk, or malignant tumors for which pTNM is not clinically relevant. It applies mainly to teenagers and adults. Carcinosarcoma and sarcomatoid carcinoma, lymphoma and leukemia, pediatric rhabdomyosarcoma, GIST, uterine sarcoma and SMARCA4-deficient tumors have separate protocols (CAP 2024a). The Soft Tissue Biopsy 4.2.0.0 template covers core needle and incisional biopsies, excludes pediatric Ewing sarcoma and rhabdomyosarcoma, and is recommended but not required for accreditation (CAP 2024b). The histologic type list of the resection protocol derives from the WHO 5th edition (CAP 2024a).

Version 4.2.0.0 change (June 2024) Resection Biopsy Source
Content and explanatory notes, including WHO histologic types Updated Updated CAP 2024a; CAP 2024b
Lymphovascular invasion Changed from optional to required (core) and renamed "Lymphatic and/or Vascular Invasion" Same change CAP 2024a; CAP 2024b
Margins Margins section updated Margins section removed CAP 2024a; CAP 2024b
Optional questions Associated syndrome, radiologic findings, preresection treatment, tumor laterality, tumor extent and depth of invasion Associated syndrome, radiologic findings, tumor laterality, clinicoradiologic tumor size, tumor extent and depth of invasion CAP 2024a; CAP 2024b
pTNM classification and special studies pTNM classification and special studies sections updated Special studies section updated CAP 2024a; CAP 2024b

The resection protocol also added the core response "Nodal Site(s) with Tumor (specify)" (CAP 2024a).

The previous version, 4.1.0.0, remains listed on the CAP cancer protocol templates page (CAP 2026).

Resection element (core unless marked optional) Responses or rule Source
Procedure Excisional biopsy, intralesional, marginal, wide or radical resection CAP 2024a
Tumor focality and site Unifocal or multifocal; head and neck, trunk/extremities/joint, abdominal or thoracic visceral organs, retroperitoneum, orbit CAP 2024a
Tumor size Greatest dimension in cm; additional and radiologic dimensions are optional CAP 2024a
Histologic type WHO type; percentage of hypercellular areas (formerly round cells) is an optional item for myxoid liposarcoma CAP 2024a
Histologic grade G1, G2, G3, GX or ungraded/not applicable CAP 2024a
Mitotic rate Per mm² or per 10 HPF CAP 2024a
Necrosis Not identified or present with percentage CAP 2024a
Treatment effect Percentage of total tumor area that is nonviable; optional patterns: geographic necrosis, fibrosis, hyalinization, hemorrhage, cystic change, histiocytic response, inflammation CAP 2024a
Lymphatic and/or vascular invasion Not identified, present or cannot be determined CAP 2024a
Margins All negative with closest margin and distance in cm, or tumor at margin with involved margins named; optional intact fascial envelope or pseudocapsule and other margins <0.5 cm CAP 2024a
Regional nodes Status, number with tumor, nodal sites with tumor and number examined CAP 2024a
Distant metastasis and pTNM Sites; y and r modifiers; pT by site, pN and pM CAP 2024a
Special studies Immunohistochemistry, cytogenetics and molecular studies; biopsy results can be carried into the resection report CAP 2024a

Procedure definitions. An intralesional resection leaves gross or microscopic tumor behind. A marginal resection removes the tumor with its pseudocapsule and a small amount of adjacent tissue, and an excisional biopsy accomplishes the same outcome. A wide resection is intracompartmental, with a cuff of normal tissue but without removal of a whole muscle group, compartment or bone. A radical resection removes an entire compartment or bone, or the adjacent muscle groups of an extracompartmental tumor (CAP 2024a).

Margins. Margin status is the most important predictor of local recurrence. CAP specifies the location of all margins <0.5 cm and the distance of the closest margin <0.5 cm. Margins are taken as perpendicular (radial) sections where possible. Uninvolved bone marrow can be scooped and submitted as a margin (CAP 2024a).

Treatment effect and necrosis. Therapy response is expressed as the percentage of total tumor area that is nonviable. A cross-section through the longest axis is sampled, with at least 1 section of necrotic tumor at its transition to viable tumor. Grossly necrotic-appearing areas may be myxoid or edematous and are sampled further. When gross necrosis exceeds histologic necrosis, the greater percentage is recorded. Adipocytic maturation after therapy in myxoid liposarcoma contains viable cells and is a distinct response pattern of unclear significance (CAP 2024a).

ICCR datasets. The International Collaboration on Cancer Reporting published consensus datasets with core and noncore items for biopsy and resection specimens of soft tissue sarcoma, with a commentary for each item and a synoptic reporting guide (Dei Tos et al. 2023).

Specimen handling and tissue triage for soft tissue tumors

  • Fresh receipt. Specimens are ideally received fresh. Tissue for histology and formalin-fixed studies is secured before tissue is set aside for cytogenetics or molecular analysis. Microbiology tissue goes directly from the operating room to the microbiology laboratory, and fresh tissue can go to flow cytometry when lymphoma is a consideration (CAP 2024a; CAP 2024b).
  • Intraoperative consultation. Precise classification on frozen section is often unreasonable. Frozen section confirms lesional tissue, builds a differential diagnosis and directs triage for flow cytometry, cytogenetics and molecular studies (CAP 2024a).
  • Core biopsies. Additional cores yielding at least 2 blocks for H&E, immunohistochemistry and molecular studies are collected at receipt (CAP 2024b).
  • Frozen tissue. About 1 cm³ of fresh tissue (less for small specimens and cores) is cut into 0.2-cm fragments after histologic tissue is reserved, stored at −70 °C and shipped on dry ice. Frozen tissue can be a requirement for clinical trial enrollment (CAP 2024a; CAP 2024b).
  • Sampling. Most tumors are sampled at 1 section per centimeter of greatest dimension, including heterogeneous and necrotic areas, with at least 2 blocks of viable tumor for H&E and ancillary studies. After neoadjuvant therapy some institutions map a full cross-section of the largest plane (CAP 2024a).
  • Decalcification. EDTA decalcification, or a separate nondecalcified block of soft tissue, preserves tissue for additional studies, and harsh acid decalcification is avoided (CAP 2024b). Formalin fixation and decalcification degrade nucleic acids. Rapid fixation in neutral-buffered formalin and EDTA decalcification give the best molecular results (Baumhoer et al. 2024).
  • RNA quality. RNA quality in archival FFPE tissue is poor and declines further after decalcification, and up to 50% of archived FFPE samples fail pre-sequencing quality control. Native tissue is snap-frozen for long-term storage when possible (Baumhoer et al. 2024).

Molecular genetic classes of soft tissue tumors and tests of choice

Bone and soft tissue tumors fall into 4 molecular classes: single nucleotide variants, gene rearrangements, copy number changes (especially amplifications) and complex genomic events (Baumhoer et al. 2024). Of 175 soft tissue and bone tumor types in the WHO 5th edition, 64 (37%) have recurrent gene fusions, including 49 of 117 soft tissue tumors (42%) and all 4 undifferentiated small round cell sarcomas (Baumhoer et al. 2024).

Tumor Defining alteration Practical test Immunohistochemical surrogate Source
Atypical lipomatous tumor/WDLPS; dedifferentiated liposarcoma MDM2 amplification (12q13-15, with CDK4) MDM2 FISH Nuclear MDM2 and CDK4 CAP 2024a; Anderson and Jo 2021
Myxoid liposarcoma FUS::DDIT3 or EWSR1::DDIT3 DDIT3 or FUS break-apart FISH Nuclear DDIT3 CAP 2024a; Anderson and Jo 2021
Solitary fibrous tumor NAB2::STAT6 (12q13 inversion) RNA-based sequencing; FISH rarely detects it Nuclear STAT6 Doyle et al. 2014; Anderson and Jo 2021
Low-grade fibromyxoid sarcoma FUS::CREB3L2 Fusion testing MUC4 CAP 2024a; Doyle et al. 2011
Sclerosing epithelioid fibrosarcoma EWSR1::CREB3L1 Fusion testing MUC4 CAP 2024a; Arbajian et al. 2014
Desmoid fibromatosis CTNNB1 or APC point mutation CTNNB1 sequencing Nuclear β-catenin CAP 2024a; Baumhoer et al. 2024
Inflammatory myofibroblastic tumor ALK fusions (various partners); ROS1 in a subset ALK or ROS1 FISH or RNA sequencing ALK; ROS1 CAP 2024a; Anderson and Jo 2021
Infantile fibrosarcoma ETV6::NTRK3 Fusion testing Pan-TRK (low specificity) Knezevich et al. 1998; Anderson and Jo 2021
Synovial sarcoma SS18::SSX1, SSX2 or SSX4 Fusion testing SS18-SSX; SSX C-terminus CAP 2024a; Anderson and Jo 2021
Alveolar soft part sarcoma ASPSCR1::TFE3 Fusion testing Nuclear TFE3 CAP 2024a; Anderson and Jo 2021
Epithelioid hemangioendothelioma WWTR1::CAMTA1 (>90%) or YAP1::TFE3 Fusion testing CAMTA1; TFE3 CAP 2024a; Anderson and Jo 2021
Pseudomyogenic hemangioendothelioma SERPINE1::FOSB or ACTB::FOSB Fusion testing Nuclear FOSB CAP 2024a; Anderson and Jo 2021
Mesenchymal chondrosarcoma HEY1::NCOA2 Fusion testing NKX3.1 CAP 2024a; Anderson and Jo 2021
Desmoplastic small round cell tumor EWSR1::WT1 EWSR1 FISH or RNA sequencing WT1 C-terminus CAP 2024a; Anderson and Jo 2021
Ewing sarcoma EWSR1 or FUS with FLI1 or ERG EWSR1 FISH or RNA sequencing NKX2.2 CAP 2024a; Anderson and Jo 2021
CIC-rearranged sarcoma CIC::DUX4 (about 95%) RNA sequencing WT1 and ETV4 CAP 2024a; Anderson and Jo 2021
Sarcoma with BCOR alteration BCOR::CCNB3; BCOR internal tandem duplication in infants RNA sequencing BCOR; CCNB3 CAP 2024a; Anderson and Jo 2021
Alveolar rhabdomyosarcoma PAX3::FOXO1 or PAX7::FOXO1 FOXO1 break-apart FISH PAX3/7-FOXO1; MUC4 Anderson and Jo 2021
Epithelioid sarcoma; extrarenal rhabdoid tumor; epithelioid MPNST SMARCB1 deletion Immunohistochemistry SMARCB1 (INI1) loss CAP 2024a; Anderson and Jo 2021
Atypical spindle cell and atypical pleomorphic lipomatous tumors (separate subtypes in STB6) Frequent RB1 deletion Immunohistochemistry Rb loss CAP 2024a; Sbaraglia et al. 2021
PEComa TSC2 mutation or TFE3 fusion Sequencing or TFE3 FISH TFE3 in the fusion subset CAP 2024a; Anderson and Jo 2021
Malignant melanotic nerve sheath tumor PRKAR1A inactivation Immunohistochemistry PRKAR1A loss CAP 2024a; Anderson and Jo 2021
MPNST SUZ12 or EED (PRC2) inactivation Immunohistochemistry H3K27me3 loss Anderson and Jo 2021
Pleomorphic liposarcoma; undifferentiated pleomorphic sarcoma Complex genome; TP53 mutation in about 60% of pleomorphic liposarcomas Not required for diagnosis No diagnostic surrogate Dwianingsih et al. 2025; Rottmann et al. 2023

Fusion-defined tumors confirmed by molecular testing:

Tumor Defining alteration Practical test Source
DFSP and giant cell fibroblastoma (Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma) COL1A1::PDGFB Fusion testing CAP 2024a
Clear cell sarcoma EWSR1::ATF1 or EWSR1::CREB1 EWSR1 FISH or RNA sequencing CAP 2024a
Angiomatoid fibrous histiocytoma EWSR1 or FUS with ATF1 or CREB1 EWSR1 FISH or RNA sequencing CAP 2024a
Extraskeletal myxoid chondrosarcoma EWSR1::NR4A3 or TAF15::NR4A3 Fusion testing CAP 2024a

FISH and RNA-based fusion testing in sarcoma

Method Strength Limitation Source
Break-apart FISH Rapid, widely available; dual-color probes flanking a gene separate when it is rearranged Partner gene unknown; misses intrachromosomal fusions such as EWSR1::PATZ1; DNA based, with no information on transcription Baumhoer et al. 2024
RT-PCR Detects a predefined fusion with specific primers Covers only predefined partners and breakpoints Baumhoer et al. 2024
Anchored multiplex RNA sequencing One gene-specific primer and a universal adapter primer detect novel partners, exons, frame and expression level One partner gene must be in the panel Baumhoer et al. 2024

Related page: Adipocytic Sarcomas, Myxoid Lesions, Extraskeletal Myxoid Chondrosarcoma and Chordoma on FNA (MDM2 and CDK4 FISH, quantitative PCR and immunohistochemistry compared in adipocytic tumors) Related page: Molecular Oncology of Solid Tumors: Oncogenes and Tumor Suppressors, MSI and Mismatch Repair, Tumor Mutational Burden, Tumor-Agnostic and Organ Biomarkers, CNS Tumor Molecular Testing and Germline Findings on Tumor Sequencing (sequencing platforms and fusion testing methods in solid tumors) Related page: Cytogenetics and Cytogenomics: Karyotype and ISCN Nomenclature, Chromosome Abnormalities, FISH, Chromosomal Microarray, Optical Genome Mapping, and Constitutional, Prenatal and Cancer Cytogenetics (FISH and karyotype methods)

Immunohistochemistry for MDM2 and CDK4 is not entirely specific: weaker staining occurs in MPNST and myxofibrosarcoma, and histiocytes stain (Anderson and Jo 2021). Negative MDM2 and CDK4 immunohistochemistry does not exclude amplification, and MDM2 amplification also occurs in nonadipocytic tumors such as MPNST, myxofibrosarcoma, intimal sarcoma and low-grade osteosarcoma (Rottmann et al. 2023). Surrogate immunohistochemistry for CTNNB1, H3-3A p.G34W and H3-3B p.K36M alterations is specific enough to omit confirmatory sequencing (Baumhoer et al. 2024).

Immunohistochemical panels for spindle, epithelioid, round and pleomorphic soft tissue tumors

Spindle cell tumor Marker result Reported performance Source
Solitary fibrous tumor Nuclear STAT6 59 of 60 (98%); all other tumors negative except weak staining in 3 dedifferentiated liposarcomas and 1 deep fibrous histiocytoma Doyle et al. 2014
Desmoid fibromatosis Nuclear β-catenin 80% of sporadic and 67% of FAP-associated desmoids (98% of sporadic desmoid specimens in another series); also 56% of superficial fibromatoses, 30% of low-grade myofibroblastic sarcomas and 22% of solitary fibrous tumors Carlson and Fletcher 2007; Lazar et al. 2008
Low-grade fibromyxoid sarcoma Cytoplasmic MUC4 49 of 49 (100%); other tumors negative except 6 of 20 (30%) monophasic synovial sarcomas Doyle et al. 2011
Synovial sarcoma Nuclear SS18-SSX 95% sensitive, 100% specific Anderson and Jo 2021
MPNST H3K27me3 loss With clone C36B11, lost in 95% of sporadic, 91% of radiation-associated and 60% of NF1-associated high-grade MPNSTs; retained in all neurofibromas, all 5 epithelioid MPNSTs, 2 of 3 low-grade MPNSTs and control tumors including 113 synovial sarcomas, 53 spindle and desmoplastic melanomas, 123 GISTs, 75 well-differentiated and dedifferentiated liposarcomas and 63 myxofibrosarcomas. In other studies, loss ranged from 30% to 90% of MPNSTs, and loss was reported in some other tumors, especially synovial sarcoma Prieto-Granada et al. 2016; Miettinen et al. 2017
Inflammatory myofibroblastic tumor ALK Cytoplasmic in most; the staining pattern reflects the fusion partner (Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma) Anderson and Jo 2021
Kinase-fusion spindle cell tumors Pan-TRK; CD30 Pan-TRK has low specificity; CD30 in 27 of 38 kinase-fusion tumors and 9 of 150 mimics Anderson and Jo 2021; Kojima et al. 2023
Epithelioid tumor Marker result Reported performance Source
Epithelioid sarcoma, epithelioid MPNST, epithelioid schwannoma, rhabdoid tumor SMARCB1 (INI1) loss Reliable surrogate for SMARCB1 inactivation; also in some extraskeletal myxoid chondrosarcomas and myoepithelial tumors Anderson and Jo 2021
Epithelioid hemangioendothelioma Nuclear CAMTA1 Almost all WWTR1::CAMTA1 tumors; negative in YAP1::TFE3 tumors (Anderson and Jo 2021). Diffuse nuclear staining in 86% of EHEs (92% of conventional and 64% of histologically malignant tumors); negative in histologic mimics, including epithelioid angiosarcoma apart from one core biopsy case (Doyle et al. 2016) Anderson and Jo 2021; Doyle et al. 2016
Alveolar soft part sarcoma, TFE3-rearranged PEComa, YAP1::TFE3 EHE Nuclear TFE3 19 of 19 alveolar soft part sarcomas and 6 of 1476 unrelated tumors; 97.5% sensitive and 99.6% specific across tumors with TFE3 fusions; 6 of 8 CAMTA1-negative EHEs; weak staining and imperfect specificity in EHE Argani et al. 2003; Doyle et al. 2016; Anderson and Jo 2021
Pseudomyogenic hemangioendothelioma Nuclear FOSB (diffuse in >50% of cells) 48 of 50 pseudomyogenic hemangioendotheliomas; also 13 of 24 epithelioid hemangiomas, including all of the angiolymphoid hyperplasia with eosinophilia type, rare nodular and proliferative fasciitis, 1 epithelioid angiosarcoma, 1 spindle cell angiosarcoma and 1 CAMTA1- and TFE3-negative EHE; epithelioid sarcoma, spindle cell rhabdomyosarcoma and leiomyosarcoma lacked diffuse staining Hung et al. 2017
Round cell tumor Marker result Reported performance Source
Ewing sarcoma NKX2.2 93% sensitive in a review; 80% of genetically confirmed Ewing sarcomas and 16% of other small round cell tumors in one series (olfactory neuroblastoma, extraskeletal myxoid chondrosarcoma, mesenchymal chondrosarcoma, small cell carcinoma, Merkel cell carcinoma); CD99 with NKX2.2 98% specific Anderson and Jo 2021; Shibuya et al. 2014
CIC-rearranged sarcoma WT1 and ETV4 95% and 90%; both in 85%; coexpression 96% specific; diffuse ETV4 more specific than WT1 Anderson and Jo 2021
BCOR::CCNB3 sarcoma CCNB3; BCOR CCNB3 100% sensitive and specific in the first series; BCOR also in 49% of synovial sarcomas Anderson and Jo 2021
Desmoplastic small round cell tumor WT1 C-terminus Almost all tumors with C-terminal WT1 antibodies, because the fusion protein retains the WT1 C-terminus; the more common N-terminal clones are not used for this purpose Anderson and Jo 2021
Alveolar rhabdomyosarcoma PAX3/7-FOXO1 91% sensitive, 100% specific; diffuse with PAX3::FOXO1, focal with PAX7::FOXO1 Anderson and Jo 2021
EWSR1::NFATC2 sarcoma; mesenchymal chondrosarcoma NKX3.1 9 of 11 and 9 of 9 with a polyclonal antibody Anderson and Jo 2021
Pleomorphic or lipomatous tumor Marker result Reported performance Source
ALT/WDLPS and dedifferentiated liposarcoma Nuclear MDM2 and CDK4 Not entirely specific; FISH supplements immunohistochemistry when histology is insufficient Anderson and Jo 2021; Sirvent et al. 2007
Myxoid liposarcoma Nuclear DDIT3 46 of 46; minimal staining in 15% of dedifferentiated liposarcomas and 25% of solitary fibrous tumors Anderson and Jo 2021
Spindle cell/pleomorphic lipoma Rb loss All spindle cell and pleomorphic lipomas; 2 of 22 (9%) conventional lipomas; intact in ALT Chen et al. 2012

FNCLCC sarcoma grade calculator

Adipocytic Tumors: Lipoma and Variants, Lipoblastoma, Hibernoma and Liposarcomas

Definition. Adipocytic tumors are mesenchymal neoplasms with adipocytic differentiation, from lipoma, the most common soft tissue tumor, to dedifferentiated and pleomorphic liposarcoma (Savarese et al. 2026). The WHO 6th edition (STB6, 2026) adds lipoblastoma-like tumor, splits atypical spindle cell and atypical pleomorphic lipomatous tumors into subtypes, separates cellular well-differentiated liposarcoma from dedifferentiated liposarcoma by mitotic count, and defines higher-grade myxoid liposarcoma by round cell area (Hornick et al. 2026).

Related page: Adipocytic Sarcomas, Myxoid Lesions, Extraskeletal Myxoid Chondrosarcoma and Chordoma on FNA (liposarcomas and myxoid tumors on FNA) Related page: Benign Soft Tissue Tumors on FNA (lipoma, spindle cell lipoma and lipoblastoma on FNA) Related page: The WHO Reporting System for Soft Tissue Cytopathology and the Approach to Soft Tissue FNA (WHO reporting categories for adipocytic aspirates) Related page: Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing (FNCLCC grading, AJCC staging and MDM2 testing methods) Related page: Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma (fat-forming solitary fibrous tumor and undifferentiated pleomorphic sarcoma) Related page: Benign Mesenchymal and Inflammatory Lesions of the Breast (mammary-type myofibroblastoma, which shares 13q deletion with spindle cell lipoma)

WHO classification of adipocytic tumors: STB6 with the STB5 rule

Behavior category STB5 (2020) adipocytic entities STB6 (2026) change Source
Benign Lipoma and lipomatosis; lipomatosis of nerve; lipoblastoma and lipoblastomatosis; angiolipoma; myolipoma of soft parts; chondroid lipoma; spindle cell/pleomorphic lipoma; atypical spindle cell/pleomorphic lipomatous tumor; hibernoma Lipoblastoma-like tumor added; atypical spindle cell and atypical pleomorphic lipomatous tumors become separate subtypes Sbaraglia et al. 2021; Hornick et al. 2026
Intermediate (locally aggressive) Atypical lipomatous tumor Nonlipogenic tumors with ≤4 mitoses/10 HPF are cellular well-differentiated liposarcoma (atypical lipomatous tumor) Sbaraglia et al. 2021; Hornick et al. 2026
Malignant Well-differentiated liposarcoma (lipoma-like, sclerosing, inflammatory); dedifferentiated, myxoid, pleomorphic and myxoid pleomorphic liposarcoma Dedifferentiated liposarcoma requires ≥5 mitoses/10 HPF in nonlipogenic tumors; "low-grade dedifferentiated liposarcoma" not recommended; higher-grade myxoid liposarcoma has >5% round cell areas Sbaraglia et al. 2021; Hornick et al. 2026

STB5 introduced atypical spindle cell/pleomorphic lipomatous tumor and myxoid pleomorphic liposarcoma as new entities (Sbaraglia et al. 2021). Most studies behind the mitotic threshold did not report the HPF diameter, so the count cannot be converted to mitoses per mm² (Hornick et al. 2026).

Lipoma, lipomatosis, intramuscular lipoma and lipoma mimics

  • Frequency and sites. Lipomas account for about half of all soft tissue tumors and are the most common subcutaneous neoplasm, usually in the fifth and sixth decades. They are superficial or deep to the investing fascia (Savarese et al. 2026).
  • Imaging. Lipomas are homogeneous fatty masses with thin septa (<2 mm). Infiltrative unencapsulated fat is termed lipomatosis. Lipomas containing mature bone, cartilage or fibrous tissue are osteolipoma, chondrolipoma or fibrolipoma, which remain lipoma subtypes (Savarese et al. 2026).
  • Intramuscular and intermuscular lipoma. These deep lipomas lack thick septa (>2 mm), nodules and nonadipose areas. A deep lesion >5 cm, heterogeneous or with suspicious septa or nodules, has a differential of lipoma variant, involutional change and liposarcoma (Savarese et al. 2026). Long-standing lipomas with involutional change can show thick fibrous septa that mimic atypical lipomatous tumor, with uniform adipocytes and no atypia (Savarese et al. 2026).
  • Genetics. Lipomas often carry 12q13-15 aberrations that rearrange HMGA2 at 12q14.3 (Panagopoulos et al. 2015).
  • Non-neoplastic and hamartomatous mimics. Lipoma arborescens is a reactive frond-like replacement of the synovial subintima by mature fat, usually in the suprapatellar recess of the knee. Lipomatosis of nerve is fibrofatty overgrowth within a peripheral nerve, most often the median nerve, with a "coaxial cable" MRI appearance, and is often associated with macrodystrophia lipomatosa (Savarese et al. 2026).

Benign lipoma variants and lipoblastoma-like tumor

Entity Clinical features Histology Immunohistochemistry and genetics Behavior Source
Angiolipoma Small, often multifocal, tender subcutaneous nodules of adolescents and young adults, especially the forearm Mature fat with thin-walled capillaries containing fibrin microthrombi, most numerous at the periphery PRKD2 mutations in 80%, at low allele frequency (3%–15%) and highest in mature fat cells Benign Savarese et al. 2026; Hofvander et al. 2017
Spindle cell/pleomorphic lipoma Middle-aged to older men; posterior neck, shoulder and upper back Mature fat, bland spindle cells in short fascicles, ropey collagen; floret-like multinucleated giant cells in the pleomorphic form; minimal mitoses CD34 positive; 13q and/or 16q deletions; Rb loss; no MDM2 or CDK4 amplification Indolent Savarese et al. 2026; Chen et al. 2012
Chondroid lipoma Women in the third and fourth decades; extremities and limb girdles Nests of lipoblast-like cells in myxoid to hyalinized chondroid matrix with mature fat t(11;16)(q13;p13) with C11orf95::MKL2 (exons 5 and 9) in 3 of 3 tumors Benign Savarese et al. 2026; Huang et al. 2010
Myolipoma Adult women; retroperitoneum in about half; large (median 10.5 cm) Intimate admixture of mature fat and fascicles of eosinophilic smooth muscle cells Desmin, SMA and ER positive; MDM2 and CDK4 usually negative No recurrence or metastasis Fukushima et al. 2017
Lipoblastoma-like tumor (new in STB6) Adults (mean age 42 years); mostly inguinogenital Lobulated and septated; fibromyxoid stroma, thin-walled plexiform vessels, univacuolated or bivacuolated lipoblasts, minor mature fat and bland spindle cells Complete RB1 loss in 5 of 12 tested tumors (42%) and partial loss in 7 (58%); no significant alterations by RNA sequencing, microarray or DNA sequencing; fibrosarcoma-like lipomatous neoplasm is the same entity Benign; rare local recurrence Gross et al. 2023; Hornick et al. 2026
Atypical spindle cell lipomatous tumor (STB6 subtype) Limbs and limb girdles of middle-aged adults, often superficial Ill-circumscribed, moderately atypical spindle cells with variable lipoblasts in fibrous to myxoid matrix Frequent RB1 loss; no MDM2 or CDK4 amplification; CD34 often positive Recurrence limited to incomplete excision; no dedifferentiation Sbaraglia et al. 2021; Savarese et al. 2026
Atypical pleomorphic lipomatous tumor (STB6 subtype) Limbs and limb girdles of middle-aged adults Pleomorphic lipoma features (floret cells, coarse collagen) with higher cellularity, more mitoses and numerous lipoblasts, including multivacuolated forms, short of pleomorphic liposarcoma Frequent RB1 loss; TP53 alteration in 20 of 21 (95%); abnormal p53 immunohistochemistry Benign course Sbaraglia et al. 2021; Cordier et al. 2025

STB5 treated atypical spindle cell/pleomorphic lipomatous tumor as one entity, formerly called spindle cell liposarcoma (Sbaraglia et al. 2021). STB6 separates the atypical spindle cell and atypical pleomorphic subtypes and clarifies their criteria (Hornick et al. 2026). TP53 alterations characterize the atypical pleomorphic subtype and are absent in the atypical spindle cell subtype (Cordier et al. 2025).

Hibernoma and its morphological patterns

  • Clinical features. Hibernoma affects adults (mean age 38 years; 9 of 170 were children), most often in the thigh, followed by the shoulder, back and neck, and measures 1–24 cm (Furlong et al. 2001).
  • Histology. All tumors contained coarsely multivacuolated fat cells with small central nuclei and no atypia (Furlong et al. 2001).
  • Morphological patterns. Typical (eosinophilic, pale and mixed cell), myxoid, spindle cell (neck or scalp, with spindle cell lipoma features) and lipoma-like hibernomas (Furlong et al. 2001).
  • Immunophenotype. S100 protein was positive in 17 of 20 tumors (85%). CD34 was positive in 1 of 20 tested tumors, a spindle cell variant; the other variants were negative (Furlong et al. 2001).
  • Imaging. Signal is slightly lower than subcutaneous fat on T1, fat suppression is incomplete, flow voids from branching vessels are common, and FDG uptake on PET is markedly increased because of thermogenesis (Savarese et al. 2026).
  • Behavior. No recurrence, metastasis or tumor death occurred in 66 patients followed for a mean of 7.7 years (Furlong et al. 2001).

Lipoblastoma and lipoblastomatosis in infants and young children

  • Clinical features. Lipoblastoma arises almost exclusively in infants and young children, with a male predominance of about 2–3:1, most often in the extremities. A circumscribed form (lipoblastoma) and an infiltrative multicentric form (diffuse lipoblastoma or lipoblastomatosis) occur (Savarese et al. 2026).
  • Histology. Lobules of immature adipocytes and lipoblasts at different stages of maturation lie in a myxoid matrix. Maturation is central, with immature tissue at the lobule edges. Myxoid liposarcoma shows the reverse pattern, with more mature adipocytes at the periphery (Savarese et al. 2026). Lipoblastoma can mature into a conventional lipoma (Savarese et al. 2026).
  • Genetics. Rearrangements of 8q12 cause promoter swapping of PLAG1, with the HAS2 or COL1A2 promoter fused to the entire PLAG1 coding sequence (Hibbard et al. 2000).
  • Age as a clue. True myxoid liposarcoma almost never occurs in children, and reported pediatric cases most likely represent lipoblastoma (Sbaraglia et al. 2021).
  • Treatment. Complete local excision with clear margins is the treatment of choice (Savarese et al. 2026).

Atypical lipomatous tumor and well-differentiated liposarcoma

  • Terminology by site. Atypical lipomatous tumor and well-differentiated liposarcoma are synonyms with the same morphology and genetics (Savarese et al. 2026). The term well-differentiated liposarcoma is used in the groin, retroperitoneum and deep skeletal muscle because of the higher potential for dedifferentiation. Atypical lipomatous tumor is preferred for superficial subcutaneous tumors, which are generally cured by limited excision (CAP 2024).
  • Frequency and sites. These tumors comprise about 50% of liposarcomas and arise at the usual liposarcoma sites: the extremities, retroperitoneum, paratesticular region and mediastinum (Savarese et al. 2026).
  • Histology. Mature adipocytes and nonlipogenic fibroblast-like spindle cells lie in irregular fibrous septa. Atypical adipocytes or stromal cells with nuclear enlargement, hyperchromasia and pleomorphism, scarce or numerous, separate the tumor from lipoma and fibrolipoma. Lipoblasts may be present (Savarese et al. 2026).
  • Subtypes. Lipoma-like (most common), sclerosing and inflammatory (Sbaraglia et al. 2021; Savarese et al. 2026). Rare tumors show low-grade heterologous osteosarcomatous or leiomyosarcomatous elements, which do not indicate dedifferentiation (Savarese et al. 2026).
  • Imaging. Predominantly fatty masses (≥75% fat) with thick (>2 mm) irregular septa, nodular nonadipose areas and septal enhancement. Size >10 cm, reduced fat fraction, globular nodules and intramuscular location favor the diagnosis over a lipoma variant (Savarese et al. 2026).
  • Genetics. Amplification of 12q13-15, seen as ring and giant marker chromosomes, includes MDM2, CDK4 and less often HMGA2 (Anderson and Jo 2021).
  • Confirmatory testing. MDM2 FISH confirms the diagnosis when lipoma and atypical lipomatous tumor cannot be separated on clinical and histologic grounds (Sirvent et al. 2007; Rottmann et al. 2023). Methods and immunohistochemical performance are compared in Adipocytic Sarcomas, Myxoid Lesions, Extraskeletal Myxoid Chondrosarcoma and Chordoma on FNA and Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing.
  • Cellular WDLPS in STB6. A nonlipogenic tumor of the WDLPS/DDLPS spectrum with up to 4 mitoses per 10 HPF is classified as cellular well-differentiated liposarcoma (atypical lipomatous tumor) (Hornick et al. 2026).
  • Behavior. Metastatic potential is low, but local recurrence is frequent and dedifferentiation occurs, so wide local excision is the usual treatment (Savarese et al. 2026).

Dedifferentiated liposarcoma

  • Definition. Dedifferentiated liposarcoma is a transition from well-differentiated liposarcoma to a high-grade nonlipogenic sarcoma, about 90% de novo and about 10% at recurrence (Savarese et al. 2026).
  • Histology. The dedifferentiated component usually resembles undifferentiated pleomorphic sarcoma, fibrosarcoma or myxofibrosarcoma. About 10% show heterologous osteosarcomatous, chondrosarcomatous, leiomyosarcomatous or rhabdomyosarcomatous differentiation or homologous pleomorphic or myxoid liposarcoma-like features (Savarese et al. 2026). The tumor formerly called inflammatory malignant fibrous histiocytoma overlaps entirely with inflammatory dedifferentiated liposarcoma (Sbaraglia et al. 2021).
  • Mitotic threshold (STB6). A nonlipogenic tumor with 5 or more mitoses per 10 HPF is dedifferentiated liposarcoma, and the designation "low-grade dedifferentiated liposarcoma" is no longer recommended (Hornick et al. 2026). The WHO 2020 classification already recognized low-grade dedifferentiation, and ≥5 mitoses/10 HPF was used as a criterion that was not universally accepted (Savarese et al. 2026). In retroperitoneal tumors, nonlipogenic tumors with ≥5 mitoses/10 HPF had worse disease-specific survival than those with 0–4 (Graham et al. 2023).
  • Imaging. A biphasic mass shows fat beside a solid enhancing nonadipose component, often with necrosis and peritumoral edema; nodules ≥1 cm are an important discriminator (Savarese et al. 2026).
  • Prognosis. The 5-year overall survival is 48%–51.5%, and local recurrence occurs in 62.4% (Dwianingsih et al. 2025).
  • Immunohistochemical pitfalls. STAT6 can be co-amplified with MDM2 and CDK4, so dedifferentiated liposarcoma can show weak STAT6 staining and mimic solitary fibrous tumor (Anderson and Jo 2021).
  • Separation from other pleomorphic sarcomas. MDM2–CDK4 FISH distinguishes dedifferentiated liposarcoma from malignant undifferentiated tumors when the well-differentiated component is not sampled (Sirvent et al. 2007). A diagnosis based solely on the characteristic genetic alteration in a high-grade sarcoma is accepted, because the well-differentiated areas may be absent from the sample or obliterated by the dedifferentiated component (Savarese et al. 2026).

Myxoid liposarcoma: FUS::DDIT3, round cell grading and extrapulmonary spread

  • Clinical features. Myxoid liposarcoma represents 20%–30% of liposarcomas (up to 50% in some series; Savarese et al. 2026), affects adults aged 30–60 years and arises in the deep soft tissue of the extremities (Dwianingsih et al. 2025). About 75%–80% arise in the lower extremities, and tumors contain <25% macroscopic fat (Savarese et al. 2026).
  • Genetics. More than 90% carry t(12;16)(q13;p11) with FUS::DDIT3, and some carry t(12;22)(q13;q12) with EWSR1::DDIT3, both detected by FISH (Dwianingsih et al. 2025). TERT promoter mutations (88%) and PI3K/AKT pathway mutations are frequent (Dermawan et al. 2022).
  • Histology. Abundant myxoid stroma contains a delicate branching "chicken-wire" capillary network, small monomorphic spindle to oval nonlipogenic cells and adipocytes at different stages, including univacuolated signet-ring lipoblasts (Savarese et al. 2026).
  • Immunohistochemistry. Nuclear DDIT3 is a surrogate for the fusion (Anderson and Jo 2021; Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing).
  • Higher-grade myxoid liposarcoma (STB6). Cellular round cell areas exceeding 5% of the tumor, usually with diminished myxoid matrix, define higher-grade disease (Hornick et al. 2026). Before STB6, reviews separated low-grade (≤5% round cells) from high-grade (>5%) myxoid liposarcoma (Savarese et al. 2026; Dwianingsih et al. 2025).
  • Imaging. Low-grade tumors are homogeneous and fluid-bright and can resemble a ganglion cyst until contrast shows prompt uniform enhancement (Savarese et al. 2026).
  • Extrapulmonary metastasis. Myxoid liposarcoma spreads to extrapulmonary sites, including the spine and paraspinous tissue. Of 164 patients, 23% developed spine or paraspinous metastases, which may be detected only by MRI (Vierra et al. 2023).

Pleomorphic liposarcoma

  • Clinical features. Pleomorphic liposarcoma affects older adults (median age 63 years) as a large deep mass, most often of the lower extremity (Gebhard et al. 2002).
  • Histology. Lipogenic areas with pleomorphic lipoblasts combine with nonlipogenic areas resembling malignant fibrous histiocytoma, round cell liposarcoma or epithelioid carcinoma. Most tumors are FNCLCC grade 3, with necrosis and brisk mitoses (Gebhard et al. 2002). About 25% show epithelioid morphology, which can mimic carcinoma such as adrenocortical carcinoma (Savarese et al. 2026), and the CAP histologic type list includes epithelioid pleomorphic liposarcoma (CAP 2024).
  • Immunohistochemistry. S100 marks lipogenic areas in about half. Nonlipogenic areas show only focal SMA, CD34, EMA or desmin, and epithelioid areas are keratin negative (Gebhard et al. 2002).
  • Genetics. Pleomorphic liposarcoma lacks MDM2 and CDK4 amplification and has a complex karyotype with TP53 mutations in about 60% (Dwianingsih et al. 2025). In a genomic study, TP53 mutations occurred in 83%, and RB1 and ATRX losses were more common than in myxoid pleomorphic liposarcoma in this series (Dermawan et al. 2022); RB1 deletion was frequent in another myxoid pleomorphic liposarcoma series (Creytens et al. 2021).
  • Behavior. Local recurrence occurred in 45% and metastasis in 42.5%, mostly to lung and pleura. Five-year overall survival was 57%. Age ≥60 years, truncal location, deep site, size >5 cm, vascular invasion and incomplete excision were adverse, and grade and histologic pattern did not affect outcome (Gebhard et al. 2002).

Myxoid pleomorphic liposarcoma

  • Clinical features. Myxoid pleomorphic liposarcoma is rare and was first described in children and adolescents with a female predominance, most often in the mediastinum, then the limbs and head and neck (Sbaraglia et al. 2021). Later series found mostly young adults without a sex bias (mean age 33 years, 6 women and 6 men; Creytens et al. 2021; median age 32 years, range 10–68; Dermawan et al. 2022). It is aggressive, with frequent recurrence and early spread to lung, bone and soft tissue (Sbaraglia et al. 2021).
  • Histology. Bland myxoid areas with a plexiform capillary network merge with cellular areas of pleomorphic spindle cells, pleomorphic lipoblasts and increased mitoses (Creytens et al. 2021).
  • Genetics. No DDIT3 rearrangement or MDM2 amplification is present. Monoallelic RB1 deletion was found in 8 of 12 tumors, and nuclear Rb expression was deficient in all tested tumors. DNA methylation profiles clustered with conventional pleomorphic liposarcoma and apart from myxoid liposarcoma (Creytens et al. 2021). TP53 mutations were present in all 8 tumors of a second series, with loss of heterozygosity across about 80% of the genome (Dermawan et al. 2022).
  • Outcome. Recurrence, metastasis and death from disease are frequent, and survival is worse than in pleomorphic and myxoid liposarcoma (Dermawan et al. 2022).

Differential diagnosis of adipocytic tumors and fat-containing mimics

Lesion Key histology Ancillary result Pitfall Source
Lipoma Uniform mature adipocytes, thin septa HMGA2 rearrangement; no MDM2 amplification Involutional thick septa mimic ALT Savarese et al. 2026; Panagopoulos et al. 2015
Atypical lipomatous tumor/WDLPS Atypical stromal cells in fibrous septa; lipoblasts optional MDM2 amplification by FISH Atypical stromal cells may be scarce Sirvent et al. 2007; Savarese et al. 2026
Spindle cell/pleomorphic lipoma Bland spindle cells, ropey collagen, floret cells; posterior neck CD34 positive; Rb loss Heterogeneous fat with septa or nodules mimics ALT on MRI Savarese et al. 2026; Chen et al. 2012
Hibernoma Multivacuolated brown fat cells without atypia S100 positive in 85% Confused with ALT/WDLPS; marked FDG uptake on PET; rare MDM2 immunoreactivity Furlong et al. 2001; Savarese et al. 2026; Rottmann et al. 2023
Lipoblastoma Lobules with central maturation in infants PLAG1 rearrangement Myxoid areas resemble myxoid liposarcoma Savarese et al. 2026; Hibbard et al. 2000
Myxoid liposarcoma Chicken-wire capillaries, signet-ring lipoblasts, myxoid stroma FUS::DDIT3; DDIT3 nuclear staining Round cell areas >5% indicate higher grade Savarese et al. 2026; Anderson and Jo 2021; Hornick et al. 2026
Dedifferentiated liposarcoma High-grade nonlipogenic sarcoma beside WDLPS MDM2 amplification Weak STAT6 or DDIT3 staining Savarese et al. 2026; Anderson and Jo 2021
Pleomorphic liposarcoma Pleomorphic lipoblasts in a high-grade sarcoma No MDM2 amplification; TP53 mutations Epithelioid areas mimic carcinoma; keratin negative Gebhard et al. 2002; Dwianingsih et al. 2025
Encapsulated fat necrosis Encapsulated necrotic fat Histologic diagnosis; no ancillary marker Heterogeneous signal and enhancement mimic liposarcoma on MRI; activated histiocytes can be MDM2 positive Lee et al. 2013; Rottmann et al. 2023
Silicone granuloma Histiocytic tissue reaction to silicone CD68-positive cells Initially interpreted as low-grade liposarcoma; history of silicone injection or implant Gonçales et al. 2009; Maly et al. 2004

Reactive Pseudosarcomas, Benign Fibroblastic and Myofibroblastic Tumors, Fibromatoses and Tenosynovial Giant Cell Tumor

Definition. This group comprises self-limited pseudosarcomas (nodular, proliferative and ischemic fasciitis, proliferative myositis and myositis ossificans), benign fibroblastic tumors of children and adults, the superficial and desmoid fibromatoses, and the fibrohistiocytic and synovial tumors (tenosynovial giant cell tumor, giant cell tumor of soft tissue and plexiform fibrohistiocytic tumor) (Sbaraglia et al. 2021; Hornick et al. 2026). Several lesions once regarded as reactive carry recurrent gene rearrangements (Erickson-Johnson et al. 2011; Makise et al. 2021).

Related page: Non-Neoplastic and Reactive Soft Tissue and Skin Lesions on FNA (nodular fasciitis, myositis ossificans and other pseudosarcomas on FNA) Related page: Benign Soft Tissue Tumors on FNA (tenosynovial giant cell tumor on FNA) Related page: Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing (WHO 2026 framework and molecular testing methods) Related page: Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma (low-grade myofibroblastic sarcoma, infantile fibrosarcoma and kinase-fusion tumors) Related page: Vascular Anomalies and Vascular Tumors, Perivascular Tumors, and Smooth Muscle Tumors of Deep Soft Tissue (myofibroma and myofibromatosis) Related page: Benign Mesenchymal and Inflammatory Lesions of the Breast (fibromatosis and nodular fasciitis of the breast) Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (gastrointestinal stromal tumor in the differential diagnosis of mesenteric fibromatosis) Related page: Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma (acral fibromyxoma and dermal fibroblastic tumors) Related page: Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others (aggressive angiomyxoma)

WHO classification of fibroblastic, myofibroblastic and fibrohistiocytic tumors: STB6 changes

Element STB6 (2026) Previous rule (STB5, 2020) Source
Benign fibroblastic entities PRRX1-rearranged fibroblastic tumor added (benign; usually PRRX1::NCOA1; paucicellular bland spindle cells in hyalinized stroma with wire-like and ropey collagen and ectatic, staghorn vessels) Absent from STB5 Hornick et al. 2026
Intermediate fibroblastic entities Nodular necrotizing fibroblastic tumor added (intermediate; superficial nodules of epithelioid cells with large vesicular nuclei and prominent nucleoli, a lymphoid rim and central necrosis; mostly YAP1::MAML2; indolent) Absent from STB5; initially suggested to be a subtype of myxoinflammatory fibroblastic sarcoma Hornick et al. 2026; Perret et al. 2022; Sbaraglia et al. 2021
Calcifying fibrous tumor Included Inadvertently omitted Hornick et al. 2026
Renamed fibroblastic entities SMAD3-rearranged fibroblastic tumor; superficial CD34-positive pleomorphic fibroblastic tumor EWSR1::SMAD3-positive fibroblastic tumor (emerging); superficial CD34-positive fibroblastic tumor (intermediate, rarely metastasizing) Hornick et al. 2026; Sbaraglia et al. 2021
Fibrohistiocytic chapter "Fibrohistiocytic and synovial tumors"; chondroid synoviocytic neoplasm and keratin-positive giant cell-rich tumor added; deep fibrous histiocytoma removed because it is a subtype of dermatofibroma, classified with skin tumors "Fibrohistiocytic tumors": tenosynovial giant cell tumor and deep benign fibrous histiocytoma (benign), plexiform fibrohistiocytic tumor and giant cell tumor of soft parts (intermediate, rarely metastasizing), malignant tenosynovial giant cell tumor Hornick et al. 2026; Sbaraglia et al. 2021

In STB5, the intermediate locally aggressive fibroblastic tumors were palmar/plantar fibromatosis, desmoid-type fibromatosis, lipofibromatosis, giant cell fibroblastoma and DFSP (Sbaraglia et al. 2021).

Nodular fasciitis

  • Clinical features. Nodular fasciitis is a rapidly growing, self-limited subcutaneous myofibroblastic proliferation, most often in the forearm of young adults (Sbaraglia et al. 2021; Erickson-Johnson et al. 2011).
  • Histology and phenotype. Rapid growth, hypercellularity and high mitotic activity mimic sarcoma (Sbaraglia et al. 2021). Spindle cells express SMA, calponin and vimentin, and myxoid areas with inflammation lack the ganglion-like cells of proliferative myositis (Gan et al. 2019).
  • Genetics. USP6 rearrangement, usually MYH9::USP6, defines nodular fasciitis as a self-limited (transient) neoplasm (Erickson-Johnson et al. 2011; data and FNA features in Non-Neoplastic and Reactive Soft Tissue and Skin Lesions on FNA). Rare USP6-rearranged malignant nodular fasciitis has been reported (Baumhoer et al. 2024).
  • Pediatric, cranial and intravascular fasciitis. In 24 pediatric cases, 16 arose in the head and neck, including 4 cranial fasciitis. Loosely woven fibroblasts and myofibroblasts lay in myxoid stroma with extravasated erythrocytes. USP6 FISH was positive in 22 of 24, and the single intravascular fasciitis was negative. No lesion recurred after complete excision (Qiao et al. 2026). Cranial fasciitis belongs to the USP6-rearranged group of lesions (Baumhoer et al. 2024).

Proliferative fasciitis, proliferative myositis and ischemic fasciitis

  • Proliferative fasciitis and myositis. These benign lesions of the extremities of middle-aged and older adults are poorly circumscribed proliferations of bland spindle cells in myxoid to fibrous stroma with large epithelioid "ganglion-like" cells (Makise et al. 2021). Ganglion-like myofibroblasts have vesicular nuclei and basophilic cytoplasm. The spindle cells of proliferative myositis are SMA positive and the ganglion-like cells are negative (Gan et al. 2019).
  • FOS rearrangement. Adult proliferative fasciitis and myositis carry FOS rearrangement with diffuse c-FOS in the ganglion-like cells (Makise et al. 2021; Non-Neoplastic and Reactive Soft Tissue and Skin Lesions on FNA).
  • FOS and FOSB immunohistochemistry and pediatric proliferative fasciitis. Diffuse nuclear FOS was present in 58% of adult proliferative fasciitis and 60% of proliferative myositis, and FOSB was negative. FOS FISH showed rearrangement in only 4 of 12 tested adult lesions, and RNA sequencing found a fusion in only 1 of 9 (FOS::TSHZ2), probably because of low neoplastic cell content. Pediatric proliferative fasciitis lacked FOS and carried FOSL1::RELA in 2 of 5 tested pediatric tumors, both in infants (Yu et al. 2026).
  • Ischemic fasciitis (atypical decubital fibroplasia). This pseudosarcomatous fibroblastic and myofibroblastic proliferation overlaps cytologically with proliferative fasciitis (Zilla et al. 2024) and was reported in a 76-year-old debilitated woman under the synonym atypical decubital fibroplasia (Washing and Zaher 2004). FOSB immunostaining was positive in 8 of 9 lesions, but FISH showed no FOS or FOSB rearrangement and RNA sequencing detected no fusion (Zilla et al. 2024). In another series, FOS and/or FOSB was expressed in 9 of 20 (Yu et al. 2026).

Myositis ossificans and fibro-osseous pseudotumor of digits

  • Histology. Myositis ossificans and fibro-osseous pseudotumor of digits are self-limited bone-forming lesions with a nodular fasciitis-like proliferation, osteoid and immature woven bone that can mature into lamellar bone. The 2 lesions overlap morphologically (Švajdler et al. 2019).
  • Zonation. Maturation proceeds from the center to the periphery: zone 1 (central) contains immature fibroblastic tissue with necrotic debris, zone 2 osteoid and immature bone, and zone 3 (peripheral) mature lamellar bone. A well-defined peripheral cortex is evident by 6–8 weeks (Gullì et al. 2026).
  • Early lesions. In the first weeks, myxoid matrix and mitotically active fibroblasts produce a pseudofibrosarcomatous appearance, and osteoid at the periphery of the myxoid zone produces a pseudo-osteosarcomatous appearance (Gullì et al. 2026).
  • Genetics. COL1A1::USP6 was found in 5 of 7 myositis ossificans and 4 of 5 fibro-osseous pseudotumors (75% overall). Referring pathologists had suggested osteosarcoma in 3 of 16 consultation cases (27 cases reviewed) (Švajdler et al. 2019).

Elastofibroma

  • Clinical features. Elastofibroma dorsi affects older adults, more often women, and lies between the inferior angle of the scapula and the chest wall, deep to the serratus anterior and latissimus dorsi. It is bilateral in a minority, does not recur after excision, and is found at autopsy in 13%–24% of elderly people (Haihua et al. 2020; Al-Darwish et al. 2026).
  • Histology. Bands of dense collagen contain abnormal coarse elastic fibers interspersed with mature fat, without atypia, mitoses or necrosis (Al-Darwish et al. 2026). The Verhoeff elastica–van Gieson stain confirms the elastic nature of the fibers (Gun et al. 2007).

Fibrous tumors of infancy and childhood

Entity Clinical features Histology Immunohistochemistry and genetics Behavior Source
Fibrous hamartoma of infancy Infants Three components: intersecting fascicles of fibroblasts and myofibroblasts in collagen, nests of primitive oval or stellate cells in mucoid stroma, mature fat EGFR exon 20 insertion/duplication in 12 of 12 tumors and in no control pediatric fatty tumor Surgery is the mainstay Park et al. 2016
Infantile digital fibroma/fibromatosis (inclusion body fibromatosis) Infants; dorsolateral finger or toe Bland fibroproliferative dome-shaped nodule beneath the epidermis; paranuclear cytoplasmic inclusions in 57 of 69 tumors Calponin, desmin, SMA and CD99 positive; nuclear β-catenin 2 of 11 Often recurs or persists but does not metastasize Laskin et al. 2009
Fibromatosis colli (sternocleidomastoid tumor of infancy) First weeks of life; most common perinatal neck mass; may cause torticollis Low-cellularity aspirates of spindle fibroblasts with degenerating skeletal muscle None required Conservative management when the diagnosis is certain Schwartz et al. 1997
Lipofibromatosis Infants and young children; hands and feet; some congenital Abundant fat with a spindled fibroblastic element in fat and muscle septa; ≤1 mitosis/10 HPF; univacuolated cells at the fat interface; no primitive nodules Focal CD99, CD34, SMA, BCL2; desmin negative Recurrent or persistent in 72% Fetsch et al. 2000
Calcifying aponeurotic fibroma Children and adolescents, more often male; deep volar fascia, tendons and aponeuroses of the hands, then the feet Fibroblastic tumor; one of the few fibrous lesions that calcify, with stippled calcification on imaging FN1::EGF in all tumors tested (8); EGF protein in 8 of 9 Benign but locally aggressive Puls et al. 2016; Kwee and Kwee 2019

Benign fibromas of adults and new STB6 fibroblastic entities

Entity Clinical features Histology Genetics and immunohistochemistry Behavior Source
Desmoplastic fibroblastoma (collagenous fibroma) Mostly men (80%), median age 50 years; arm and shoulder girdle most often; predominantly subcutaneous Hypocellular fibrous tumor with stellate-shaped fibroblasts that overlaps histologically with fibroma of tendon sheath FOSL1 rearrangement in 10 of 15, FOS in 2 of 15; FOSL1 immunohistochemistry 90% concordant with RNA sequencing Benign; no recurrence in 39 patients with follow-up Miettinen and Fetsch 1998; De Noon et al. 2023
Fibroma of tendon sheath Associated with tenosynovial tissue "Classic" and "cellular" forms USP6 fusion in 17 of 18 regardless of cellularity (partners MYH9, COL1A1, ASPN and others); USP6-negative cellular lesions tend to be myofibromas (Vascular Anomalies and Vascular Tumors, Perivascular Tumors, and Smooth Muscle Tumors of Deep Soft Tissue) Benign Pižem et al. 2021
Nuchal-type fibroma Adult men; posterior neck, also extranuchal Superficial paucicellular thick lobulated collagen bundles with entrapped fat and traumatic neuroma-like nerve twigs Associated with diabetes; rare Gardner syndrome association Nondestructive local recurrence in 5 Michal et al. 1999
Gardner fibroma 78% diagnosed in the first decade; back and paraspinal region in 61% Bland hypocellular haphazard coarse collagen with inconspicuous spindle cells and sparse mast cells 69% had FAP or APC alteration; nuclear β-catenin in 64%; desmoid fibromatosis concurrently or later in 18% Benign; may precede or accompany desmoid fibromatosis Coffin et al. 2007
Calcifying fibrous tumor (restored in STB6) Gastrointestinal calcifying fibrous tumor: adults, female predominance; often incidental Spindle cells in densely hyalinized stroma with scattered calcifications and lymphoplasmacytic inflammation CD34 and factor XIIIa positive Cured by local resection; low recurrence Turbiville and Zhang 2020; Hornick et al. 2026
Nodular necrotizing fibroblastic tumor (new in STB6) Adults; small superficial nodules Nodules of epithelioid cells with large vesicular nuclei and prominent nucleoli, central necrosis, polymorphous inflammation YAP1::MAML2 in most (3 of 7 by RNA sequencing in the index series); keratin and cyclin D1 in a subset Intermediate (STB6); indolent Hornick et al. 2026; Perret et al. 2022

SMAD3-rearranged, superficial CD34-positive and angiofibromatous tumors, myofibroblastoma and genital stromal tumors

Entity Clinical features Histology Immunohistochemistry and genetics Behavior Source
SMAD3-rearranged fibroblastic tumor (STB5: EWSR1::SMAD3-positive fibroblastic tumor) Hands and feet; broad age range Intersecting cellular fascicles of bland monomorphic spindle cells alternating with hypocellular hyalinized areas Nuclear ERG; EWSR1::SMAD3 Benign Sbaraglia et al. 2021; Hornick et al. 2026
Superficial CD34-positive pleomorphic fibroblastic tumor (STB5: superficial CD34-positive fibroblastic tumor) Skin and subcutis of the lower extremities of middle-aged adults Spindle and epithelioid cells, often with striking cytologic atypia but insignificant mitotic activity and no necrosis CD34 positive in all No recurrence after complete excision; intermediate (rarely metastasizing) in STB5 Sbaraglia et al. 2021; Hornick et al. 2026
Angiofibroma of soft tissue Subcutis of the extremities of adults Uniform spindle cells in myxoid to collagenous stroma with a rich network of thin-walled branching vessels CD34 and EMA; desmin in dendritic cells; AHRR::NCOA2 in most Benign Sbaraglia et al. 2021
Myofibroblastoma of soft tissue Adults in the fifth and sixth decades, twice as often men; inguinal and groin region in half; median 6.5 cm Circumscribed monotonous spindle cells in short fascicles with mature fat, mast cells and hyalinized stroma Desmin and CD34 coexpressed; SMA in a third; 13q14 loss with Rb loss in 90% Benign; local excision curative Libbrecht et al. 2021
Angiomyofibroblastoma Vulva and vagina of reproductive-age women; usually <5 cm; often mistaken for a Bartholin gland cyst Circumscribed; alternating hypocellular and hypercellular areas of plump spindled to epithelioid (plasmacytoid) cells clustered around thin-walled vessels; mature fat common ER; variable desmin; CD34 in a minority; no 13q14 deletion; MTG1::CYP2E1 fusion with CYP2E1 overexpression Benign Angelico et al. 2022
Cellular angiofibroma Vulvovaginal region of middle-aged women; inguinoscrotal region of older men Uniformly cellular bland spindle cells in fibrous stroma with wispy collagen and numerous small to medium-sized hyalinized vessels; adipocytes in half CD34, ER and PR; desmin usually negative; Rb loss and 13q14 deletion Benign; recurrence rare, even with atypia or sarcomatous change Angelico et al. 2022; Libbrecht et al. 2021

Myofibroblastoma, cellular angiofibroma and spindle cell lipoma share 13q14 deletion with Rb loss, and desmin separates myofibroblastoma from spindle cell lipoma in most cases (Libbrecht et al. 2021). Deep (aggressive) angiomyxoma is distinguished from these genital stromal tumors because of its relatively high risk of local recurrence (Angelico et al. 2022; Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others). Juvenile hyaline fibromatosis, a benign fibroblastic entity in STB5 (Sbaraglia et al. 2021), is an autosomal recessive ANTXR2 (4q21) disorder grouped with infantile systemic hyalinosis (Warman et al. 2011). Acral fibromyxoma is taught in Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma.

Superficial fibromatoses: palmar, plantar and penile fibromatosis

  • Sites. Superficial (fascial) fibromatoses arise from fascia or aponeuroses at palmar, plantar, penile (Peyronie disease) and knuckle pad sites. Palmar fibromatosis is the most common, followed by plantar fibromatosis, and coexists with plantar fibromatosis, Peyronie disease and knuckle pads (Walker et al. 2012).

  • Palmar fibromatosis (Dupuytren disease). Palmar fibromatosis is the most common fibromatosis. It affects mainly white middle-aged and older men at the distal palmar crease, causes nodules and contracture, and often recurs after surgery (Stewart and Nascimento 2021).

  • Plantar fibromatosis (Ledderhose disease). Plantar fibromatosis involves the plantar aponeurosis of middle-aged patients and causes painful nodules, usually without contracture (Stewart and Nascimento 2021).

  • Histology. Both are bland cellular proliferations of fibroblasts and myofibroblasts with a bluish appearance and variable collagen depending on lesion age (Stewart and Nascimento 2021).

Desmoid fibromatosis: CTNNB1, APC and management by active surveillance

  • Definition and epidemiology. Desmoid tumor is a rare, locally aggressive, monoclonal fibroblastic proliferation with a variable and often unpredictable course (Desmoid Tumor Working Group 2020). The incidence is about 2–4 per million per year. Prior trauma and hormonal factors are associated (Nahi and Dann 2026).
  • Histology. Bland fibroblastic and myofibroblastic spindle cells are arranged in fascicles and grow infiltratively, without atypia or significant mitotic activity. Seven patterns are described: conventional fascicular, hyalinized, staghorn vessel, hypocellular/myxoid, keloidal, nodular fasciitis-like and hypercellular. The nodular fasciitis-like and staghorn vessel patterns can suggest nodular fasciitis and solitary fibrous tumor (Ng et al. 2026).
  • Genetics. CTNNB1 mutations occur in 85% of sporadic desmoids (T41A, S45F, S45P), and S45F carries the highest recurrence risk (Lazar et al. 2008). Germline APC mutations underlie desmoids of familial adenomatous polyposis (Nahi and Dann 2026; CAP 2024).
  • Nuclear β-catenin. Nuclear β-catenin also occurs in superficial fibromatoses, low-grade myofibroblastic sarcoma and solitary fibrous tumor, so positivity supports the diagnosis and negativity does not exclude it (Carlson and Fletcher 2007; Lazar et al. 2008; figures in Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing).
  • Mesenteric differential diagnosis. Spindle cell mimics of intra-abdominal desmoid include gastrointestinal stromal tumor, leiomyosarcoma, dedifferentiated liposarcoma and sarcomatoid carcinoma (Ng et al. 2026). GIST expresses KIT and DOG1 (Anderson and Jo 2021; Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine).
  • Management. The global consensus guideline (2018 Milan meeting, published 2020) shifted management from primary surgery toward a conservative approach (Desmoid Tumor Working Group 2020). Active surveillance is the initial approach for selected patients because prolonged stability and spontaneous regression occur, and systemic therapy is introduced for progression, symptoms or functional compromise (Desmoid Tumor Working Group 2020; Nahi and Dann 2026).
  • Systemic therapy. Options include NSAIDs, anthracycline-based chemotherapy such as pegylated liposomal doxorubicin, the tyrosine kinase inhibitor sorafenib and the γ-secretase inhibitor nirogacestat, the first FDA-approved therapy for progressing desmoid tumors (Nahi and Dann 2026).

Tenosynovial giant cell tumor and chondroid synoviocytic neoplasm

  • Clinical forms. Tenosynovial giant cell tumor (TGCT) affects the synovium of joints, tendon sheaths and bursae of young adults with a modest female predominance. About 90% are localized, forming a single circumscribed mass of about 2 cm. The diffuse form (formerly pigmented villonodular synovitis) involves a compartment or the whole synovium of a large joint, most often the knee, with more recurrence and joint destruction (Robert et al. 2022).
  • Histology. Synovial hyperplasia and villonodular hypertrophy contain mononuclear cells, multinucleated osteoclast-like giant cells (CD68, TRAP and calcitonin receptor positive) and hemosiderin (Robert et al. 2022).
  • Genetics. Translocations at 1p13 rearrange CSF1, sometimes fused to COL6A3 (2q35), and lead to CSF1 overexpression. The translocation is present in a minority of cells, which recruit CSF1R-expressing nonneoplastic cells into the mass (a landscape effect) (West et al. 2006). The COL6A3::CSF1 translocation is found in 2%–16% of lesional cells, and loss or replacement of the 3′ regulatory region of CSF1 is even more frequent (Robert et al. 2022).
  • Malignancy. About 1%–3% of TGCTs undergo malignant transformation (Robert et al. 2022). Malignant TGCT is classified as a malignant tumor with a CSF1 fusion (Sbaraglia et al. 2021; CAP 2024).
  • CSF1R inhibition. The CSF1R inhibitor pexidartinib produced responses in about 60% of patients with symptomatic TGCT not amenable to surgery in the ENLIVEN trial (Wagner et al. 2025). The CSF1R inhibitor vimseltinib produced an objective response rate of 40% versus 0% with placebo in the phase 3 MOTION trial (Gelderblom et al. 2024).
  • Chondroid synoviocytic neoplasm (new in STB6). Also called chondroid tenosynovial giant cell tumor or calcified chondroid mesenchymal neoplasm, it arises mainly in the temporomandibular joint region and the distal extremities of adults (Hornick et al. 2026; Gross and Fritchie 2026). Large eosinophilic moderately pleomorphic synoviocytes, osteoclastic giant cells, hyaline cartilage and calcified matrix are present, with frequent FN1 fusions. STB6 classifies it as intermediate (Hornick et al. 2026).

Giant cell tumor of soft tissue, plexiform fibrohistiocytic tumor and keratin-positive giant cell-rich tumor

Entity Clinical features Histology Immunohistochemistry and genetics Behavior Source
Giant cell tumor of soft tissue Superficial soft tissue of the extremities Round to oval mononuclear cells and osteoclast-like giant cells, resembling giant cell tumor of bone Immunohistochemistry has a limited role; lacks the H3-3A mutations of giant cell tumor of bone Intermediate (rarely metastasizing); incomplete resection followed by recurrence; malignant tumors with high-grade features metastasize more often Nishio et al. 2024; Sbaraglia et al. 2021
Plexiform fibrohistiocytic tumor Children and young adults; upper extremity; small dermal or subcutaneous mass Multinodular or plexiform mixture of histiocyte-like cells, osteoclast-like giant cells and spindle cells CD68, CD163 and CD11c in histiocyte-like and giant cells; focal SMA in spindle cells; nuclear cyclin D1 in all 3 cell types Locally aggressive and rarely metastasizing; wide local excision Nishio et al. 2026

Keratin-positive giant cell-rich tumor (new in STB6). This intermediate mesenchymal neoplasm of uncertain lineage contains osteoclast-type or Touton giant cells, histiocytes, inflammatory cells and a small number of keratin-positive mononuclear cells with paranuclear AE1/AE3 staining, and it carries HMGA2::NCOR2 (Hornick et al. 2026). It has also been reported as xanthogranulomatous epithelial tumor of soft tissue (Baumhoer et al. 2024).

Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma

Definition. The intermediate and malignant fibroblastic and myofibroblastic tumors are solitary fibrous tumor, inflammatory myofibroblastic tumor, low-grade myofibroblastic sarcoma, myxoinflammatory fibroblastic sarcoma, infantile fibrosarcoma, myxofibrosarcoma, low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, with undifferentiated pleomorphic sarcoma; kinase-altered spindle cell neoplasms (still classified among tumors of uncertain differentiation) and the hemosiderotic fibrolipomatous tumor and pleomorphic hyalinizing angiectatic tumor spectrum (Sbaraglia et al. 2021; Hornick et al. 2026).

Related page: Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing (FNCLCC grading, AJCC staging and fusion testing methods) Related page: Reactive Pseudosarcomas, Benign Fibroblastic and Myofibroblastic Tumors, Fibromatoses and Tenosynovial Giant Cell Tumor (nodular fasciitis, desmoid fibromatosis and benign fibromas) Related page: Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others (synovial sarcoma and angiomatoid fibrous histiocytoma) Related page: Peripheral Nerve Sheath Tumors: Schwannoma, Neurofibroma and ANNUBP, Perineurioma, Granular Cell Tumor and MPNST (MPNST) Related page: Vascular Anomalies and Vascular Tumors, Perivascular Tumors, and Smooth Muscle Tumors of Deep Soft Tissue (leiomyosarcoma) Related page: Benign Soft Tissue Tumors on FNA (solitary fibrous tumor on FNA) Related page: Round Cell, Spindle Cell and Pleomorphic Sarcomas on FNA (spindle and pleomorphic sarcomas on FNA) Related page: Other Lung Tumors: Hamartoma, Sclerosing Pneumocytoma, Adenomas, Salivary Gland-Type, Mesenchymal and Lymphoid Tumors, and Metastases (pleural solitary fibrous tumor and pulmonary inflammatory myofibroblastic tumor) Related page: Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder (inflammatory myofibroblastic tumor of the bladder) Related page: Uterine Mesenchymal Tumors: Smooth Muscle Tumors, Endometrial Stromal Tumors, Adenosarcoma and Other Sarcomas (inflammatory myofibroblastic tumor of the uterus) Related page: Pediatric, Mesenchymal and Other Renal Tumors, Nephrectomy Grossing, WHO/ISUP Grading and Kidney Cancer Staging (cellular congenital mesoblastic nephroma) Related page: Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma (DFSP, fibrosarcomatous DFSP and the dermal NTRK-rearranged spindle cell neoplasm)

STB6 changes in fibroblastic sarcomas with the STB5 rule

Entity STB6 (2026) Previous rule (STB5, 2020) Source
Adult fibrosarcoma Removed; former cases are reclassified with contemporary methods, for example as monophasic synovial sarcoma, MPNST or fibrosarcomatous DFSP "Fibrosarcoma NOS" listed among malignant fibroblastic tumors Hornick et al. 2026; Sbaraglia et al. 2021
Infantile fibrosarcoma Retained; in the kidney the accepted term is cellular congenital mesoblastic nephroma Intermediate (rarely metastasizing) Hornick et al. 2026; Sbaraglia et al. 2021
Undifferentiated pleomorphic sarcoma Moved to fibroblastic and myofibroblastic tumors; still a diagnosis of exclusion; low-grade monomorphic spindle cell sarcomas are excluded from UPS Subtype within "undifferentiated soft tissue sarcoma" among tumors of uncertain differentiation Hornick et al. 2026; Sbaraglia et al. 2021
Sclerosing epithelioid fibrosarcoma MUC4-negative SEF-like tumors with YAP1 or KMT2A fusions co-classified with SEF, pending outcome data No SEF-like category Hornick et al. 2026; Sbaraglia et al. 2021
Kinase-altered spindle cell neoplasms Expanded category including other kinase fusions and point mutations (still among tumors of uncertain differentiation) NTRK-rearranged spindle cell neoplasm (emerging entity, tumors of uncertain differentiation) Hornick et al. 2026; Sbaraglia et al. 2021
Nodular necrotizing fibroblastic tumor (Reactive Pseudosarcomas, Benign Fibroblastic and Myofibroblastic Tumors, Fibromatoses and Tenosynovial Giant Cell Tumor) Separate entity (intermediate); superficial epithelioid tumor with brisk inflammation and often central necrosis; most with YAP1::MAML2 Absent from STB5; initially suggested to be a subtype of myxoinflammatory fibroblastic sarcoma Hornick et al. 2026; Perret et al. 2022; Sbaraglia et al. 2021

Solitary fibrous tumor and the Demicco risk model

  • Genetics. Whole-exome sequencing identified NAB2::STAT6 as the defining fusion, with 7 transcript variants (Chmielecki et al. 2013). NAB2::STAT6 arises from a small paracentric inversion of 12q13 (Anderson and Jo 2021).
  • STAT6 immunohistochemistry. Diffuse strong nuclear STAT6 is the surrogate for the fusion (Doyle et al. 2014; performance in Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing). STAT6 expression is also reported in GLI1-amplified tumors (Machado et al. 2021).
  • Histology. Spindled to ovoid cells grow in a patternless architecture with stromal collagen and staghorn (hemangiopericytoma-like) vessels. CD34 is characteristic but nonspecific (Doyle et al. 2014). CD34, BCL2 and CD99 are commonly expressed, and aberrant epithelial, muscle or neuroendocrine markers occur (Machado et al. 2021).
  • Morphologic spectrum. Round cell, giant cell-rich, myxoid, pleomorphic, fat-forming and dedifferentiated forms occur (Machado et al. 2021).
  • Fusion variants. NAB2 exon 4–STAT6 exon 2 tumors are often thoracic, less cellular and fibrotic, and arise in older patients. NAB2 exon 6–STAT6 exon 16/17 tumors are more cellular round to ovoid tumors of the abdomen, retroperitoneum, pelvis or CNS in younger patients, with more mitoses and recurrence (Machado et al. 2021).
  • Secondary alterations. TERT promoter and TP53 mutations are associated with malignant behavior and are not yet part of any risk model (Machado et al. 2021).
  • Behavior. Solitary fibrous tumors metastasize in 5%–25% (Demicco et al. 2017).
Demicco variable Categories and points Source
Age (years) <55: 0; ≥55: 1 Demicco et al. 2017; CAP 2024; Machado et al. 2021
Tumor size (cm) <5: 0; 5 to <10: 1; 10 to <15: 2; ≥15: 3 Demicco et al. 2017; CAP 2024; Machado et al. 2021
Mitotic count (per 10 HPF) 0: 0; 1–3: 1; ≥4: 2 Demicco et al. 2017; CAP 2024; Machado et al. 2021
Tumor necrosis <10%: 0; ≥10%: 1 Demicco et al. 2017; CAP 2024; Machado et al. 2021
Risk class (total score) Proportion and outcome in the validation cohort Source
Low (0–3) 66% of tumors; no metastasis at 10 years Demicco et al. 2017
Intermediate (4–5) 24%; 10% risk of metastasis at 10 years Demicco et al. 2017
High (6–7) 10%; 73% risk of metastasis at 5 years Demicco et al. 2017

Adding necrosis as a fourth variable enhanced predictive power, and the 4-variable risk groups separated significantly on survival analysis (Demicco et al. 2017). A mitotic count of ≥4/10 HPF is the strongest histologic predictor of malignant behavior, and low-risk tumors occasionally recur or metastasize late (Machado et al. 2021).

  • Dedifferentiated solitary fibrous tumor. An abrupt transition to a pleomorphic, epithelioid, spindle cell or round cell high-grade component occurs, sometimes with heterologous elements. STAT6 is completely lost in about one-third, and complete loss was associated with shorter disease-specific survival in a pooled analysis with published cases (Simon et al. 2025).

Inflammatory myofibroblastic tumor and epithelioid inflammatory myofibroblastic sarcoma

  • Definition. Inflammatory myofibroblastic tumor (IMT) is a neoplasm of intermediate (rarely metastasizing) malignancy of fibroblastic and myofibroblastic spindle cells with an inflammatory infiltrate (Anderson and Jo 2021).
  • Kinase fusions. ALK (2p23) is rearranged in about 50%–60%, with many 5′ partners that homodimerize (Anderson and Jo 2021). Kinase fusions (ALK, ROS1, rarely RET) occur in most IMTs and in more than 90% of pediatric tumors, and fusion-negative tumors are mostly adult (Antonescu et al. 2015; series data in Other Lung Tumors: Hamartoma, Sclerosing Pneumocytoma, Adenomas, Salivary Gland-Type, Mesenchymal and Lymphoid Tumors, and Metastases).
  • ALK staining patterns. Cytoplasmic staining is usual; granular cytoplasmic staining corresponds to CLTC::ALK, nuclear membrane staining to RANBP2::ALK and perinuclear staining to RRBP1::ALK (Anderson and Jo 2021). ROS1-rearranged IMTs show fascicles of spindle cells with long processes and are often ROS1 positive (Antonescu et al. 2015).
  • Sites and behavior. Abdominopelvic IMTs recur most often, and the rare metastasizing tumors were ALK negative, in older patients and more pleomorphic (Coffin et al. 2007).
  • Targeted therapy. Crizotinib produced objective responses in ALK- or ROS1-rearranged IMT (Anderson and Jo 2021).
  • Epithelioid inflammatory myofibroblastic sarcoma. This aggressive intra-abdominal (mesenteric or omental) variant, mostly in males, consists of sheets of round to epithelioid cells with vesicular nuclei, large nucleoli, myxoid stroma and neutrophils. ALK shows nuclear membrane or perinuclear staining, desmin and CD30 are positive, RANBP2::ALK is the usual fusion, and recurrence is rapid with frequent death from disease (Mariño-Enríquez et al. 2011).
  • CD30. CD30 was expressed in 3 of 15 ALK- or ROS1-positive IMTs (Kojima et al. 2023).

Low-grade myofibroblastic sarcoma and myxoinflammatory fibroblastic sarcoma

  • Low-grade myofibroblastic sarcoma. This myofibroblastic tumor has a high tendency to local recurrence, a low probability of metastasis and a predilection for the head and neck, especially the oral cavity. Oval to spindle cells lie in fibrous to myxoid stroma. SMA is positive, desmin is variable and h-caldesmon is negative (Giraldo-Roldan et al. 2023).
  • Myxoinflammatory fibroblastic sarcoma (MIFS). MIFS favors the distal extremities and recurs locally. Spindle cells and bizarre epithelioid cells resembling virocytes lie in fibrous to myxoid stroma with abundant inflammation (Perret et al. 2022).
  • MIFS genetics and outcome. VGLL3 amplification is the most frequent alteration, with BRAF fusions or amplification and TGFBR3/MGEA5 rearrangements in subsets. Recurrence is related to positive margins, and metastasis is rare (Hirose et al. 2025; Liu et al. 2019).

Infantile fibrosarcoma

  • Clinical features and behavior. Infantile (congenital) fibrosarcoma arises in patients aged 2 years or younger and has an excellent prognosis and a very low metastatic rate despite histology identical to adult-type fibrosarcoma (Knezevich et al. 1998). Tumors display histologic features of malignancy and frequently recur (Bourgeois et al. 2000).
  • Histology. Intersecting highly cellular fascicles of spindle cells form a herringbone pattern (Anderson and Jo 2021).
  • Genetics. t(12;15)(p13;q25) fuses the HLH dimerization domain of ETV6 to the tyrosine kinase domain of NTRK3. The fusion was absent from adult-type fibrosarcoma and infantile fibromatosis (Knezevich et al. 1998).
  • Diagnostic testing. RT-PCR detected ETV6::NTRK3 in 10 of 11 infantile fibrosarcomas and in none of 51 other benign or malignant pediatric spindle cell tumors, and it outperformed cytogenetics and NTRK3 immunohistochemistry (Bourgeois et al. 2000).
  • Other kinase fusions. Tumors with infantile fibrosarcoma-like morphology can carry other kinase fusions, including NTRK1, NTRK2, MET, RET, RAF1 and BRAF fusions, as well as activating BRAF point mutations (Penning et al. 2021).
  • Therapy. TRK inhibitors (larotrectinib) produce responses in TRK fusion-positive tumors (Drilon et al. 2018).
  • Renal counterpart. In the kidney, the tumor is termed cellular congenital mesoblastic nephroma (Hornick et al. 2026; Pediatric, Mesenchymal and Other Renal Tumors, Nephrectomy Grossing, WHO/ISUP Grading and Kidney Cancer Staging).

Adult fibrosarcoma: removed in STB6

STB6 removes adult fibrosarcoma because essentially all tumors once diagnosed as adult fibrosarcoma are now reclassified with contemporary methods, for example as monophasic synovial sarcoma, MPNST or fibrosarcomatous DFSP (Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma) (Hornick et al. 2026). STB5 listed fibrosarcoma NOS among malignant fibroblastic tumors (Sbaraglia et al. 2021). Adult-type fibrosarcoma has the same histology as infantile fibrosarcoma but is an aggressive malignancy of adults and older children with a poor prognosis (Knezevich et al. 1998). Fibrosarcoma of bone, formerly a diagnosis of exclusion, was removed in parallel (Hornick et al. 2026).

Myxofibrosarcoma

  • Clinical features. Myxofibrosarcoma affects older adults (median age 66 years), mostly on the extremities, and most tumors are dermal or subcutaneous (Mentzel et al. 1996).
  • Histology. A nodular growth pattern, myxoid matrix with elongated curvilinear capillaries and fusiform, round or stellate cells with hyperchromatic atypical nuclei are characteristic. Tumors range from hypocellular low-grade myxoid spindle cell lesions to high-grade pleomorphic lesions with multinucleated giant cells, high mitotic activity and necrosis. Immunohistochemistry shows only vimentin and occasional actin (Mentzel et al. 1996).
  • Infiltrative growth. Atypical cells extend along fascial planes beyond the MRI margin, which explains positive margins and recurrence (Kaya et al. 2008).
  • Behavior. Local recurrence occurred in 54% and was independent of grade. Only intermediate- and high-grade tumors metastasized, and tumors became progressively higher grade in recurrences (Mentzel et al. 1996).
  • Distinction from UPS. Myxofibrosarcoma (≥10% myxoid area) recurs locally more often than undifferentiated pleomorphic sarcoma but metastasizes and causes death less often (Yoshimoto et al. 2020).
  • MDM2 in myxofibrosarcoma. MDM2 immunostaining and MDM2 amplification occur in some myxofibrosarcomas (Anderson and Jo 2021; Rottmann et al. 2023).

Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma

  • Low-grade fibromyxoid sarcoma (LGFMS). LGFMS shows alternating collagenous and myxoid areas, deceptively bland spindle cells and a whorling architecture (Doyle et al. 2011). LGFMS affects young adults, deep in the trunk and lower extremities. Giant collagen rosettes in 30% place hyalinizing spindle cell tumor with giant rosettes in the same spectrum (Folpe et al. 2000).
  • LGFMS genetics. About 90% carry FUS::CREB3L2, and fewer carry FUS::CREB3L1 (Arbajian et al. 2014; Anderson and Jo 2021).
  • MUC4. Diffuse cytoplasmic MUC4 marks LGFMS and SEF. Some monophasic synovial sarcomas are also positive (Doyle et al. 2011; performance in Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing).
  • Sclerosing epithelioid fibrosarcoma (SEF). Pure SEF usually carries EWSR1::CREB3L1 and is diffusely MUC4 positive. Hybrid LGFMS-SEF and LGFMS progressing to SEF carry FUS::CREB3L2, and SEF behaves more aggressively than LGFMS (Arbajian et al. 2014).
  • STB6 co-classification. MUC4-negative SEF-like tumors with YAP1 or KMT2A fusions are co-classified with SEF (Hornick et al. 2026).

Kinase-altered spindle cell neoplasms

  • STB6 definition. The STB5 emerging category of NTRK-rearranged spindle cell neoplasm is expanded to kinase-altered spindle cell neoplasms because a wide range of kinase fusions and point mutations occur in this tumor class (Hornick et al. 2026). Infantile fibrosarcoma remains a separate entity (Sbaraglia et al. 2021).
  • Morphologic spectrum. Tumors occur most often in the superficial or deep soft tissue of the extremities of children and adolescents, most often with NTRK1 rearrangement. Lipofibromatosis-like neural tumor is composed of monomorphic spindle cells coexpressing S100 and CD34 that infiltrate subcutaneous fat; it recurs locally without metastatic potential. Solid tumors of uniform spindle cells, often with hyalinized collagen, resemble MPNST in higher-grade examples, and high-grade tumors metastasize to the lungs (Sbaraglia et al. 2021). The dermal presentation is taught in Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma.
  • Kinases and pathway. Driver alterations involve NTRK, ALK, BRAF, RET, RAF, FGFR1 or ABL1 and are potentially targetable. Tumors with KANK1::NTRK or TPR::NTRK fusions show higher-grade spindled and pleomorphic morphology with necrosis, mitoses and unfavorable outcomes (CAP 2024).
  • When to test. CAP advises RNA-based NGS for fusions in spindled pleomorphic tumors of patients younger than 50 years, especially in soft tissue or bone, with ovoid to epithelioid morphology, collagenous to myxoid stroma, gaping to staghorn vessels and focal CD34 or S100 without SOX10 (CAP 2024).
  • Immunophenotype. CD34 and S100 are coexpressed in most tumors and CD30 in many, while MPNST is CD30 positive in a minority, mostly weakly (Kojima et al. 2023). Tumors with RAF1 fusions coexpress S100 and CD34 without SOX10 and show stromal and perivascular hyalinization (Gong et al. 2022).

Undifferentiated pleomorphic sarcoma and radiation-associated sarcoma

  • Definition. Undifferentiated pleomorphic sarcoma (UPS) is a diagnosis of exclusion. STB6 places it among fibroblastic and myofibroblastic tumors because in many cases the tumor cells show fibroblastic and sometimes myofibroblastic differentiation (Hornick et al. 2026).
  • History. Malignant fibrous histiocytoma accounted for about 50% of sarcoma diagnoses until the early 2000s. UPS is the current name for its storiform-pleomorphic form. Giant cell MFH is replaced by giant cell tumor of soft tissue, extraskeletal osteosarcoma and giant cell-rich osteosarcoma. Myxoid MFH is myxofibrosarcoma, inflammatory MFH overlaps with inflammatory dedifferentiated liposarcoma, and angiomatoid MFH is angiomatoid fibrous histiocytoma (Sbaraglia et al. 2021).
  • Reclassification. Of 159 tumors diagnosed as pleomorphic sarcoma, 97 (63%) proved to be specific sarcomas, 20 were nonmesenchymal neoplasms and only 13% were eligible as MFH (Fletcher 1992).
  • Genetics. UPS has extensive genetic complexity and no corresponding nonpleomorphic tumor (Rottmann et al. 2023).
  • Radiation-associated sarcoma. After breast cancer radiotherapy, angiosarcoma is the most common radiation-associated sarcoma, and its proportion is rising (Salminen et al. 2018; breast angiosarcoma in Angiosarcoma, Lymphoma and Metastases in the Breast).
Pleomorphic or spindle cell sarcoma to exclude before UPS Discriminating finding Source
Dedifferentiated liposarcoma (Adipocytic Tumors: Lipoma and Variants, Lipoblastoma, Hibernoma and Liposarcomas) MDM2 amplification by FISH, with or without a sampled well-differentiated component Sirvent et al. 2007
Pleomorphic liposarcoma (Adipocytic Tumors: Lipoma and Variants, Lipoblastoma, Hibernoma and Liposarcomas) Pleomorphic lipoblasts Gebhard et al. 2002; Rottmann et al. 2023
Myxofibrosarcoma Myxoid area ≥10% with curvilinear vessels and infiltrative growth Yoshimoto et al. 2020; Mentzel et al. 1996
MPNST (Peripheral Nerve Sheath Tumors: Schwannoma, Neurofibroma and ANNUBP, Perineurioma, Granular Cell Tumor and MPNST) H3K27me3 loss in a subset (variable sensitivity) Anderson and Jo 2021
Dedifferentiated solitary fibrous tumor STAT6 retained in many; NAB2::STAT6; STAT6 lost in 36% Simon et al. 2025
Kinase-fusion sarcoma CD34 and S100 coexpression without SOX10; CD30; RNA fusion testing CAP 2024; Kojima et al. 2023
Nonmesenchymal neoplasm Keratin, S100/SOX10, melanocytic and lymphoid markers Fletcher 1992

Hemosiderotic fibrolipomatous tumor and pleomorphic hyalinizing angiectatic tumor

  • Hemosiderotic fibrolipomatous tumor (HFLT). HFLT affects adults, mostly women, on the foot, often after trauma or with vasculopathy. Mature adipocytes, spindle cells and hemosiderin occur in varying proportions. It recurs locally and does not metastasize (Moretti et al. 2010).
  • Pleomorphic hyalinizing angiectatic tumor (PHAT). PHAT arises in the subcutis of the ankle, foot and leg of adults. Atypical stromal cells contain hemosiderin and intranuclear pseudoinclusions, and partially thrombosed ectatic vessels show circumferential hyalinization. "Early PHAT", a monomorphic hemosiderin-stippled spindle cell lesion that infiltrates fat around damaged vessels, is essentially identical to HFLT and is a precursor of PHAT. PHAT recurs without metastasis and was regarded by its describers as of intermediate malignancy (Folpe and Weiss 2004). STB5 listed PHAT as benign and HFLT as intermediate (locally aggressive), both among tumors of uncertain differentiation (Sbaraglia et al. 2021), and the STB6 summary describes no change to either (Hornick et al. 2026).
  • Shared genetics. Rearrangements of both TGFBR3 (1p22) and MGEA5 (10q24), from an unbalanced der(10)t(1;10)(p22;q24), occurred in 83% of MIFS, HFLT and hybrid tumors, and VGLL3 amplification in 10 of 12 (Antonescu et al. 2011). t(1;10) has been reported in 55 patients distributed among HFLT, PHAT, MIFS and hybrid tumors, so morphology does not reliably identify the translocation-positive subset (Liu et al. 2019). The current HGNC symbol of MGEA5 is OGA (CAP 2024).

Differential diagnosis of fibroblastic and myofibroblastic spindle cell sarcomas

Tumor Key morphology Defining test Behavior Source
Solitary fibrous tumor Patternless spindled to ovoid cells, staghorn vessels Nuclear STAT6; NAB2::STAT6 Demicco risk class Doyle et al. 2014; Demicco et al. 2017
Inflammatory myofibroblastic tumor Myofibroblasts with inflammation ALK or ROS1; kinase fusion in 68% Intermediate; abdominopelvic recurrence Antonescu et al. 2015; Coffin et al. 2007
Low-grade myofibroblastic sarcoma Spindle cells in fibrous and myxoid stroma; head and neck SMA positive, h-caldesmon negative Local recurrence; rare metastasis Giraldo-Roldan et al. 2023
Infantile fibrosarcoma Herringbone fascicles in patients ≤2 years ETV6::NTRK3 Excellent prognosis Knezevich et al. 1998
Myxofibrosarcoma Curvilinear vessels, atypical cells, infiltrative edges; older adults No defining alteration; morphologic diagnosis 54% local recurrence Mentzel et al. 1996
Low-grade fibromyxoid sarcoma Bland whorled cells, collagenous and myxoid zones MUC4; FUS::CREB3L2 Late metastasis Doyle et al. 2011; Folpe et al. 2000; CAP 2024
Kinase-altered spindle cell neoplasm Monomorphic spindle cells, hyalinized collagen, fat infiltration CD34 and S100 without SOX10; RNA fusion testing Grade-dependent Sbaraglia et al. 2021; CAP 2024
Monophasic synovial sarcoma (Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others) Monomorphic spindle cell fascicles SS18::SSX fusion; SS18-SSX IHC; MUC4 in some Malignant Anderson and Jo 2021; Doyle et al. 2011
MPNST (Peripheral Nerve Sheath Tumors: Schwannoma, Neurofibroma and ANNUBP, Perineurioma, Granular Cell Tumor and MPNST) Spindle cell fascicles; NF1 or radiation history H3K27me3 loss in a subset (variable sensitivity) Malignant Anderson and Jo 2021
Leiomyosarcoma (Vascular Anomalies and Vascular Tumors, Perivascular Tumors, and Smooth Muscle Tumors of Deep Soft Tissue) Atypical cells resembling smooth muscle; pleomorphic evolution possible SMA nearly uniform, desmin usual, KIT negative; complex karyotype without a recurrent translocation Malignant Miettinen 2014
Fibrosarcomatous DFSP (Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma) Sarcomatous transformation in DFSP, sometimes UPS-like or myxofibrosarcoma-like CD34 reduced or lost in some; COL1A1::PDGFB or PDGFB rearrangement retained High risk of recurrence and metastasis Chen et al. 2026

Vascular Anomalies and Vascular Tumors, Perivascular Tumors, and Smooth Muscle Tumors of Deep Soft Tissue

Definition and classification. The WHO Classification of Soft Tissue and Bone Tumours, 6th edition (STB6, 2026), combines the vascular tumors of soft tissue and bone in one chapter, renames lesions formerly known as hemangiomas and lymphangiomas using vascular anomaly (and lymphatic malformation) terminology aligned with the International Society for the Study of Vascular Anomalies (ISSVA), restores spindle cell hemangioma, separates YAP1::TFE3 hemangioendothelioma from epithelioid hemangioendothelioma, adds SRF-rearranged myoid neoplasm to the pericytic tumors and moves inflammatory leiomyosarcoma out of the smooth muscle tumors as inflammatory rhabdomyoblastic tumor (Hornick et al. 2026). In the 5th edition (STB5, 2020), vascular tumors of soft tissue and of bone were separate sections, and EBV-associated smooth muscle tumor and inflammatory leiomyosarcoma were added as smooth muscle entities (Hornick et al. 2026; Sbaraglia et al. 2021).

Related page: Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing (FNCLCC grading, AJCC staging, CAP reporting and the soft tissue molecular table) Related page: Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma (solitary fibrous tumor and the former hemangiopericytoma) Related page: Rhabdomyoma, Rhabdomyosarcoma and Risk Stratification, Ewing Sarcoma and Other Small Round Cell Sarcomas (inflammatory rhabdomyoblastic tumor and skeletal muscle tumors) Related page: Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others (PEComa, intimal sarcoma and the epithelioid tumor differential) Related page: Intrahepatic Cholangiocarcinoma, Biliary Cystic and Benign Tumors, Pediatric and Mesenchymal Liver Tumors, Metastases and Lymphoma (hepatic epithelioid hemangioendothelioma and hepatic angiosarcoma) Related page: Angiosarcoma, Lymphoma and Metastases in the Breast (primary and radiation-associated angiosarcoma of the breast and MYC) Related page: Benign Mesenchymal and Inflammatory Lesions of the Breast (benign vascular lesions of the breast) Related page: Uterine Mesenchymal Tumors: Smooth Muscle Tumors, Endometrial Stromal Tumors, Adenosarcoma and Other Sarcomas (uterine leiomyosarcoma, STUMP and PEComa of the uterus) Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (GIST, gastrointestinal glomus tumor and Kaposi sarcoma) Related page: Other Lung Tumors: Hamartoma, Sclerosing Pneumocytoma, Adenomas, Salivary Gland-Type, Mesenchymal and Lymphoid Tumors, and Metastases (pulmonary epithelioid hemangioendothelioma and pulmonary artery intimal sarcoma) Related page: GIST and smooth muscle tumors of the GI wall on EUS-FNA (smooth muscle tumors and GIST on FNA) Related page: Round Cell, Spindle Cell and Pleomorphic Sarcomas on FNA (spindle cell sarcomas on FNA) Related page: Vascular Anomalies and Vascular Tumors of Skin, Kaposi Sarcoma and Angiosarcoma, Cutaneous Histiocytic and Mast Cell Infiltrates, and Metastases to Skin (cutaneous vascular anomalies, the full ISSVA 2025 classification, infantile and congenital hemangiomas, pyogenic granuloma, Kaposi sarcoma, cutaneous angiosarcoma and atypical vascular lesion) Related page: Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma (cutaneous glomus tumor, myopericytoma, angioleiomyoma, cutaneous leiomyoma and atypical intradermal smooth muscle neoplasm)

Vascular anomalies of deep soft tissue: STB6 and ISSVA 2025 terminology

Element Current rule Previous rule Source
WHO chapter One chapter for vascular tumors of soft tissue and bone; bone and soft tissue differences marked within each section Separate vascular sections in the soft tissue and bone chapters (STB5) Hornick et al. 2026
Benign lesions formerly named hemangioma and lymphangioma Vascular anomaly and lymphatic malformation terminology aligned with ISSVA (STB6) Hemangioma and lymphangioma names (STB5) Hornick et al. 2026
Spindle cell hemangioma (Vascular Anomalies and Vascular Tumors of Skin, Kaposi Sarcoma and Angiosarcoma, Cutaneous Histiocytic and Mast Cell Infiltrates, and Metastases to Skin) Included (STB6) Omitted inadvertently (STB5) Hornick et al. 2026
YAP1::TFE3 hemangioendothelioma Separate malignant entity (STB6) TFE3-related morphological and molecular variant of epithelioid hemangioendothelioma (STB5) Hornick et al. 2026; Sbaraglia et al. 2021
  • ISSVA 2025. ISSVA 2025 separates vascular tumors from vascular malformations, and classifies malformations as fast-flow, slow-flow and developmental anomalies of named vessels. Fast-flow and venous malformations are subdivided into isolated, multifocal and syndromic types; lymphatic malformations into isolated lymphatic malformations, complex lymphatic anomalies and lymphedemas; and combined malformations into isolated and syndromic types (Goldenberg et al. 2025; Vascular Anomalies and Vascular Tumors of Skin, Kaposi Sarcoma and Angiosarcoma, Cutaneous Histiocytic and Mast Cell Infiltrates, and Metastases to Skin).
  • ISSVA terms for intramuscular lesions. Intramuscular fast-flow vascular anomaly is a new term among the isolated fast-flow malformations. Fibroadipose vascular anomaly is listed among the isolated venous malformations (Goldenberg et al. 2025).
  • Intramuscular angioma. In 74 intramuscular angiomas (mean age 17.6 years), almost all lesions were of mixed vessel type, often with one predominant vessel type, most often venous (42%). More than 90% contained a variably prominent adipocytic component, and more than half recurred (Beham and Fletcher 1991).
  • Cystic lymphatic malformation (cystic lymphangioma). Up to 90% present before the second year of life, mostly in the head, neck and axilla (Mišánik et al. 2024). Focal smooth muscle and lymphoid tissue in the cyst wall support the diagnosis in deep sites such as the mesentery (Kwak et al. 2024).
  • Lymphatic endothelial markers. D2-40 stained 10 of 10 lymphangiomas and 0 of 10 hemangiomas, whereas CD31 was absent in 5 of 10 lymphangiomas (Kahn et al. 2002). PROX1 was consistently expressed in lymphangiomas and venous hemangiomas and generally absent in capillary and cavernous hemangiomas (Miettinen and Wang 2012).
  • Anastomosing hemangioma (STB5). Anastomosing capillary-sized vessels with scattered hobnail endothelial cells form the lesion. Endothelial atypia, when present, is mild and never multilayered, which separates it from angiosarcoma (Sbaraglia et al. 2021).

Endothelial markers in vascular tumors of deep soft tissue

Marker Pattern Expression Source
ERG Nuclear Nearly all benign and malignant endothelial tumors, including 96% of angiosarcomas, nearly all epithelioid hemangioendotheliomas and all Kaposi sarcomas. Outside endothelium: a subset of prostatic adenocarcinomas, blastic extramedullary myeloid tumors and rare Ewing sarcomas Miettinen et al. 2011
CD31 Membranous All benign and malignant vascular lesions tested except glomus tumors (0 of 3) and half of lymphangiomas; 22 of 47 pseudomyogenic hemangioendotheliomas Kahn et al. 2002; Hornick and Fletcher 2011
CD34 Membranous Negative in all pseudomyogenic hemangioendotheliomas; 5 of 10 composite hemangioendotheliomas; inverse correlation with PROX1 Hornick and Fletcher 2011; Perry et al. 2017; Miettinen and Wang 2012
FLI1 Nuclear All pseudomyogenic and composite hemangioendotheliomas tested Hornick and Fletcher 2011; Perry et al. 2017
D2-40 (podoplanin) Membranous Lymphangiomas (10 of 10), Kaposi sarcoma (24 of 24), angiosarcoma (3 of 7); hemangiomas negative Kahn et al. 2002
PROX1 Nuclear Lymphangiomas, venous hemangiomas, Kaposi sarcoma, spindle cell hemangioma, kaposiform and retiform hemangioendothelioma, half of epithelioid hemangioendotheliomas, most cutaneous angiosarcomas; less often deep angiosarcomas Miettinen and Wang 2012
GLUT1 Membranous, endothelial Marker of infantile hemangioma; its use against malformations and angiosarcoma in Vascular Anomalies and Vascular Tumors of Skin, Kaposi Sarcoma and Angiosarcoma, Cutaneous Histiocytic and Mast Cell Infiltrates, and Metastases to Skin North et al. 2000
CAMTA1 Nuclear Surrogate for WWTR1::CAMTA1 in conventional epithelioid hemangioendothelioma (performance in Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing; hepatic tumors in Intrahepatic Cholangiocarcinoma, Biliary Cystic and Benign Tumors, Pediatric and Mesenchymal Liver Tumors, Metastases and Lymphoma) Doyle et al. 2016
TFE3 Nuclear Surrogate for YAP1::TFE3 in YAP1::TFE3 hemangioendothelioma (performance in Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing) Antonescu et al. 2013
FOSB Nuclear, diffuse in >50% of cells Surrogate for the FOSB fusions of pseudomyogenic hemangioendothelioma; also epithelioid hemangioma (performance in Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing) Hung et al. 2017
MYC (amplification) FISH Secondary angiosarcoma (Angiosarcoma, Lymphoma and Metastases in the Breast; Vascular Anomalies and Vascular Tumors of Skin, Kaposi Sarcoma and Angiosarcoma, Cutaneous Histiocytic and Mast Cell Infiltrates, and Metastases to Skin) Manner et al. 2010

Epithelioid hemangioendothelioma and YAP1::TFE3 hemangioendothelioma

  • Behavior category. Epithelioid hemangioendothelioma (EHE) is ranked with the malignant vascular tumors despite its name. Its overall metastatic rate is approximately 15%, and it is aggressive in the lung and pleura (Sbaraglia et al. 2021). YAP1::TFE3 hemangioendothelioma is classified as a separate malignant vascular neoplasm in STB6, with a more favorable outcome than conventional EHE. In STB5, the CAMTA1-related and TFE3-related tumors were two variants of EHE without a statistically significant difference in behavior (Hornick et al. 2026; Sbaraglia et al. 2021).
  • Genetics of conventional EHE. WWTR1::CAMTA1 from t(1;3)(p36.3;q25) is present at all sites and absent in epithelioid hemangioma and epithelioid angiosarcoma (Errani et al. 2011). YAP1::TFE3 defines a small subset (Doyle et al. 2016).
  • Morphology of conventional EHE. Epithelioid cells form cords and single files in a myxochondroid, hyaline or sclerotic stroma. Vasoformation is limited to intracytoplasmic lumina ("blister cells"), and the cytoplasm is glassy (Antonescu et al. 2013; Errani et al. 2011).
  • Risk stratification of soft tissue EHE. Tumors with >3 mitoses per 50 HPF and size >3.0 cm are high risk, and no patient with a low-risk tumor died. Cytologic atypia, necrosis, spindling and site did not predict survival (Deyrup et al. 2008).
Feature Conventional EHE YAP1::TFE3 hemangioendothelioma Epithelioid angiosarcoma of deep soft tissue Source
Patients and sites Adults (9–93 years in one series); extremities most often Young adults (mean 30 years); soft tissue, lung, bone Older men (mean 58 years); deep limb and limb-girdle muscle Deyrup et al. 2008; Antonescu et al. 2013; Fletcher et al. 1991
Architecture Cords and single cells in myxohyaline stroma; intracytoplasmic lumina only Solid areas with at least focal well-formed vascular channels Diffuse sheets with only focal vascular differentiation; intracytoplasmic lumina Antonescu et al. 2013; Fletcher et al. 1991
Cytoplasm Glassy, hyaline Abundant eosinophilic Epithelioid, vacuolated Antonescu et al. 2013; Hornick et al. 2026; Fletcher et al. 1991
Ancillary result WWTR1::CAMTA1; nuclear CAMTA1 YAP1::TFE3; strong nuclear TFE3 Keratin coexpressed with endothelial markers Errani et al. 2011; Doyle et al. 2016; Antonescu et al. 2013; Fletcher et al. 1991
Behavior Malignant; risk by mitoses and size Malignant (STB6); more favorable than conventional EHE High grade; rapid metastasis Deyrup et al. 2008; Hornick et al. 2026; Fletcher et al. 1991

Locally aggressive and rarely metastasizing hemangioendotheliomas

Tumor Clinical setting Histology Ancillary findings Behavior Source
Kaposiform hemangioendothelioma Infants and neonates; skin, deep soft tissue, retroperitoneum or thorax; thrombocytopenia Infiltrating, rounded, confluent nodules of spindled endothelial cells forming malformed lymphatic channels and slit-like lumina with erythrocytes, platelet thrombi, eosinophilic hyaline bodies and hemosiderin CD31, CD34, D2-40 and PROX1 positive; GLUT1 and HHV8 negative Kasabach–Merritt phenomenon in 71%; highest with retroperitoneal and intrathoracic tumors and with infiltration of muscle or deeper tissue Croteau et al. 2013; Ji et al. 2020; Miettinen and Wang 2012
Retiform hemangioendothelioma Young adults; limbs and trunk Long arborizing vessels in a rete testis-like pattern, monomorphic hobnail endothelium, prominent lymphocytes, focal papillae with hyaline cores PROX1 positive Frequent local recurrence; very low metastatic rate Calonje et al. 1994; Miettinen and Wang 2012
Composite hemangioendothelioma with neuroendocrine marker expression Ages 9–55 years; superficial and deep sites, including periaortic tissue, liver and vertebra Retiform hobnail channels with solid epithelioid areas resembling EHE; mitoses usually <1 per 10 HPF CD31, FLI1 and ERG positive; synaptophysin positive; keratin and CAMTA1 negative Metastasis in half of patients with follow-up; this subset is deeper and more aggressive than composite hemangioendothelioma in general Perry et al. 2017
Pseudomyogenic hemangioendothelioma Young adult men; lower limb; multifocal in two-thirds, across dermis, subcutis, muscle and bone Loose fascicles and sheets of plump spindle cells with abundant bright eosinophilic, rhabdomyoblast-like cytoplasm and a minority of epithelioid cells Keratin (AE1/AE3) and FLI1 positive; CD31 in about half; CD34 negative; INI1 retained; diffuse nuclear FOSB; SERPINE1::FOSB or ACTB::FOSB Local recurrence or new nodules in about half; distant metastasis rare Hornick and Fletcher 2011; Walther et al. 2014; Zhu et al. 2019; Hung et al. 2017
  • Epithelioid hemangioma genetics. FOS rearrangement was found in 17 of 58 epithelioid hemangiomas (29%), in 59% of those in bone and mostly in the cellular type, and in none of 12 with angiolymphoid hyperplasia with eosinophilia histology. FOS rearrangement helps separate cellular epithelioid hemangioma from malignant epithelioid vascular tumors (Huang et al. 2015).
  • Pseudomyogenic hemangioendothelioma versus epithelioid sarcoma. Both affect the distal limbs of young adults and express keratin. Pseudomyogenic hemangioendothelioma retains INI1 and lacks CD34 (Hornick and Fletcher 2011), whereas epithelioid sarcoma loses INI1 (Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others).

Angiosarcoma of deep soft tissue

  • Epithelioid angiosarcoma. This deep intramuscular tumor of the limbs and limb girdles of older men forms diffuse sheets of epithelioid cells with only focal vascular differentiation and intracytoplasmic vacuoles or lumina, sometimes containing red cells. All cases coexpressed keratin and endothelial markers, and the tumors metastasized rapidly. Intracytoplasmic lumina and the reticulin pattern separate it from metastatic carcinoma (Fletcher et al. 1991).
  • Primary versus secondary angiosarcoma. High-level MYC amplification separates angiosarcoma after irradiation or chronic lymphedema from primary angiosarcoma (Manner et al. 2010; Angiosarcoma, Lymphoma and Metastases in the Breast).
  • Markers. ERG was extensively expressed in 96 of 100 angiosarcomas (Miettinen et al. 2011). PROX1 is less common in deep and visceral angiosarcomas than in cutaneous angiosarcomas (Miettinen and Wang 2012).
  • Cardiac angiosarcoma. Cardiac angiosarcoma arises almost exclusively in the right heart (Neuville et al. 2014).

Pericytic (perivascular) tumors

Pericytic tumors grow around vessels and range from epithelioid (glomus tumor) to spindle cell (myopericytoma, myofibroma, angioleiomyoma) morphology. Most are benign. The diffuse forms, glomangiomatosis and myofibromatosis, cause significant local morbidity. Hemangiopericytoma is no longer a diagnosis; most such tumors are solitary fibrous tumors (Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma), and a hemangiopericytoma-like vascular pattern also occurs in myopericytoma, synovial sarcoma, MPNST and mesenchymal chondrosarcoma (Sbaraglia et al. 2021).

Tumor Clinical features Histology Immunohistochemistry and genetics Behavior Source
Glomus tumor Extremities; superficial or deep; rarely visceral Cells resembling the modified smooth muscle cells of the glomus body, arranged around vessels CD31 negative; NOTCH2 rearrangement (often MIR143::NOTCH2) in 52%, including all malignant tumors; BRAF V600E in 6%, all malignant or of uncertain malignant potential Benign unless the criteria for malignant glomus tumor or uncertain malignant potential are met Oide et al. 2016; Kahn et al. 2002; Mosquera et al. 2013; Karamzadeh Dashti et al. 2017
Myofibroma and myofibromatosis Most frequent fibrous tumor of children; multicentric form (myofibromatosis) is life-threatening Spindle cell perivascular (pericytic) growth pattern PDGFRB variants (Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma) are gain-of-function and imatinib-sensitive in vitro Multicentric disease is severe Dachy et al. 2019; Sbaraglia et al. 2021
SRF-rearranged myoid neoplasm (STB6; a subset was previously described as the atypical cellular variant of myofibroma, STB5) Ages 3 months to 63 years (mean 17) Densely packed oval to spindle cells with fibrillary eosinophilic cytoplasm in fascicles or nests around a rich vascular network; no pleomorphism or necrosis SRF fusions, mostly SRF::RELA; SMA and desmin coexpressed; myogenin negative Predominantly benign; mimics a myogenic sarcoma Antonescu et al. 2017; Hornick et al. 2026

Myopericytoma and angioleiomyoma, which arise mostly in the dermis and subcutis, are described in Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma.

The current WHO criteria for malignant glomus tumor, glomus tumor of uncertain malignant potential and symplastic glomus tumor (WHO 4th edition, 2013), with the Folpe 2001 rule beside them, are given in Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma.

  • Visceral glomus tumors. Visceral glomus tumors without malignant histology are classified as of uncertain malignant potential because of their deep location (Oide et al. 2016).
  • Behavior by WHO category. In 102 glomus tumors classified by WHO criteria, progressive disease occurred in 3 of 11 malignant tumors with follow-up and 2 of 4 tumors of uncertain malignant potential, and local recurrence in 3 of 44 benign tumors (Karamzadeh Dashti et al. 2017).
  • Glomangiomatosis. Diffuse angiomatosis with excess glomus cells did not metastasize (Folpe et al. 2001).

Smooth muscle tumors of deep soft tissue

  • Leiomyoma of deep somatic soft tissue. It is diagnosed only with stringent criteria: no atypia, no necrosis and no or minimal mitoses. It occurs in the limbs and trunk of either sex, is often calcified, was ER and PR negative in all 3 tumors tested, and does not recur (Billings et al. 2001).
  • Retroperitoneal and abdominal leiomyoma of women. It resembles uterine leiomyoma, may arise years after hysterectomy, was ER positive in 5 of 6 and PR positive in 6 of 6 tumors tested, tolerates up to about 10 mitoses per 50 HPF, and does not metastasize (Billings et al. 2001). These tumors express SMA, desmin and h-caldesmon and show nuclear WT1 (Miettinen 2014). Deep leiomyomas are therefore diagnosed by site-specific criteria (Billings et al. 2001).
  • Leiomyosarcoma: diagnosis. Nuclear atypia with essentially any mitotic activity defines leiomyosarcoma of deep soft tissue (Weiss 2002). Smooth muscle tumor of uncertain biologic potential is used for tumors that fit neither leiomyoma nor leiomyosarcoma, often on needle core biopsies (Miettinen 2014).
  • Leiomyosarcoma: sites. The retroperitoneum is the most common site, followed by deep somatic soft tissue (Weiss 2002) and the proximal limbs (Miettinen 2014). Leiomyosarcomas of deep somatic tissue commonly arise from small veins (Weiss 2002). Retroperitoneal leiomyosarcoma often arises from the inferior vena cava, and sometimes from the renal or iliac veins (Miettinen 2014).
  • Leiomyosarcoma: immunohistochemistry and genetics. SMA is nearly uniform. Desmin is positive in 70–80%, and most tumors express h-caldesmon and smooth muscle myosin (Miettinen 2014). h-caldesmon and smooth muscle myosin separate leiomyosarcoma from myofibroblastic sarcomas, which lack them. Absence of KIT separates leiomyosarcoma from GIST, although SMA and h-caldesmon occur in both. Karyotypes are complex, often aneuploid or polyploid, and no recurrent tumor-specific translocation is known (Miettinen 2014).
  • Leiomyosarcoma: prognosis. Age and grade predict the behavior of deep somatic leiomyosarcoma. Few factors are prognostic in retroperitoneal leiomyosarcoma, and nearly all are fatal (Weiss 2002).
  • Leiomyosarcoma of the inferior vena cava. It arises most often in the lower and middle caval segments. Upper-segment involvement, Budd–Chiari syndrome, intraluminal growth and caval occlusion predict death (Mingoli et al. 1996).
  • EBV-associated smooth muscle tumor. It arises after organ transplantation, in HIV infection or with other immunosuppression, is often multiple, and is EBER positive. Tumors are well differentiated, with primitive round cell areas and intratumoral T lymphocytes. Multiple tumors in one patient are clonally distinct and consistent with separate infection events, and histology does not predict outcome (Deyrup et al. 2006). HIV-associated tumors favor the central nervous system, post-transplant tumors favor the liver, and prognosis follows the course of immunosuppression (Sbaraglia et al. 2021).
  • Inflammatory rhabdomyoblastic tumor. STB6 reclassifies inflammatory leiomyosarcoma (STB5) as inflammatory rhabdomyoblastic tumor, a skeletal muscle neoplasm with near-haploidy (Hornick et al. 2026; Rhabdomyoma, Rhabdomyosarcoma and Risk Stratification, Ewing Sarcoma and Other Small Round Cell Sarcomas).

Myoid and perivascular spindle cell tumors of deep soft tissue compared

Tumor Key histology SMA Desmin Other discriminating results Source
Leiomyosarcoma Fascicles of atypical smooth muscle cells with mitoses Nearly uniform 70–80% h-caldesmon and smooth muscle myosin positive in most; KIT negative; complex karyotype Miettinen 2014
SRF-rearranged myoid neoplasm Dense fascicles or nests; no pleomorphism or necrosis Positive Positive SRF fusion; myogenin negative Antonescu et al. 2017
EBV-associated smooth muscle tumor Bland fascicles, primitive round cell areas, T lymphocytes All (actin) About half EBER positive Deyrup et al. 2006
Pseudomyogenic hemangioendothelioma Plump rhabdomyoblast-like spindle cells Focal in 14 of 42 Negative AE1/AE3, FLI1 and FOSB positive Hornick and Fletcher 2011; Hung et al. 2017

Rhabdomyoma, Rhabdomyosarcoma and Risk Stratification, Ewing Sarcoma and Other Small Round Cell Sarcomas

Definition and classification. Skeletal muscle tumors range from benign rhabdomyomas to rhabdomyosarcomas (RMS), the malignant tumors with skeletal muscle differentiation. The undifferentiated spindle and small round cell sarcomas of the WHO Classification of Soft Tissue and Bone Tumours, 6th edition (STB6, 2026), are Ewing sarcoma, NFATC2-rearranged sarcoma, sarcomas with BCOR genetic alterations and CIC-rearranged sarcoma (Hornick et al. 2026). In STB5, extrarenal rhabdoid tumor and desmoplastic small round cell tumor (DSRCT) were classified among the tumors of uncertain differentiation, and both enter the same differential diagnosis (Sbaraglia et al. 2021).

Related page: Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing (molecular methods, FNCLCC grading and AJCC staging of adult sarcomas) Related page: Vascular Anomalies and Vascular Tumors, Perivascular Tumors, and Smooth Muscle Tumors of Deep Soft Tissue (leiomyosarcoma and SRF-rearranged myoid neoplasm in the differential of spindle cell RMS) Related page: Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others (synovial sarcoma, epithelioid sarcoma, myoepithelial tumors and FET-CREB family tumors) Related page: Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder (rhabdomyosarcoma of the bladder) Related page: Pediatric, Mesenchymal and Other Renal Tumors, Nephrectomy Grossing, WHO/ISUP Grading and Kidney Cancer Staging (rhabdoid tumor of the kidney, clear cell sarcoma of the kidney and Wilms tumor) Related page: Ovarian, Tubal and Peritoneal Cancer Staging and Reporting, Peritoneal Lesions and Metastases to the Ovary (peritoneal desmoplastic small round cell tumor) Related page: Uterine Mesenchymal Tumors: Smooth Muscle Tumors, Endometrial Stromal Tumors, Adenosarcoma and Other Sarcomas (BCOR-altered sarcoma of the uterus) Related page: Intrahepatic Cholangiocarcinoma, Biliary Cystic and Benign Tumors, Pediatric and Mesenchymal Liver Tumors, Metastases and Lymphoma (undifferentiated embryonal sarcoma of the liver) Related page: Pheochromocytoma, Paraganglioma, Hereditary Paraganglioma Syndromes, Neuroblastic Tumors and the Classification of Neuroendocrine Neoplasms (neuroblastoma) Related page: Lymphoblastic Lymphoma in Cytology (lymphoblastic lymphoma) Related page: Lung Neuroendocrine Neoplasms: Typical and Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, Small Cell Carcinoma and DIPNECH (small cell carcinoma) Related page: Round Cell, Spindle Cell and Pleomorphic Sarcomas on FNA (round cell sarcomas on FNA) Related page: Molecular and Ancillary Testing of Soft Tissue FNA Material (fusion testing on cytology material) Related page: Bone FNA (Ewing sarcoma and other bone tumors on FNA) Related page: Keratoacanthoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma and Merkel Cell Carcinoma: Subtypes, Risk Stratification, Staging, CAP Reporting and Mohs Surgery (Merkel cell carcinoma) Related page: Molecular Oncology of Solid Tumors: Oncogenes and Tumor Suppressors, MSI and Mismatch Repair, Tumor Mutational Burden, Tumor-Agnostic and Organ Biomarkers, CNS Tumor Molecular Testing and Germline Findings on Tumor Sequencing (sarcoma translocation testing methods) Related page: Cytogenetics and Cytogenomics: Karyotype and ISCN Nomenclature, Chromosome Abnormalities, FISH, Chromosomal Microarray, Optical Genome Mapping, and Constitutional, Prenatal and Cancer Cytogenetics (FISH and karyotype methods)

STB6 changes in skeletal muscle tumors and round cell sarcomas, with the STB5 rules

Element STB6 (current) STB5 (previous) Source
Spindle cell and sclerosing RMS Split into fusion-associated spindle cell RMS and MYOD1-mutant spindle cell/sclerosing RMS (soft tissue chapter) and TFCP2-rearranged RMS (bone chapter) One entity, spindle cell/sclerosing RMS Hornick et al. 2026
Inflammatory rhabdomyoblastic tumor New intermediate (rarely metastasizing) skeletal muscle tumor with near-haploidy Inflammatory leiomyosarcoma, a smooth muscle tumor Hornick et al. 2026; Sbaraglia et al. 2021
Ectomesenchymoma Removed; now embryonal RMS with divergent neuroectodermal differentiation Separate entity Hornick et al. 2026
Round cell sarcoma chapter Undifferentiated spindle and small round cell sarcomas, because some show spindle cell morphology Undifferentiated small round cell sarcomas of bone and soft tissue Hornick et al. 2026; Sbaraglia et al. 2021
Round cell sarcomas with EWSR1–non-ETS fusions Split into NFATC2-rearranged sarcoma (round cell chapter) and PATZ1-rearranged sarcoma (tumors of uncertain differentiation) One category Hornick et al. 2026

Rhabdomyoma: adult, fetal and genital types

Rhabdomyomas are benign skeletal muscle tumors divided into cardiac and extracardiac types. Extracardiac rhabdomyomas favor the head and neck and genital sites and are subclassified as adult, fetal and genital rhabdomyomas (Acosta et al. 2022).

Type Patients and sites Features Source
Adult rhabdomyoma Head and neck most often Benign Arega et al. 2025; Acosta et al. 2022
Fetal rhabdomyoma Head and neck most often, including children Local excision gave favorable outcomes in 3 pediatric cases Arega et al. 2025; Acosta et al. 2022
Genital rhabdomyoma Middle-aged women; vagina and cervix; small (<2 cm) Benign; does not recur; separated from fetal rhabdomyoma by age and site Schoolmeester et al. 2018
Paratesticular (sclerosing) rhabdomyoma Paratesticular tissue Distinctive sclerosing morphology Acosta et al. 2022

Fetal rhabdomyoma versus well-differentiated embryonal RMS. Increased mitoses (>15 per 50 HPF), marked hypercellularity, a cambium layer and atypical nuclei favor RMS (CAP RMS 2025).

Rhabdomyosarcoma subtypes

Subtype Patients and sites Histology Immunohistochemistry Genetics Behavior Source
Embryonal RMS (typical, dense and botryoid patterns) More than half of all RMS; botryoid pattern beside epithelium of bladder (Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder), vagina, nasal cavity, sinuses and biliary tract Round, stellate or spindled cells in alternating hypo- and hypercellular myxoid areas; tadpole and strap cells; cross-striations in fewer than half; cambium layer of condensed rhabdomyoblasts beneath intact epithelium in botryoid tumors Myogenin in fewer than half of nuclei; AP2β absent; strong diffuse HMGA2 Nearly always FOXO1 fusion-negative (>95%); DICER1-associated in the uterine corpus and cervix (Uterine Mesenchymal Tumors: Smooth Muscle Tumors, Endometrial Stromal Tumors, Adenosarcoma and Other Sarcomas) Fusion-negative status carries a better outcome than fusion-positive status CAP RMS 2025; Hibbitts et al. 2019
Alveolar RMS Pediatric patients; FOXO1 fusion-positive tumors are unfavorable at any site Discohesive round cells with lymphocyte-like nuclei lining thin fibrous septa; solid pattern; multinucleated myoblasts Strong diffuse myogenin (typically >80%) and AP2β; weak or absent HMGA2 PAX3::FOXO1 t(2;13)(q35;q14) or PAX7::FOXO1 t(1;13)(p36;q14) in about 80% (60% and 20%); about 15%–20% of histologic alveolar RMS are fusion-negative Fusion testing required for risk stratification in all cases CAP RMS 2025; Hibbitts et al. 2019
  • Embryonal RMS with divergent neuroectodermal differentiation. STB6 removes ectomesenchymoma as an entity and classifies it as a subtype of embryonal RMS with intermixed neuroblastic elements (Hornick et al. 2026). The tumor consists of RMS, embryonal more often than alveolar, with a ganglionic or neuroblastic component. Age, sex, site and outcome resemble embryonal RMS, and RMS-based therapy is used (CAP RMS 2025).
  • Pleomorphic RMS in adults. Pleomorphic RMS is a high-grade sarcoma of middle-aged adults, mostly men (28 of 38; median age 54 years), usually in the lower extremity. Scattered large pleomorphic rhabdomyoblasts with at least one skeletal muscle-specific marker establish the diagnosis; desmin was positive in 36 of 38 tumors and myogenin in 19 of 34. Classic, round cell and spindle cell patterns occur, and 70% of patients with follow-up died of disease (Furlong et al. 2001).
  • Pleomorphic RMS in children. Pleomorphic RMS is exceedingly rare in children, and many pediatric cases are better considered RMS with diffuse anaplasia (CAP RMS 2025).
  • Mixed alveolar and embryonal RMS. Rare tumors combine both patterns with differential myogenin expression. They are fusion-positive (most often PAX7::FOXO1) or fusion-negative, with the same genetic profile in both components (CAP RMS 2025).
  • RMS, not otherwise specified. The term is reserved for RMS confirmed by immunohistochemistry that cannot be subclassified because of necrosis, crush or other limits of the specimen (CAP RMS 2025).

Spindle cell and sclerosing RMS: STB6 subtypes with the STB5 rule

Under STB5 and CAP RMS 2025, spindle cell/sclerosing RMS is one histologic category (3%–10% of RMS) with three genetic subtypes. A dominant (at least 80%) spindled or sclerosing pattern is required, because small spindled or sclerosing foci are common in embryonal RMS. Sclerosing RMS shows dense hyalinized collagen with round or spindle cells in nests, single files and pseudovascular microalveolar profiles. These tumors may show only focal desmin and myogenin but typically express MYOD1 strongly (CAP RMS 2025). STB6 separates the genetic subtypes into entities (Hornick et al. 2026).

STB6 entity Patients and sites Morphology Genetics Behavior Source
Fusion-associated spindle cell RMS Congenital and infantile tumors; 10 of 11 congenital or infantile cases were fusion-positive Monomorphic fascicular spindle cells, sometimes smooth muscle-like; at least 2 skeletal muscle markers VGLL2 fusions (VGLL2::CITED2, VGLL2::NCOA2), NCOA2 fusions (TEAD1::NCOA2, SRF::NCOA2) and fusions involving ZFP64, NCOA3, VGLL3 and CITED2 All fusion-positive infantile patients with long-term follow-up in one series were alive without metastasis; a later series found recurrence, metastasis and death in a subset, including late events; prognosis varies by fusion Alaggio et al. 2016; CAP RMS 2025; Hornick et al. 2026
MYOD1-mutant spindle cell/sclerosing RMS Adolescents and adults more than children (15 of 30 were children in the largest series); head and neck, especially parameningeal Pure sclerosing, pure spindle cell or hybrid with primitive areas; MYOD1 typically diffuse and intense MYOD1 p.L122R Aggressive, with frequent local and distant recurrence and death from disease in children and adults Agaram et al. 2019; CAP RMS 2025; Hornick et al. 2026
TFCP2-rearranged RMS (bone chapter) Predilection for maxillofacial bones Epithelioid, spindle or mixed cells with skeletal muscle differentiation EWSR1::TFCP2 or FUS::TFCP2; keratin and ALK coexpressed without ALK rearrangement Highly aggressive Hornick et al. 2026; Sbaraglia et al. 2021
  • Alternative fusion in intraosseous RMS (STB5). The STB5 summary noted an alternative MEIS1::NCOA2 fusion in primary intraosseous RMS (Sbaraglia et al. 2021).
  • Spindle cell RMS without a recurrent alteration. All 5 fusion- and mutation-negative pediatric spindle cell RMS in one series were intra-abdominal or paratesticular (Alaggio et al. 2016). Spindle cell RMS accounts for 26.7% of paratesticular RMS, has excellent 5-year survival and is regarded by CAP as possibly a spindled embryonal RMS (CAP RMS 2025).
  • Differential diagnosis of spindle cell RMS. It includes leiomyosarcoma, fibrosarcoma, undifferentiated spindle cell sarcoma, rhabdomyoma, leiomyoma and nodular fasciitis. MYOD1, myogenin and myoglobin establish skeletal muscle differentiation. Sclerosing RMS mimics sclerosing epithelioid fibrosarcoma, infiltrating carcinoma, osteosarcoma and angiosarcoma (CAP RMS 2025).

Inflammatory rhabdomyoblastic tumor

STB6 defines inflammatory rhabdomyoblastic tumor as an intermediate (rarely metastasizing) neoplasm with skeletal muscle differentiation, a marked lymphohistiocytic infiltrate and near-haploidization. Spindled or epithelioid cells with eosinophilic cytoplasm show variable atypia and low mitotic activity. Progression to RMS shows high mitotic activity and often necrosis (Hornick et al. 2026). Under STB5 the same tumors were inflammatory leiomyosarcoma: low-grade smooth muscle cells overshadowed by a lymphoplasmacytic or xanthomatous histiocytic infiltrate in the deep soft tissue of the lower limbs, trunk and retroperitoneum of adults in the third and fourth decades (Sbaraglia et al. 2021).

Immunohistochemistry, anaplasia and treatment effect in RMS

  • Myogenic markers. Nearly all RMS express desmin and nuclear myogenin and MYOD1. Desmin is also frequent in blastemal Wilms tumor, tenosynovial giant cell tumor and DSRCT. Myogenin is more specific but occurs in melanotic neuroectodermal tumor of infancy, Wilms tumor, teratoma, pleuropulmonary blastoma and MPNST with rhabdomyoblastic differentiation, and in injured skeletal muscle at the tumor interface (CAP RMS 2025).
  • Anaplasia. Anaplastic cells have large, lobate, hyperchromatic nuclei at least 3 times the size of neighboring nuclei, or atypical multipolar mitoses, visible with a 10× objective. Focal anaplasia is single or scattered cells; diffuse anaplasia is clusters or sheets. Anaplasia occurs in up to 16% of RMS, is not an independent adverse prognostic factor, and is associated with TP53 mutation (69% of TP53-mutated tumors were anaplastic); germline TP53 screening may be indicated (CAP RMS 2025).
  • Treatment effect. RMS may show extensive cytodifferentiation after therapy, more often in embryonal RMS. Matured cells appear to have little malignant potential (CAP RMS 2025).
  • Mimics of embryonal RMS. Undifferentiated embryonal sarcoma of the liver generally lacks MYOD1 and myogenin and contains hyaline globules. Tenosynovial giant cell tumor lacking giant cells is desmin positive but CD68 positive and myogenin negative. Pseudosarcomatous fibroepithelial polyps of the lower female genital tract express desmin but lack a cambium layer, striated cells and myogenin (CAP RMS 2025).
  • Predisposition. Embryonal RMS or another soft tissue sarcoma within the first 2 years of life raises concern for Li–Fraumeni syndrome, basal cell nevus syndrome, neurofibromatosis and DICER1-related pleuropulmonary blastoma syndrome. A genetic predisposition is present in 7%–33% of children with soft tissue sarcoma (CAP RMS 2025).

Risk stratification of pediatric RMS by FOXO1 fusion status

FOXO1 fusion status, in place of histology, now drives prognosis and risk stratification in childhood RMS (CAP RMS 2025). In 1727 patients from Children's Oncology Group (COG) trials, metastatic disease was the strongest adverse factor and fusion-positive status the second, in both localized and metastatic disease (Hibbitts et al. 2019).

Proposed risk group (Hibbitts 2019) Definition Source
Low (5-year EFS ≥90%) Clinical group I, favorable site, fusion-negative Hibbitts et al. 2019
Intermediate (5-year EFS ≥40% to <90%) Groups II–III, favorable site, fusion-negative Hibbitts et al. 2019
Intermediate Groups I–III, unfavorable site, fusion-negative Hibbitts et al. 2019
Intermediate Groups I–III, fusion-positive Hibbitts et al. 2019
Intermediate Group IV, fusion-negative, one metastatic site Hibbitts et al. 2019
High (5-year EFS <40%) Group IV, fusion-negative, more than one metastatic site Hibbitts et al. 2019
High Group IV, fusion-positive Hibbitts et al. 2019
  • Favorable and unfavorable sites. Favorable sites are the orbit, head and neck excluding parameningeal sites, genitourinary sites excluding bladder and prostate, and the biliary tract and liver. Unfavorable sites are the bladder and prostate, extremity, cranial parameningeal and other sites, including trunk, retroperitoneum and pelvis (Hibbitts et al. 2019).
  • Previous risk assignment. The COG D-series and ARST-series trials (1997–2013) assigned risk by histology, stage and clinical group: low risk was limited to embryonal RMS, and alveolar RMS of stage 1–3, group I–III was intermediate risk (Hibbitts et al. 2019).
  • AJCC staging. AJCC and UICC TNM staging do not apply to pediatric RMS. Adult RMS is reported with the soft tissue protocol and AJCC staging (CAP RMS 2025).

Intergroup Rhabdomyosarcoma Study postsurgical clinical grouping (CAP RMS 2025)

Group Definition
IA Localized tumor, confined to site of origin, completely resected
IB Localized tumor, infiltrating beyond site of origin, completely resected
IIA Localized tumor, gross total resection, but with microscopic residual disease
IIB Locally extensive tumor (spread to regional lymph nodes), completely resected
IIC Locally extensive tumor (spread to regional lymph nodes), gross total resection, but microscopic residual disease
IIIA Localized or locally extensive tumor, gross residual disease after biopsy only
IIIB Localized or locally extensive tumor, gross residual disease after major resection (greater than 50% debulking)
IV Any size primary tumor, with or without regional lymph node involvement, with distant metastases, without respect to surgical approach to primary tumor

Modified site, size and metastasis staging for RMS (pretreatment clinical stage; CAP RMS 2025)

Stage Requirements
1 Favorable site (biliary tract or liver, orbit, head and neck excluding parameningeal, or genitourinary site excluding bladder and prostate), and no distant metastasis
2 Unfavorable site (bladder or prostate, extremity, parameningeal or other site not in stage 1), tumor ≤5 cm, no lymph node involvement and no distant metastasis
3 Unfavorable site, ≤5 cm with regional lymph node involvement and no distant metastasis; or unfavorable site, >5 cm with or without regional lymph node involvement and no distant metastasis
4 Distant metastases present

CAP rhabdomyosarcoma protocol 5.0.0.1

Element Content Source
Scope Resections from pediatric patients with all RMS variants and ectomesenchymoma; biopsies use the companion biopsy protocol; adult RMS uses the soft tissue protocol CAP RMS 2025
Tissue submission At least 100 mg of viable tumor snap-frozen when feasible; FISH or RT-PCR for fusion status on paraffin, frozen tissue or touch preparations CAP RMS 2025
Procedure Marginal, wide local or radical resection, or amputation; inking and orientation before cutting are mandatory CAP RMS 2025
Tumor Site (bile duct, bladder/prostate, cranial/parameningeal, extremity, other genitourinary, head and neck, orbit, other), size, histologic type (embryonal, alveolar, spindle cell/sclerosing, ectomesenchymoma, RMS NOS), anaplasia (focal or diffuse), and optional treatment effect and therapy-induced cytodifferentiation percentages CAP RMS 2025
Margins, nodes and metastasis Margin status, closest margin and distance; nodes examined and involved; distant sites CAP RMS 2025
Pathologic stage IRS clinical group and modified site, size and metastasis stage, assigned by the pathologist when the information is available CAP RMS 2025
Gene fusion studies No FOXO1 rearrangement, or FOXO1 rearrangement with PAX3, PAX7 or an unknown or variant partner (such as PAX3::NCOA1), and the method CAP RMS 2025
Optional molecular studies DICER1 mutation, MYOD1 p.L122R, VGLL2 or NCOA2 fusions, EWSR1::TFCP2 or FUS::TFCP2 fusion CAP RMS 2025
Version change 5.0.0.1 (June 2025): accreditation statement and electronic explanatory note links updated. 5.0.0.0 (September 2023): protocol updated for the accreditation requirement. The required case summary elements are the same in both versions CAP RMS 2025; CAP RMS 2023

Ewing sarcoma of bone and soft tissue

  • Definition and genetics. The 2020 WHO classification defines Ewing sarcoma as a round cell sarcoma with a FET-ETS gene fusion. EWSR1 (22q12) fuses with FLI1 (11q24) in 90%–95% and with ERG (21q22) in 5%–10%. Other EWSR1 or FUS fusions with ETS partners such as ETV1, ETV4 and FEV make up 5%–10%. The specific fusion and exon type do not influence treatment or outcome (CAP Ewing 2025).
  • Histology. Lobules of monotonous round cells have nuclei 10–15 µm across with distinct membranes, finely granular chromatin and 1–2 inconspicuous nucleoli, and scant pale cytoplasm that may be vacuolated by glycogen. Multinucleated giant cells are absent. Necrosis with ghost cells can dominate a biopsy. Homer Wright rosettes and, rarely, Flexner–Wintersteiner rosettes or ganglionic differentiation occur. In the adamantinoma-like pattern, most common in the head and neck, keratin may be diffusely positive. No histologic pattern has established prognostic value, and extraosseous Ewing sarcoma is treated like intraosseous Ewing sarcoma (CAP Ewing 2025).
  • CD99. Membranous CD99 is diffuse in virtually all Ewing sarcomas. CD99 also occurs in lymphoblastic lymphoma, RMS, synovial sarcoma, solitary fibrous tumor, rhabdoid tumor, neuroendocrine tumors, DSRCT and mesenchymal chondrosarcoma, with membranous staining in lymphoblastic lymphoma, some poorly differentiated synovial sarcomas and alveolar RMS. Muscle, S100, epithelial, INI1 and lymphoid markers (CD45, CD30, TdT) accompany CD99 (CAP Ewing 2025).
  • NKX2.2. NKX2.2, a transcriptional target of EWSR1::FLI1, is a nuclear marker of Ewing sarcoma that also stains olfactory neuroblastoma, extraskeletal myxoid chondrosarcoma, mesenchymal chondrosarcoma, small cell carcinoma and Merkel cell carcinoma, and combined CD99 and NKX2.2 is highly specific (Shibuya et al. 2014; figures in Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing).
  • Molecular testing strategy. EWSR1 (or FUS) FISH is a useful first step but is not diagnostic alone, because EWSR1 rearrangements also occur in angiomatoid fibrous histiocytoma, clear cell sarcoma, DSRCT, extraskeletal myxoid chondrosarcoma, some myxoid liposarcomas and myoepithelial carcinoma. A negative RT-PCR for EWSR1::FLI1 or EWSR1::ERG does not exclude Ewing sarcoma; a negative result may reflect a true absence, test failure (FISH can miss EWSR1::ERG) or a mismatch between test and fusion (CAP Ewing 2025).

Prognostic factors in Ewing sarcoma (CAP Ewing 2025)

Factor Favorable Unfavorable Source
Age <18 years ≥18 years CAP Ewing 2025
Site Distal or proximal extremity Pelvis CAP Ewing 2025
Size <8 cm ≥8 cm CAP Ewing 2025
Stage Nonmetastatic Metastatic CAP Ewing 2025

CAP Ewing sarcoma protocol 5.0.0.1

Element Content Source
Scope Resections from pediatric patients with osseous and extraosseous Ewing sarcoma; adult Ewing sarcoma uses the bone or soft tissue protocol with AJCC staging; round cell sarcomas with EWSR1–non-ETS fusions, CIC-rearranged and BCOR-altered sarcomas use the bone or soft tissue protocols CAP Ewing 2025
Tissue handling Fresh tissue preferred; formalin-fixed tissue for morphology first; at least one block without decalcification or decalcified in EDTA or EDTA-acid to preserve nucleic acids, because pure acid decalcification degrades them; fresh tissue for cytogenetics and at least 100 mg snap-frozen when needed CAP Ewing 2025
Gross examination of bone resections Inking and orientation by the surgeon; soft tissue and marrow margins taken before sectioning; a full sagittal section through the greatest dimension, photographed and mapped for microscopic examination and the necrosis estimate CAP Ewing 2025
Tumor Multiple primary sites, osseous or extraosseous site, size, sites involved by direct extension (epiphysis or apophysis, metaphysis, diaphysis, cortex, medullary cavity, surface, joint, soft tissue), lymphatic and/or vascular invasion, treatment effect with percentage CAP Ewing 2025
Margins Any tumor at the margin, viable or treated, is positive; treated tumor at the margin is reported. Adequate margins: cortical bone 2–5 cm; fascia, periosteum and intermuscular septa 2 mm; fat, muscle and medullary bone 5 mm CAP Ewing 2025
Necrosis after therapy Harder to assess than in osteosarcoma because no acellular osteoid framework marks the tumor bed; not formally used to guide therapy, but the estimated percentage is reported CAP Ewing 2025
Staging AJCC 8th edition bone or soft tissue TNM may be used; presence or absence of metastasis is the main factor in pediatric staging and treatment CAP Ewing 2025
Cytogenetic findings EWSR1 rearrangement with unknown partner, EWSR1::FLI1, EWSR1::ERG, non-EWSR1 variant, or no rearrangement, with the method CAP Ewing 2025
Version change 5.0.0.1 (June 2025): "Lymphovascular Invasion" renamed "Lymphatic and/or Vascular Invasion"; the staging heading reads "pTNM Classification (AJCC 8th Edition)"; accreditation statement and electronic note links updated. 5.0.0.0 (September 2023): protocol updated for the accreditation requirement CAP Ewing 2025; CAP Ewing 2023

CIC-rearranged, BCOR-altered, NFATC2-rearranged and PATZ1-rearranged sarcomas

Sarcoma Patients and sites Morphology Immunohistochemistry Genetics Behavior Source
CIC-rearranged sarcoma Young adults; deep soft tissue of trunk and extremities, rarely viscera or bone Round to ovoid cells with focal spindle and epithelioid or rhabdoid areas in half; focal pleomorphism; myxoid stroma; geographic necrosis in 84% CD99 patchy, rarely diffuse; nuclear WT1; strong diffuse nuclear ETV4, with only focal weak staining in mimics CIC::DUX4 (DUX4 on 4q35 or 10q26) More aggressive than Ewing sarcoma (5-year survival 43% versus 77%) Antonescu et al. 2017; Le Guellec et al. 2016; Sbaraglia et al. 2021
Sarcoma with BCOR genetic alteration (BCOR::CCNB3 prototype) Children and adolescents, strongly male; bone more than soft tissue Round to spindle cells with monomorphic nuclei and fine chromatin, a delicate capillary network and myxoid or collagenous stroma; spindled morphology common BCOR, SATB2, cyclin D1 and TLE1 BCOR::CCNB3; BCOR internal tandem duplication and BCOR::MAML3 tumors share morphology and immunophenotype; molecular confirmation essential in STB6 Survival similar to Ewing sarcoma and better than CIC-rearranged sarcoma Kao et al. 2018; Hornick et al. 2026; Sbaraglia et al. 2021
NFATC2-rearranged sarcoma (STB6; STB5 round cell sarcoma with EWSR1–non-ETS fusion) Bone predominant (metaphysis or diaphysis of long bones); strong male predominance; young to middle-aged adults Round and spindle cells in a fibrohyaline stroma; epithelioid features CD99 almost always (diffuse in about half); NKX2.2 and PAX7 positive in EWSR1::NFATC2 tumors, a pitfall for Ewing sarcoma; NKX3.1 in most EWSR1::NFATC2 sarcomas; AGGRECAN regardless of partner; NKX2.2, PAX7 and NKX3.1 usually negative with FUS::NFATC2 EWSR1::NFATC2 or FUS::NFATC2; EWSR1 rearrangement with concomitant amplification by FISH is highly suggestive Local and distant recurrence; poor response to Ewing sarcoma chemotherapy Hornick et al. 2026; Machado et al. 2024; Sbaraglia et al. 2021
PATZ1-rearranged sarcoma (STB6 tumor of uncertain differentiation; STB5 round cell sarcoma with EWSR1–non-ETS fusion) Wide age range; deep soft tissue of the chest wall and abdomen Round and spindle cells; sclerotic background Coexpression of neural markers (S100 and GFAP in most; SOX10 in some) and myogenic markers (desmin, MYOD1, PAX7; myogenin in some); NKX2.2 and NKX3.1 negative EWSR1::PATZ1; the same fusion occurs in some CNS tumors and thyroid-like follicular carcinoma of the kidney Aggressive in most reported cases Hornick et al. 2026; Machado et al. 2024; Sbaraglia et al. 2021
  • BCOR immunohistochemistry pitfalls. Both synovial sarcoma and BCOR::CCNB3 sarcoma express TLE1, and SATB2 occurs in 12% of synovial sarcomas. Cyclin D1 is expressed in both Ewing sarcoma and BCOR::CCNB3 sarcoma (Kao et al. 2018).
  • NFATC2 fusions outside sarcoma. Identical EWSR1::NFATC2 and FUS::NFATC2 fusions occur in simple bone cysts and osseous vascular tumors, without EWSR1 amplification (Machado et al. 2024).

Extrarenal rhabdoid tumor and rhabdoid tumor predisposition

  • Clinical and histologic features. Malignant rhabdoid tumor of soft tissue is a highly aggressive tumor of infancy and childhood in deep axial sites such as the neck and paraspinal region. Sheets and nests of rounded or polygonal cells have eccentric nuclei, prominent nucleoli and glassy eosinophilic cytoplasm with hyaline-like inclusions (Oda and Tsuneyoshi 2006).
  • Immunohistochemistry and genetics. The tumor expresses vimentin, keratin and EMA, and SMARCB1 on the long arm of chromosome 22 is altered (Oda and Tsuneyoshi 2006). INI1 expression was absent in all 10 control rhabdoid tumors of brain, liver, soft tissue and kidney (Hornick et al. 2009). Rhabdoid cells also occur in synovial sarcoma, extraskeletal myxoid chondrosarcoma and leiomyosarcoma (Oda and Tsuneyoshi 2006).
  • Versus proximal-type epithelioid sarcoma. Both show rhabdoid morphology, keratin and EMA expression and SMARCB1 alteration. Proximal-type epithelioid sarcoma (Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others) is occasionally positive for CD34 and β-catenin, which rhabdoid tumor lacks (Oda and Tsuneyoshi 2006).
  • Rhabdoid tumor predisposition syndrome. Germline SMARCB1 variants (type 1) or SMARCA4 variants (type 2) underlie the syndrome. Among newly diagnosed rhabdoid tumors, 25%–35% carry a germline SMARCB1 variant. Affected children usually present before 1 year of age, and 35% develop synchronous or multifocal tumors. The syndrome is considered in any patient with rhabdoid tumor, especially with multiple primary tumors or a family history, and genetic counseling and surveillance of family members are recommended (Del Baldo et al. 2021).

Desmoplastic small round cell tumor

  • Clinical features. DSRCT arises from the abdominal serosa of adolescent and young adult males, with peritoneal implants (Mello et al. 2021; peritoneal series in Ovarian, Tubal and Peritoneal Cancer Staging and Reporting, Peritoneal Lesions and Metastases to the Ovary).
  • Histology. Solid sheets, nests, clumps or cords of cohesive small round, ovoid or spindled cells with inconspicuous nucleoli and scant cytoplasm lie in a hypocellular desmoplastic collagenous stroma (Mello et al. 2021).
  • Immunohistochemistry. The tumor expresses desmin, EMA, keratins (AE1/AE3 and CAM5.2) and neural markers (neuron-specific enolase, CD57), less often chromogranin, synaptophysin, CD56, neurofilament and S100 protein. Nuclear WT1 is detected with antibodies to the carboxy terminus. The immunoprofile is polyphenotypic and varies within and between tumors (Mello et al. 2021). Desmin shows a perinuclear dot pattern, present in 81% of 32 tumors in one series, with keratin in 87% (Lae et al. 2002).
  • Genetics. The EWSR1::WT1 fusion is the defining alteration and acts as a transcriptional activator of growth factor genes. The fusion protein induces PDGFRA, which accounts for the desmoplastic stroma (Mello et al. 2021).

Small round cell tumors of soft tissue and bone: immunohistochemical panel and distinguishing findings

A first panel combines CD99, NKX2.2, desmin, myogenin or MYOD1, WT1, keratin, CD45, TdT and INI1, followed by fusion testing by FISH, RT-PCR or RNA sequencing (CAP Ewing 2025; CAP RMS 2025). Because the round cell sarcomas are defined largely by their fusion genes, an NGS-based molecular approach is preferred (Sbaraglia et al. 2021).

Tumor Distinguishing findings Source
Ewing sarcoma Monotonous lobular round cells; diffuse membranous CD99; NKX2.2; FET-ETS fusion CAP Ewing 2025; Shibuya et al. 2014
CIC-rearranged sarcoma Focal pleomorphism, myxoid stroma and necrosis; patchy CD99; nuclear WT1 and ETV4 Antonescu et al. 2017; Le Guellec et al. 2016
Sarcoma with BCOR genetic alteration Monomorphic round to spindle cells with delicate capillaries; BCOR, SATB2 and cyclin D1 Kao et al. 2018
NFATC2-rearranged sarcoma Bone; fibrohyaline stroma; NKX2.2 positive, mimicking Ewing sarcoma; NKX3.1 and AGGRECAN; EWSR1 rearrangement with amplification Hornick et al. 2026; Machado et al. 2024
Alveolar RMS Round cells along fibrous septa; desmin, strong diffuse myogenin and MYOD1; membranous CD99 in some CAP RMS 2025; CAP Ewing 2025
Embryonal RMS, dense pattern Hypercellular embryonal RMS; myogenin in fewer than half of nuclei; HMGA2 strong; fusion-negative CAP RMS 2025
DSRCT Abdominal serosa; nests in desmoplastic stroma; dot-like desmin, keratin, EMA and C-terminal WT1; EWSR1::WT1 Mello et al. 2021; Lae et al. 2002
Extrarenal rhabdoid tumor Infant; axial site; rhabdoid cells with hyaline inclusions; keratin and EMA; INI1 lost Oda and Tsuneyoshi 2006; Hornick et al. 2009
Poorly differentiated synovial sarcoma (Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others) SS18-SSX fusion-specific and SSX C-terminal antibodies positive Baranov et al. 2020
Neuroblastoma (Pheochromocytoma, Paraganglioma, Hereditary Paraganglioma Syndromes, Neuroblastic Tumors and the Classification of Neuroendocrine Neoplasms) Neuroblastic cells in nests separated by delicate, often incomplete septa with Schwannian stroma <50% CAP Neuroblastoma 2025
Lymphoblastic lymphoma (Lymphoblastic Lymphoma in Cytology) Distinct membranous CD99, mimicking Ewing sarcoma; CD45 and TdT among the lymphoid markers that separate it CAP Ewing 2025
Small cell carcinoma (Lung Neuroendocrine Neoplasms: Typical and Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, Small Cell Carcinoma and DIPNECH) and Merkel cell carcinoma (Keratoacanthoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma and Merkel Cell Carcinoma: Subtypes, Risk Stratification, Staging, CAP Reporting and Mohs Surgery) NKX2.2 positive in some; one small cell carcinoma coexpressed CD99 and NKX2.2 Shibuya et al. 2014
Mesenchymal chondrosarcoma CD99 positive; NKX2.2 in some, with CD99 and NKX2.2 coexpressed in one case; NKX3.1 and AGGRECAN in the primitive round cells; PAX7 usually negative; HEY1::NCOA2 fusion helps confirm it CAP Ewing 2025; Shibuya et al. 2014; Machado et al. 2024; Sbaraglia et al. 2021

Peripheral Nerve Sheath Tumors: Schwannoma, Neurofibroma and ANNUBP, Perineurioma, Granular Cell Tumor and MPNST

Definition and classification. Peripheral nerve sheath tumors show Schwann cell, perineurial or mixed nerve sheath differentiation and range from benign schwannoma, neurofibroma and perineurioma to malignant peripheral nerve sheath tumor (MPNST) (Rodriguez et al. 2012). The WHO Classification of Soft Tissue and Bone Tumours, 6th edition (STB6, 2026), recognizes epithelioid MPNST as a separate entity on the basis of its epithelioid morphology and molecular pathogenesis (SMARCB1 [INI1] loss); in the 5th edition (STB5, 2020) it was a subtype of MPNST (Hornick et al. 2026). STB5 reclassified melanotic schwannoma as malignant melanotic nerve sheath tumor (Sbaraglia et al. 2021).

Related page: Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing (FNCLCC grading and the soft tissue IHC approach) Related page: Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others (synovial sarcoma, ossifying fibromyxoid tumor and the epithelioid tumor differential) Related page: Rhabdomyoma, Rhabdomyosarcoma and Risk Stratification, Ewing Sarcoma and Other Small Round Cell Sarcomas (rhabdomyosarcoma and the INI1-deficient rhabdoid tumor) Related page: Posterior Mediastinal Neurogenic Tumors and Retroperitoneal Mass FNA (schwannoma, MPNST and ganglioneuroma on FNA) Related page: Paraganglioma and Granular Cell Tumor on Head and Neck FNA (granular cell tumor on FNA) Related page: Benign Soft Tissue Tumors on FNA (schwannoma on FNA) Related page: Anal Canal Neoplasia, Colorectal Neuroendocrine Tumors and Other Lower GI Tumors (mucosal perineurioma, ganglioneuroma and other mucosal neural lesions) Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (gastrointestinal schwannoma) Related page: Pheochromocytoma, Paraganglioma, Hereditary Paraganglioma Syndromes, Neuroblastic Tumors and the Classification of Neuroendocrine Neoplasms (adrenal ganglioneuroma and neuroblastic tumors) Related page: Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes (mucosal neuromas of MEN2B) Related page: Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma (neurothekeoma, dermal nerve sheath myxoma, palisaded encapsulated neuroma and cutaneous neuromas) Related page: Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma (low-grade fibromyxoid sarcoma)

Classification changes for nerve sheath tumors, with the previous rules

Element Current rule or consensus proposal Previous or established rule Source
Epithelioid MPNST Separate entity (STB6) based on epithelioid morphology and SMARCB1 (INI1) loss Subtype of MPNST (STB5) Hornick et al. 2026
Melanotic tumor of nerve sheath Malignant melanotic nerve sheath tumor (STB5, retained) Melanotic schwannoma, an intermediate tumor (before STB5) Sbaraglia et al. 2021
Neurofibromatous tumor with worrisome histology in NF1 Consensus proposal: ANNUBP defined by histology, with or without CDKN2A/B inactivation, or by CDKN2A/B homozygous inactivation alone (Lucas 2025) Established criteria: ANNUBP defined by histology alone (Miettinen 2017), codified in the WHO classifications Lucas et al. 2025; Miettinen et al. 2017
Tumor with ANNUBP features and 3–9 mitoses per 10 HPF without necrosis Consensus proposal: "ANNUBP with increased proliferation", provided no molecular feature of MPNST is present (Lucas 2025) Established criteria: low-grade MPNST (Miettinen 2017) Lucas et al. 2025; Miettinen et al. 2017
MPNST in NF1 Consensus proposal: histologic criteria, or SUZ12, EED or TP53 inactivating mutation, or significant aneuploidy, even without high-grade histology (Lucas 2025) Established criteria: histologic criteria (Miettinen 2017) Lucas et al. 2025; Miettinen et al. 2017
Precancerous NF1 nerve sheath tumors Consensus proposal: "at-risk" PNST defined by combined histologic, molecular and imaging features; patients divided into higher-risk and average-risk groups (Romo 2026) Established criteria: ANNUBP defined by histopathology (Miettinen 2017) Romo et al. 2026; Miettinen et al. 2017
Nomenclature of NF2 and schwannomatosis NF2-related, SMARCB1-related, LZTR1-related and 22q-related schwannomatosis, schwannomatosis-NOS and schwannomatosis-NEC; the term "neurofibromatosis 2" is retired (2022 consensus) Neurofibromatosis type 2 and schwannomatosis as separate syndromes Plotkin et al. 2022; Nagasaka and Phi 2025

Lucas 2025 and Romo 2026 are consensus proposals. Hornick 2026 does not report their adoption in STB6, and the WHO-codified criteria remain those of Miettinen 2017 (Lucas et al. 2025; Hornick et al. 2026).

Schwannoma and its morphological patterns

  • Gross and microscopic features. Schwannoma is a well-circumscribed, encapsulated benign Schwann cell neoplasm with compact spindled Antoni A areas and hypocellular microcystic Antoni B areas rich in macrophages and collagen, hyalinized vessels and degenerative changes (Rodriguez et al. 2012).
  • Immunohistochemistry. S100 protein is diffuse and strong, and pericellular collagen type IV reflects a continuous basal lamina. SOX10, podoplanin and calretinin are frequently positive, and GFAP in a subset. Neurofilament protein usually highlights only entrapped peripheral axons. Rare keratin staining in GFAP-rich schwannomas is likely cross-reactivity (Rodriguez et al. 2012).
Pattern or subtype Defining features Behavior and pitfalls Source
Cellular schwannoma Almost entirely compact fascicular bland Schwann cells; no Verocay bodies; Antoni B <10%; foamy histiocyte aggregates; capsule with lymphoid aggregates; diffuse strong S100 and collagen IV; SMA, desmin, KIT and DOG1 negative Mitoses usually <5 per 10 HPF, rarely >10; local recurrence 5%–40%; never metastasizes; may erode bone Rodriguez et al. 2012
Plexiform schwannoma Plexiform (intraneural-nodular) growth, usually superficial, mostly Antoni A, may lack a capsule Weak association (about 5%) with NF2 and schwannomatosis (Rodriguez 2012 terms); deep examples may be cellular and mitotically active but have negligible malignant potential, with local recurrence in about half Rodriguez et al. 2012
Ancient schwannoma Degenerative nuclear atypia Not a sign of malignancy Rodriguez et al. 2012
Reticular (microcystic) schwannoma Abundant myxoid change and microcysts Tends to arise in viscera Rodriguez et al. 2012
Epithelioid schwannoma Benign epithelioid change Most MPNSTs arising in schwannoma are epithelioid Rodriguez et al. 2012
Melanotic schwannoma Reclassified as malignant melanotic nerve sheath tumor Malignant Sbaraglia et al. 2021
  • Plexiform cellular schwannoma of infancy and childhood. Tumors once reported as plexiform MPNST of childhood show strong uniform S100 and did not metastasize despite mitoses up to 31 per 10 HPF, and some authors classify them as plexiform cellular schwannomas (Rodriguez et al. 2012).

Schwannomatosis and hybrid nerve sheath tumors

  • SMARCB1- and LZTR1-related schwannomatosis. These subtypes (previously "schwannomatosis", distinct from NF2) predispose to multiple schwannomas and, less often, meningiomas. Germline SMARCB1 or LZTR1 mutations were found in 86% of familial and 40% of sporadic cases. SMARCB1 mutations in schwannomatosis are mainly hypomorphic, unlike the complete loss-of-function mutations of rhabdoid tumors. Tumors also inactivate NF2, often through loss of heterozygosity of chromosome 22q, which carries SMARCB1, LZTR1 and NF2 (Kehrer-Sawatzki et al. 2017).
  • 2022 nomenclature. The 2022 international consensus incorporated genetic testing and mosaic forms, updated the nomenclature to emphasize the phenotypic overlap and to minimize misdiagnosis with NF1, and retired the term "neurofibromatosis 2" to improve diagnostic specificity (Plotkin et al. 2022). Neurofibromatosis type 2 is now NF2-related schwannomatosis, and the other subtypes are SMARCB1-related, LZTR1-related and 22q-related schwannomatosis, schwannomatosis-NOS and schwannomatosis-NEC (Nagasaka and Phi 2025).
  • Hybrid schwannoma/perineurioma. This dermal or subcutaneous tumor of a wide age range has schwannian cytology in a storiform, whorled or lamellar perineurioma-like architecture, without Antoni zones or hyalinized vessels. S100 and EMA mark separate, alternating cells, and CD34 and claudin-1 are often positive. It is not associated with neurofibromatosis and rarely recurs (Hornick, Bundock and Fletcher 2009). VGLL3 rearrangement, most often CHD7::VGLL3, distinguishes its pathogenesis from schwannoma and perineurioma (Dickson et al. 2021).
  • Hybrid neurofibroma/schwannoma. Tumors with distinct schwannoma and neurofibroma components are often plexiform and overlap with neurofibroma containing schwannian nodules (Rodriguez et al. 2012).

Neurofibroma, NF1 and the ANNUBP spectrum

  • Types. Neurofibroma grows as a well-demarcated intraneural mass or as diffuse infiltration of extraneural soft tissue. Localized cutaneous neurofibroma is the most common type and is usually sporadic; localized intraneural neurofibroma expands a nerve trunk. Diffuse neurofibroma forms a plaque-like enlargement, usually in the head and neck, often with S100-positive pseudomeissnerian corpuscles. About 10% of neurofibromas prove to be associated with neurofibromatosis type 1 (NF1) (Rodriguez et al. 2012).
  • Plexiform neurofibroma. Plexiform neurofibroma involves numerous adjacent fascicles or several components of a plexus and, like the rare massive soft tissue neurofibroma, is almost always associated with NF1. It is the recognized precursor of MPNST in NF1 (Rodriguez et al. 2012). NF1 diagnostic criteria were revised by international consensus in 2021 (Legius et al. 2021).
  • Histology and immunohistochemistry. Thin, often wavy nuclei with wispy processes lie in a myxoid to collagenous matrix with "shredded carrot" collagen. S100 and SOX10 are extensive but not diffuse, a lattice-like CD34-positive fibroblast network is present, and plexiform tumors are delineated by EMA-positive perineurial cells (Miettinen et al. 2017).
  • Pathogenesis. In NF1, neurofibromas follow somatic loss of the remaining wild-type NF1 allele in Schwann cells. Loss of CDKN2A (p16) and of the polycomb repressive complex 2 components EED and SUZ12 is associated with MPNST. The lifetime risk of MPNST in NF1 is estimated at 8%–16% (Miettinen et al. 2017).
  • Neurofibroma with atypia or hypercellularity. Scattered bizarre nuclei without hypercellularity, mitoses or loss of architecture ("ancient neurofibroma") are not worrisome. Cellular neurofibroma has hypercellularity alone with retained architecture and <1 mitosis per 50 HPF (Miettinen et al. 2017).
  • Mimics of neurofibroma. Desmoplastic melanoma can closely resemble neurofibroma, and both express S100. Sun damage, melanoma in situ, long hyperchromatic cells, dense fibrosis and deep lymphoid aggregates favor melanoma. A "fingerprint" CD34 pattern favors neurofibroma (Rodriguez et al. 2012).

NF1-associated nerve sheath tumors: established 2017 histologic criteria and the 2025 integrated consensus proposal

Diagnosis Miettinen 2017 (established histologic criteria) Lucas 2025 (integrated consensus proposal) Source
Neurofibroma Benign Schwann cell neoplasm with retained architecture Lacks histologic and molecular features sufficient for ANNUBP or MPNST Miettinen et al. 2017; Lucas et al. 2025
ANNUBP At least 2 of 4 features: cytologic atypia, loss of neurofibroma architecture, hypercellularity, mitotic index >1 per 50 HPF and <3 per 10 HPF The same histologic criteria with or without CDKN2A/B inactivation; or CDKN2A/B homozygous inactivation with or without any histologic feature; or heterozygous CDKN2A/B inactivation with ≥1 histologic feature; and no molecular feature of MPNST Miettinen et al. 2017; Lucas et al. 2025
Tumor with ANNUBP features, 3–9 mitoses per 10 HPF and no necrosis Low-grade MPNST ANNUBP with increased proliferation, provided no molecular feature of MPNST is present Miettinen et al. 2017; Lucas et al. 2025
MPNST At least 10 mitoses per 10 HPF, or 3–9 per 10 HPF with necrosis The same histology, or SUZ12/EED inactivating mutation, TP53 inactivating mutation or significant aneuploidy (segmental gain or loss of at least 8 chromosome arms), any of which suffices without high-grade histology Miettinen et al. 2017; Lucas et al. 2025
  • Definitions used in the criteria. Loss of neurofibroma architecture is fascicular growth and/or loss of the CD34-positive network; hypercellularity is a "blue" low-power appearance with nuclear overlap (Miettinen et al. 2017). The mitotic count is per 10 HPF, typically about 2 mm² (Lucas et al. 2025).
  • Rules for CDKN2A/B in the 2025 proposal. Heterozygous or subclonal CDKN2A/B inactivation alone is insufficient for ANNUBP, and CDKN2A/B inactivation is not required when 2 of the 4 histologic criteria are present (Lucas et al. 2025).
  • Reporting set in the 2025 proposal. Every NF1-associated nerve sheath tumor report states cytologic atypia, loss of neurofibromatous architecture, hypercellularity, mitotic count per 10 HPF and necrosis (Lucas et al. 2025).
  • Ancillary findings. Ki-67 is usually <2%–5% in ordinary and atypical neurofibromas, whereas >10% may indicate MPNST. Complete loss of p16 can occur in atypical and even conventional neurofibromas and is not sufficient for malignancy. p53 accumulation also occurs in cellular schwannoma (Miettinen et al. 2017). Worrisome immunohistochemical features are reduced SOX10 or S100, loss of the CD34 lattice, complete loss of p16 or H3K27me3, increased or null p53 and increased Ki-67 (Lucas et al. 2025).
  • Sampling under the 2025 consensus. Molecular profiling is recommended for clinically or radiologically worrisome noncutaneous lesions, by image-guided core biopsy targeted to FDG-PET-avid regions and a comprehensive NGS panel with copy number and zygosity assessment. Cutaneous neurofibromas, which almost never transform, are generally outside the scope of these recommendations (Lucas et al. 2025).
  • "At-risk" consensus proposal. The consensus from the Atypical Neurofibroma Symposium, held in April 2024 and published in 2026, defines premalignant "at-risk" nerve sheath tumors by combined histologic, molecular and imaging features, and divides NF1 patients into higher-risk and average-risk groups by germline NF1 variant, internal tumor burden and history of malignancy or radiotherapy (Lucas et al. 2025; Romo et al. 2026).

Perineurioma

  • Types. Intraneural perineurioma causes localized expansion of one or more nerve fascicles, with perineurial cells encircling nerve fibers as "pseudo-onion bulbs". Soft tissue perineurioma almost always lacks an associated nerve and consists of slender cells with delicate overlapping processes in loose fascicles or whorls. Reticular and sclerosing variants exist; sclerosing perineurioma occurs most often in the hands of young men. 22q deletions in both types support a neoplastic nature (Rodriguez et al. 2012).
  • Soft tissue perineurioma. This subcutaneous tumor of adults grows in storiform and whorled patterns. It is EMA positive in all cases, CD34 positive in most and S100 positive only rarely. Scattered pleomorphic cells and infiltrative margins have no clinical significance, and it rarely recurs (Hornick and Fletcher 2005).
  • Claudin-1 and GLUT1. Claudin-1 stained 11 of 12 perineuriomas, often more strongly than EMA, and was absent in dermatofibrosarcoma protuberans, low-grade fibromyxoid sarcoma, desmoplastic fibroblastoma and fibromatosis (Folpe et al. 2002). GLUT1 is another perineurial marker; neither marker is entirely specific (Rodriguez et al. 2012).
  • Versus low-grade fibromyxoid sarcoma. EMA occurs in up to 40% of low-grade fibromyxoid sarcomas; MUC4 expression and FUS rearrangement establish that diagnosis (Rodriguez et al. 2012; Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma).

Granular cell tumor

  • Malignancy criteria (Fanburg-Smith 1998). Six criteria are assessed: necrosis, spindling, vesicular nuclei with large nucleoli, >2 mitoses per 10 HPF (at 200× magnification), high nuclear-to-cytoplasmic ratio and pleomorphism. Three or more criteria classify a tumor as malignant, one or two as atypical, and focal pleomorphism alone as benign. Of 28 malignant tumors with follow-up, 39% of patients died of disease and 50% had metastases; atypical and benign multicentric tumors did not metastasize (Fanburg-Smith et al. 1998; Paraganglioma and Granular Cell Tumor on Head and Neck FNA).
  • Immunohistochemistry. S100, SOX10, CD68, inhibin and calretinin are positive; SMA, desmin, keratin and HMB45 are negative, and TFE3 is positive in 91% (Fanburg-Smith et al. 1998; Chamberlain et al. 2014).

Malignant melanotic nerve sheath tumor

  • Clinical features. The tumor most often arises in the midline in spinal and autonomic nerves of adults, and a subset occurs in Carney complex (Sbaraglia et al. 2021). Most involve paravertebral spinal nerve roots (Torres-Mora et al. 2014).
  • Histology and immunohistochemistry. Spindle and epithelioid cells in sheets and short fascicles have nuclear pseudoinclusions and variable, sometimes massive melanin pigment; about half contain psammoma bodies (Sbaraglia et al. 2021). Melanocytic markers (HMB45, Melan-A, tyrosinase) and S100 are expressed, GFAP and EMA are negative, SMARCB1 is retained and PRKAR1A is lost in a subset (Torres-Mora et al. 2014).
  • Genetics and behavior. Most tumors have inactivating PRKAR1A mutations (Sbaraglia et al. 2021). Metastasis occurs in a substantial proportion. In one series of 40 tumors, only a mitotic rate >2 per 10 HPF correlated with metastasis, psammoma bodies did not affect behavior, and PRKAR1A loss suggested Carney complex even without that history (Torres-Mora et al. 2014). The STB5 summary states that necrosis and mitotic activity do not seem to predict outcome (Sbaraglia et al. 2021).

Malignant peripheral nerve sheath tumor

  • Definition and settings. MPNST arises from a peripheral nerve or a benign nerve sheath tumor, or in soft tissue with nerve sheath differentiation. A spindle cell sarcoma in a patient with NF1 is considered MPNST until proven otherwise (Rodriguez et al. 2012). About 50% of MPNSTs occur in NF1, about 10% follow radiotherapy and the remainder are sporadic (Prieto-Granada et al. 2016).
  • Histology. Fascicles of alternating cellularity with a "marbled" low-power appearance, whorls and palisades, perivascular (subendothelial) accentuation and geographic necrosis are frequent (Rodriguez et al. 2012; Prieto-Granada et al. 2016).
  • Divergent differentiation. Heterologous cartilage, bone, skeletal muscle (malignant triton tumor), smooth muscle, angiosarcoma and glands occur, particularly in NF1 (Rodriguez et al. 2012). Heterologous components were present in 9 of 68 MPNSTs, most often rhabdomyosarcomatous (Prieto-Granada et al. 2016).
  • S100 and SOX10. Partial or complete loss of S100 separates MPNST from benign Schwann cell tumors, and diffuse S100 in a spindle cell nerve sheath tumor favors cellular schwannoma (Rodriguez et al. 2012). SOX10 is positive in 49% to 67% and S100 in 30% to 39% of MPNSTs in published series (Prieto-Granada et al. 2016).
  • H3K27me3. Loss of H3K27me3 reflects PRC2 inactivation. It is most frequent in sporadic and radiation-associated high-grade MPNSTs, less frequent in NF1-associated tumors; neurofibromas and epithelioid MPNSTs retain it (Prieto-Granada et al. 2016; figures in Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing; FNA use in Posterior Mediastinal Neurogenic Tumors and Retroperitoneal Mass FNA). A mosaic pattern of loss is much less specific than complete loss, and positive internal control staining in endothelial, lymphoid or other normal cells is required for a valid result (Miettinen et al. 2017).
  • Grading. About 15% of MPNSTs are low grade and 85% high grade (Rodriguez et al. 2012). In NF1, the 2025 consensus proposes renaming low-grade MPNST "ANNUBP with increased proliferation" (Lucas et al. 2025).
  • Mimics. Synovial sarcoma (Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others), especially monophasic and intraneural, is the closest mimic. Pleomorphic cells essentially exclude synovial sarcoma; high-molecular-weight keratins occur only in synovial sarcoma; CD34 is absent in synovial sarcoma; SS18::SSX1 or SS18::SSX2 fusion confirms synovial sarcoma (Rodriguez et al. 2012). MPNST lacks a specific translocation and usually has a complex karyotype (Rodriguez et al. 2012).
  • Prognosis. Five-year overall survival of MPNST is approximately 20% to 50% (Miettinen et al. 2017).

Epithelioid MPNST (STB6 separate entity)

  • Clinical features. Epithelioid MPNST affects adults, is rarely associated with NF1, favors the lower extremity and trunk, is mostly superficial, and may arise in a schwannoma (Jo and Fletcher 2015).
  • Histology. Lobules and nests of round to polygonal epithelioid cells with vesicular nuclei, prominent nucleoli and amphophilic to pale eosinophilic cytoplasm lie in myxoid or fibrous stroma; one third show focal spindling (Jo and Fletcher 2015).
  • Immunohistochemistry and genetics. All tumors expressed S100, mostly strong and diffuse; Melan-A, HMB45 and MITF were negative and keratin was consistently negative. INI1 was lost in about two-thirds (Jo and Fletcher 2015) and in 81% of a 2026 series (Richman et al. 2026), and it is retained in metastatic melanoma (Hornick, Dal Cin and Fletcher 2009). H3K27me3 was retained in all 5 epithelioid MPNSTs studied (Prieto-Granada et al. 2016).
  • Behavior. Recurrence and metastasis were independent of site and depth (Jo and Fletcher 2015). Tumor size and mitotic rate were independent adverse factors. Median progression-free survival was 34 versus 19 months in conventional MPNST, a difference that was not statistically significant (Richman et al. 2026).
  • Differential diagnosis. Lack of melanocytic markers separates epithelioid MPNST from melanoma and clear cell sarcoma, and absent keratin separates it from carcinoma and epithelioid sarcoma. Epithelioid MPNST and epithelioid sarcoma can both lose INI1 (Rodriguez et al. 2012; Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others).

Ganglioneuroma

Ganglioneuroma is the Schwannian stroma-dominant neuroblastic tumor, of favorable histology at any age (CAP Neuroblastoma 2025; Posterior Mediastinal Neurogenic Tumors and Retroperitoneal Mass FNA). In soft tissue its mimic is neurofibroma infiltrating a dorsal root or sympathetic ganglion. The ganglion cells of ganglioneuroma vary in size, are often binucleated and are haphazardly distributed, and MPNST rarely arises in ganglioneuroma (Rodriguez et al. 2012).

Schwannoma, neurofibroma, perineurioma and MPNST compared

Feature Schwannoma Neurofibroma Perineurioma MPNST Source
Capsule Well formed Absent Soft tissue type well circumscribed, may have a capsule Absent Rodriguez et al. 2012
Architecture Antoni A and B areas, Verocay bodies, hyalinized vessels Haphazard wavy cells in "shredded carrot" collagen and mucin Storiform and whorled slender cells; pseudo-onion bulbs in the intraneural type Fascicles of alternating cellularity, geographic necrosis Rodriguez et al. 2012
S100 and SOX10 Diffuse and strong Extensive but not diffuse S100 in 5% Partial or absent S100; SOX10 in 49%–67% Rodriguez et al. 2012; Miettinen et al. 2017; Hornick and Fletcher 2005; Prieto-Granada et al. 2016
Perineurial markers Claudin-1 in a perivascular subpopulation of 1 of 4 schwannomas Claudin-1-positive perineurial cells in 6 of 9; EMA-positive perineurial cells delineate plexiform fascicles EMA in all; claudin-1 in 29% to 92% depending on the series EMA in MPNST with perineurial differentiation Folpe et al. 2002; Miettinen et al. 2017; Hornick and Fletcher 2005; Rodriguez et al. 2012
Other discriminating findings Pericellular collagen IV Lattice-like CD34-positive fibroblast network CD34 in 64% Loss of the CD34 network; H3K27me3 lost in most sporadic and radiation-associated tumors Rodriguez et al. 2012; Miettinen et al. 2017; Hornick and Fletcher 2005; Prieto-Granada et al. 2016
Mitoses and necrosis Low; brisk activity allowed in cellular schwannoma Rare Rare Brisk mitoses; necrosis Rodriguez et al. 2012

Soft Tissue Tumors of Uncertain Differentiation and Chondro-Osseous Tumors: Synovial Sarcoma, Epithelioid Sarcoma, ASPS, Clear Cell Sarcoma, PEComa and Others

Definition and classification. Tumors of uncertain differentiation lack a recognizable normal counterpart and are defined by morphology, immunophenotype and, increasingly, by recurrent genetic alterations. The WHO Classification of Soft Tissue and Bone Tumours, 6th edition (STB6, 2026), adds eight entities to this chapter and expands the NTRK-rearranged spindle cell neoplasm of the 5th edition (STB5, 2020) into kinase-altered spindle cell neoplasms (Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma) (Hornick et al. 2026). No significant change was made to the chondro-osseous tumors (Hornick et al. 2026); in STB5, soft tissue chondroma and extraskeletal osteosarcoma were the exceedingly rare members of that chapter (Sbaraglia et al. 2021).

Related page: Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing (FNCLCC grading, AJCC staging and the molecular methods table) Related page: Solitary Fibrous Tumor, Inflammatory Myofibroblastic Tumor, Fibrosarcomas, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma (kinase-altered spindle cell neoplasms, undifferentiated pleomorphic sarcoma and low-grade fibromyxoid sarcoma) Related page: Rhabdomyoma, Rhabdomyosarcoma and Risk Stratification, Ewing Sarcoma and Other Small Round Cell Sarcomas (PATZ1-rearranged sarcoma, rhabdoid tumor and the round cell differential) Related page: Peripheral Nerve Sheath Tumors: Schwannoma, Neurofibroma and ANNUBP, Perineurioma, Granular Cell Tumor and MPNST (MPNST, epithelioid MPNST and granular cell tumor) Related page: Vascular Anomalies and Vascular Tumors, Perivascular Tumors, and Smooth Muscle Tumors of Deep Soft Tissue (epithelioid hemangioendothelioma and epithelioid angiosarcoma) Related page: Other Lung Tumors: Hamartoma, Sclerosing Pneumocytoma, Adenomas, Salivary Gland-Type, Mesenchymal and Lymphoid Tumors, and Metastases (pulmonary artery intimal sarcoma) Related page: Uterine Mesenchymal Tumors: Smooth Muscle Tumors, Endometrial Stromal Tumors, Adenosarcoma and Other Sarcomas (uterine PEComa) Related page: Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder (PEComa of the bladder) Related page: Adipocytic Sarcomas, Myxoid Lesions, Extraskeletal Myxoid Chondrosarcoma and Chordoma on FNA (myxoid tumors on FNA) Related page: Round Cell, Spindle Cell and Pleomorphic Sarcomas on FNA (synovial sarcoma and other sarcomas on FNA) Related page: Molecular and Ancillary Testing of Soft Tissue FNA Material (fusion testing on cytology material) Related page: Melanoma, Merkel Cell Carcinoma and Skin FNA (clear cell sarcoma versus melanoma on FNA) Related page: Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma (dermal tumors, including atypical fibroxanthoma, removed from STB6) Related page: Paraganglioma and Granular Cell Tumor on Head and Neck FNA (granular cell tumor markers, including the comparison with alveolar soft part sarcoma) Related page: Benign Soft Tissue Tumors on FNA (intramuscular myxoma and its mimics on small samples) Related page: Molecular Oncology of Solid Tumors: Oncogenes and Tumor Suppressors, MSI and Mismatch Repair, Tumor Mutational Burden, Tumor-Agnostic and Organ Biomarkers, CNS Tumor Molecular Testing and Germline Findings on Tumor Sequencing (sarcoma translocation testing methods)

STB6 changes in tumors of uncertain differentiation

Element STB6 (current) STB5 (previous) Source
New entities OGT-rearranged mesenchymal neoplasm, acral fibrochondromyxoid tumor, GLI1-altered mesenchymal tumors, superficial FET-ETS family neurocristic tumor, pseudoendocrine sarcoma, NUT-rearranged sarcoma, FET-CREB family epithelioid mesenchymal tumor, PATZ1-rearranged sarcoma Absent from STB5; PATZ1-rearranged sarcoma was within round cell sarcomas with EWSR1–non-ETS fusions Hornick et al. 2026
Spindle cell tumors with kinase alterations Kinase-altered spindle cell neoplasms (wide range of kinase fusions and point mutations) NTRK-rearranged spindle cell neoplasm, an emerging entity Hornick et al. 2026; Sbaraglia et al. 2021
Removed Atypical fibroxanthoma and ectopic hamartomatous thymoma Included Hornick et al. 2026; Sbaraglia et al. 2021 (AFX)
Chondro-osseous tumors No significant change Soft tissue chondroma and extraskeletal osteosarcoma Hornick et al. 2026; Sbaraglia et al. 2021

New entities of uncertain differentiation in STB6 (Hornick et al. 2026, Table 2; PATZ1-rearranged sarcoma from Table 1 and text; GLI1 and neurocristic comments from the text and Fig. 6)

Entity Behavior Key molecular alteration Morphology and immunophenotype Site or comment
OGT-rearranged mesenchymal neoplasm Benign OGT rearrangement Cords or nests of epithelioid cells in hyalinized or fibromyxoid stroma Acral; formerly OGT-rearranged acral mesenchymal neoplasm
Acral fibrochondromyxoid tumor Benign THBS1 rearrangement, frequently with ADGRF5 Multinodular fibrous, myxoid or chondroid stroma with fibrovascular septa; bland spindle or round cells; CD34 and ERG positive Acral
GLI1-altered mesenchymal tumors Variable GLI1 amplification or rearrangement Lobules and nests of epithelioid or ovoid cells with branching capillaries; S100 in about 30% Bland tumors with few mitoses are usually indolent
Superficial FET-ETS family neurocristic tumor Benign EWSR1 or FUS fused with FLI1, ERG, ETV1, ETV5 and others Nests, cords and trabeculae of small bland round to ovoid cells; strong diffuse SOX10, S100 and CD99 Shares fusion type with Ewing sarcoma
Pseudoendocrine sarcoma Malignant CTNNB1 alteration Mimics a neuroendocrine tumor; keratin and neuroendocrine markers negative; nuclear β-catenin Paravertebral soft tissue
NUT-rearranged sarcoma Malignant NUTM1 (or other NUT family) rearrangement Round, epithelioid or spindle cells with monomorphic nuclei; NUT positive Highly aggressive
FET-CREB family epithelioid mesenchymal tumor Malignant EWSR1 or FUS fused with CREM, ATF1 or CREB1 Monomorphic epithelioid to round cells; keratin positive Mesothelial-lined cavities
PATZ1-rearranged sarcoma Sarcoma (moved from round cell sarcomas) EWSR1::PATZ1 Round and spindle cells; myoepithelial and skeletal muscle markers coexpressed Formerly a round cell sarcoma with EWSR1–non-ETS fusion (STB5); Rhabdomyoma, Rhabdomyosarcoma and Risk Stratification, Ewing Sarcoma and Other Small Round Cell Sarcomas

Intramuscular myxoma and aggressive angiomyxoma

  • Intramuscular myxoma. Intramuscular myxoma is a rare benign soft tissue tumor that is usually sporadic and less often accompanies fibrous dysplasia (Mazabraud syndrome). Activating GNAS mutations were detected in 61% of cases with a sensitive PCR method, in no myxofibrosarcomas and in no controls, so mutation testing helps separate intramuscular myxoma from low-grade myxofibrosarcoma (Delaney et al. 2009). The tumor is hypocellular with abundant myxoid stroma and occasional hypercellular areas (Bekers et al. 2019; Benign Soft Tissue Tumors on FNA).
  • Juxta-articular myxoma. In 65 cases, 88% arose in the region of the knee, cystic change resembling a ganglion cyst was frequent, and 10 of 29 tumors with follow-up (34%) recurred (Meis and Enzinger 1992).
  • Aggressive angiomyxoma. This tumor of the pelvis, perineum and vulva of women of reproductive age is usually large (≥10 cm) and consists of bland stellate and spindle cells in a loose myxoid-collagenous matrix with vessels of varied caliber. Desmin, SMA, ER and PR are expressed, CD34 is variable and S100 is negative. It recurs locally, sometimes years later, and does not metastasize (Fetsch et al. 1996).
  • HMGA2 in aggressive angiomyxoma. Nuclear HMGA2 helps assess margins and re-excisions but also stains some vulvovaginal leiomyomas (McCluggage et al. 2010).

Angiomatoid fibrous histiocytoma and FET-CREB family tumors

  • Histology. Nodules of ovoid and spindle cells contain blood-filled cystic spaces and are surrounded by a dense lymphoplasmacytic infiltrate. The morphologic spectrum is broad, the immunoprofile is not specific, and a small risk of metastasis and death exists (Thway and Fisher 2015).
  • Patients and immunophenotype. In 158 tumors (98 studied by immunohistochemistry), patients were 2 to 71 years old, and tumors arose in the extremities, then the trunk and the head and neck. Desmin was positive in 51%, CD99 in 45% and CD68 (KP-1) in 15% (Fanburg-Smith and Miettinen 1999).
  • Genetics. EWSR1::CREB1 was present in 8 of 9 tumors and EWSR1::ATF1 in 1; FUS::ATF1 is rare. EWSR1::ATF1 and EWSR1::CREB1 also define clear cell sarcoma (Antonescu et al. 2007; Thway and Fisher 2015).
  • FET-CREB family epithelioid mesenchymal tumor (STB6). Its keratin-positive epithelioid cells in mesothelial-lined cavities can mimic epithelioid mesothelioma, and its inflammatory infiltrate resembles that of angiomatoid fibrous histiocytoma (Hornick et al. 2026).

Synovial sarcoma

  • Definition and sites. Synovial sarcoma is an aggressive sarcoma with a predilection for the extremities of young adults. It harbors the pathognomonic t(X;18)(p11;q11), which fuses SS18 with SSX1 in about two-thirds, SSX2 in one-third and SSX4 rarely; RT-PCR for SS18::SSX1 and SS18::SSX2 misses SSX4 fusions (Baranov et al. 2020). It can involve nerves, including intraneural examples (Rodriguez et al. 2012), and accounted for 7 of 100 primary cardiac sarcomas in one series (Neuville et al. 2014).
  • Histology. Monophasic synovial sarcoma consists of uniform spindle cells with overlapping hyperchromatic ovoid to elongated nuclei in dense fascicles, within a collagenous matrix with wiry collagen and sometimes chunky calcifications; myxoid stroma and staghorn vessels occur. Biphasic synovial sarcoma adds an epithelial component of glands, nests or cords. Poorly differentiated synovial sarcoma consists of round or spindle cells with a high mitotic rate and mimics round cell sarcomas and high-grade MPNST (Baranov et al. 2020).
  • SS18-SSX immunohistochemistry. The SS18-SSX fusion-specific antibody is the most specific marker and can replace molecular testing in most cases, while the SSX C-terminal antibody is more sensitive but less specific (Baranov et al. 2020; Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing).
  • TLE1 and its limits. TLE1 was expressed in 18 of 20 synovial sarcomas and in 37% of other tumors, including 100% of schwannomas, 33% of neurofibromas and 30% of MPNSTs. It is used only within a panel (Kosemehmetoglu et al. 2009).
  • Other immunohistochemical pitfalls. BCOR and SATB2 stain a subset of synovial sarcomas (Rhabdomyoma, Rhabdomyosarcoma and Risk Stratification, Ewing Sarcoma and Other Small Round Cell Sarcomas).
  • Versus MPNST. Glands in synovial sarcoma are lined by cuboidal cells, often with necrotic luminal debris, whereas glands in MPNST resemble enteric epithelium (Rodriguez et al. 2012; Peripheral Nerve Sheath Tumors: Schwannoma, Neurofibroma and ANNUBP, Perineurioma, Granular Cell Tumor and MPNST).

Epithelioid sarcoma

  • Types. Conventional (distal) and proximal-type (large cell) epithelioid sarcoma are recognized, and hybrid tumors occur (Hornick et al. 2009; Chbani et al. 2009).
  • Conventional type. The tumor occurs mainly in the distal extremities of young adults and forms nodular aggregates of epithelioid and spindle cells with zonal necrosis. CD34 was positive in 52% of cases in a series of 112 tumors (Miettinen et al. 1999). Granuloma-like aggregates of epithelioid and spindled tumor cells with central necrosis characterize the classic type (Li et al. 2014).
  • INI1 loss. Complete loss of INI1 occurs in more than 90% of conventional and proximal-type epithelioid sarcomas (Hornick et al. 2009). Among epithelioid mimics, INI1 is also lost in rhabdoid tumor, some epithelioid MPNSTs and some myoepithelial carcinomas, and retained in carcinoma, melanoma, mesothelioma, epithelioid angiosarcoma and EHE (Hornick et al. 2009; Rhabdomyoma, Rhabdomyosarcoma and Risk Stratification, Ewing Sarcoma and Other Small Round Cell Sarcomas).
  • Behavior. Metastasis occurs in about half of patients, and proximal location, size, multifocality and mitotic index predict survival (Chbani et al. 2009).
  • Tazemetostat. Loss of INI1 creates dependence on EZH2, and the EZH2 inhibitor tazemetostat produces responses in a minority of patients with advanced INI1-negative epithelioid sarcoma (Gounder et al. 2020).

Alveolar soft part sarcoma

  • Genetics. The der(17)t(X;17)(p11;q25) fuses ASPSCR1 (formerly ASPL) at 17q25 to TFE3; the ASPSCR1::TFE3 transcript was found in 12 of 12 tumors, and the translocation is usually non-reciprocal (Ladanyi et al. 2001).
  • Histology and patients. Nests of large polygonal cells have abundant eosinophilic cytoplasm, and the PAS stain highlights intracytoplasmic rhomboid crystals (Carter et al. 2008); the PAS-positive material is diastase resistant (Martínez et al. 2018). The tumor occurs mainly in adolescents and young adults with a female preponderance. In children the head and neck is commonly affected, most often the orbit and tongue (Kinger et al. 2014). In adults it arises in the buttocks or thigh, often with metastases to lung, brain or bone (Fanburg-Smith et al. 2004).
  • TFE3 immunohistochemistry. Nuclear TFE3 is a sensitive and specific surrogate for the fusion (Argani et al. 2003; figures in Soft Tissue Tumors: WHO 2026 Classification, FNCLCC Grading, AJCC Staging, CAP Reporting and Ancillary Testing).
  • Versus granular cell tumor. TFE3 stains both tumors, but granular cell tumor is S100, SOX10 and inhibin positive and has coarse PAS-diastase-positive granules, whereas alveolar soft part sarcoma has PAS-diastase-positive crystals (Chamberlain et al. 2014; Paraganglioma and Granular Cell Tumor on Head and Neck FNA).

Clear cell sarcoma

  • Clinical features. Clear cell sarcoma arises in the deep soft tissue of the extremities, trunk and limb girdles of young adults (median age 30 years), with a male predominance (Hisaoka et al. 2008).
  • Histology and immunohistochemistry. Spindle or epithelioid cells grow in short fascicles or solid sheets, sometimes with rhabdoid or pleomorphic cells. S100 is positive in all, with HMB45, MITF and Melan-A in most, and keratin is almost always negative (Hisaoka et al. 2008).
  • Genetics. RT-PCR detects EWSR1::ATF1 in most tumors and EWSR1::CREB1 in a minority; EWSR1::CREB1 is also found in clear cell sarcoma of the gastrointestinal tract. Molecular detection of the fusion separates clear cell sarcoma from melanoma, which shares its melanocytic phenotype (Hisaoka et al. 2008).
  • Behavior. Metastasis is frequent, and 5-year overall survival was 63% (Hisaoka et al. 2008).

PEComa

  • Definition. Perivascular epithelioid cell neoplasms coexpress muscle and melanocytic markers. The family includes angiomyolipoma, clear cell sugar tumor of the lung, lymphangioleiomyomatosis and rare tumors elsewhere, occasionally with tuberous sclerosis complex (Folpe et al. 2005).
  • Soft tissue and gynecologic PEComas. These tumors occur mostly in women, in the omentum, mesentery, uterus and pelvic soft tissue. HMB45 and SMA are coexpressed in most, Melan-A is often positive, and desmin, S100, TFE3 and keratin are positive in a minority (Folpe et al. 2005).
  • Classification of behavior (Folpe criteria). Recurrence and metastasis were associated with size >8 cm, mitotic activity >1 per 50 HPF and necrosis (Folpe et al. 2005). The six worrisome features are size >5 cm, infiltrative growth, high nuclear grade and cellularity, mitotic rate ≥1 per 50 HPF, necrosis and vascular invasion. Tumors with none are benign; nuclear pleomorphism or multinucleated giant cells alone, or size >5 cm alone, indicate uncertain malignant potential; two or more of the six worrisome features indicate malignancy (Folpe et al. 2005; Oliver-Perez et al. 2025).
  • TFE3-rearranged PEComa. Four of 16 nonrenal PEComas had TFE3 rearrangement. These patients were young (mean 24 years), lacked tuberous sclerosis, and had alveolar architecture, epithelioid cytology, minimal muscle marker expression and strong TFE3 (Argani et al. 2010).

Ossifying fibromyxoid tumor

  • Clinical and histologic features. OFMT is a subcutaneous or deep mass of the trunk and proximal limbs of adults, often with a peripheral shell of bone, and S100 is positive in about 60% (Folpe and Weiss 2003; Rodriguez et al. 2012). A mosaic pattern of INI1 loss occurs (Rodriguez et al. 2012).
  • Malignant criteria. High nuclear grade, or high cellularity with >2 mitoses per 50 HPF, indicate malignant OFMT with significant metastatic potential. The remaining tumors carry a very low risk of metastasis, and OFMT is considered an intermediate tumor (Folpe and Weiss 2003).
  • Genetics. PHF1 rearrangement occurs in about half of typical, atypical and malignant OFMTs (Graham et al. 2013).
  • Versus MPNST. Paraspinal OFMT with S100 expression and a spindle cell component can mimic low-grade MPNST (Rodriguez et al. 2012).

Myoepithelioma, mixed tumor and myoepithelial carcinoma of soft tissue

  • Clinical and histologic features. Myoepithelial tumors of soft tissue arise mostly in the limbs and limb girdles of adults. Lobules of cords or nests of epithelioid, ovoid or spindled cells lie in chondromyxoid or hyalinized stroma, and ductules define mixed tumor (Hornick and Fletcher 2003).
  • Immunohistochemistry. All coexpress keratin or EMA with S100 in most, and calponin, GFAP, SMA and p63 are variable (Hornick and Fletcher 2003).
  • Myoepithelial carcinoma. Moderate to severe atypia (vesicular or coarse chromatin, prominent nucleoli, pleomorphism) defines myoepithelial carcinoma. Cytologically malignant tumors recurred in 42% and metastasized in 32%, whereas benign or low-grade tumors recurred in 18% and did not metastasize (Hornick and Fletcher 2003).
  • Genetics. Half of myoepithelial tumors of soft tissue and bone carry EWSR1 or FUS fusions, whereas salivary gland and cutaneous tumors often carry PLAG1 or HMGA2 rearrangements (Suurmeijer et al. 2020).

Intimal sarcoma

Soft tissue chondroma, phosphaturic mesenchymal tumor, extraskeletal osteosarcoma and extraskeletal myxoid chondrosarcoma

  • Soft tissue chondroma. FN1 alterations were found by FISH in 50% of soft tissue chondromas, with FN1::FGFR1 or FN1::FGFR2 fusions in tumors with grungy calcification; FGF23 was not elevated. Synovial chondromatosis instead carries FN1::ACVR2A, and no malignant soft tissue chondroma has been reported (Amary et al. 2019).
  • Phosphaturic mesenchymal tumor. This tumor of soft tissue or bone causes tumor-induced osteomalacia through phosphate wasting. Classic tumors show low cellularity, myxoid change, bland spindle cells, distinctive "grungy" calcified matrix, fat, hemangiopericytoma-like vessels, microcysts, hemorrhage, osteoclasts and an incomplete rim of membranous ossification; rare hypercellular, atypical tumors are malignant. FGF23 was expressed in 17 of 21 tumors, and complete resection cures the osteomalacia (Folpe et al. 2004). FN1::FGFR1 was found in 9 of 15 tumors (Lee et al. 2015). In STB5 it was a tumor of uncertain differentiation (Sbaraglia et al. 2021).
  • Extraskeletal osteosarcoma. This aggressive tumor of older adults often presents with or develops lung metastases, and age >40 years and tumor size predict survival (Sbaraglia et al. 2021; Longhi et al. 2017).
  • Extraskeletal myxoid chondrosarcoma: definition. Despite its name, its chondroid nature is unproven, and it is classified among tumors of uncertain differentiation. Rearrangements of 9q22, such as t(9;22)(q22;q12), create NR4A3 fusions specific for this tumor, and it follows a protracted course (Hisaoka and Hashimoto 2005).
  • Extraskeletal myxoid chondrosarcoma: histology. Most tumors are multinodular and lobular, with monotonous oval to short spindled cells in cords or a reticular pattern within a diffusely myxoid matrix; cellular tumors show trabeculae and closely packed cords, and some have epithelioid or rhabdoid cells (Agaram et al. 2014).
  • Extraskeletal myxoid chondrosarcoma: fusion partners. EWSR1::NR4A3 occurs in about 75% of tumors; TAF15, TCF12 and TFG are other partners. EWSR1-rearranged tumors are mostly low grade, whereas tumors with variant (non-EWSR1) fusions more often show high-grade morphology, half with plasmacytoid or rhabdoid cells, and behave more aggressively. NR4A3 FISH confirms the diagnosis (Agaram et al. 2014).

Epithelioid soft tissue tumors compared

Tumor Typical setting Key immunophenotype Molecular or other discriminating finding Source
Epithelioid sarcoma Distal extremities of young adults (conventional type); proximal location is adverse Keratin and EMA; INI1 lost in >90%; CD34 in about half SMARCB1 inactivation Hornick et al. 2009; Miettinen et al. 1999; Chbani et al. 2009
Epithelioid angiosarcoma (Vascular Anomalies and Vascular Tumors, Perivascular Tumors, and Smooth Muscle Tumors of Deep Soft Tissue) Deep limb muscle of older men Keratin with endothelial markers; intracytoplasmic lumina Nuclear CAMTA1 absent, apart from one core biopsy case Fletcher et al. 1991; Doyle et al. 2016
Epithelioid hemangioendothelioma (Vascular Anomalies and Vascular Tumors, Perivascular Tumors, and Smooth Muscle Tumors of Deep Soft Tissue) Adults; extremities most often in soft tissue Nuclear CAMTA1; INI1 retained WWTR1::CAMTA1 Deyrup et al. 2008; Doyle et al. 2016; Hornick et al. 2009
Epithelioid MPNST (Peripheral Nerve Sheath Tumors: Schwannoma, Neurofibroma and ANNUBP, Perineurioma, Granular Cell Tumor and MPNST) Superficial limbs and trunk Diffuse S100; melanocytic markers and keratin negative; INI1 lost in 67% SMARCB1 inactivation Jo and Fletcher 2015
Alveolar soft part sarcoma Buttocks or thigh of young adults; head and neck (orbit, tongue) in children Nuclear TFE3; PAS-diastase-positive crystals ASPSCR1::TFE3 Ladanyi et al. 2001; Argani et al. 2003; Chamberlain et al. 2014; Fanburg-Smith et al. 2004; Kinger et al. 2014
PEComa Women; omentum, mesentery, uterus, pelvis HMB45 and SMA coexpressed; TFE3 in a subset TFE3 rearrangement in a subset Folpe et al. 2005; Argani et al. 2010
Clear cell sarcoma Deep extremities of young adults S100, HMB45, MITF, Melan-A EWSR1::ATF1 or EWSR1::CREB1 Hisaoka et al. 2008
Melanoma Mimic of clear cell sarcoma and epithelioid MPNST Shares the melanocytic phenotype of clear cell sarcoma; INI1 retained Lacks the EWSR1 fusions of clear cell sarcoma Hisaoka et al. 2008; Hornick et al. 2009
Metastatic carcinoma Metastasis from lung, breast, stomach, colorectum, kidney, prostate or pancreas Keratin; INI1 retained Intracytoplasmic lumina and the reticulin pattern of epithelioid angiosarcoma are absent Hornick et al. 2009; Fletcher et al. 1991
Malignant rhabdoid tumor (Rhabdomyoma, Rhabdomyosarcoma and Risk Stratification, Ewing Sarcoma and Other Small Round Cell Sarcomas) Infants and children; axial sites Keratin and EMA; INI1 lost; CD34 negative SMARCB1 inactivation Oda and Tsuneyoshi 2006; Hornick et al. 2009

References

  1. Acosta AM, McKenney JK, Sholl LM, et al. Molecular assessment of paratesticular rhabdomyomas demonstrates recurrent findings, including a novel H3C2 p.K37I mutation. Mod Pathol. 2022;35(12):1921–1928. doi:10.1038/s41379-022-01134-3. PMID 35842480
  2. Agaram NP, LaQuaglia MP, Alaggio R, et al. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod Pathol. 2019;32(1):27–36. doi:10.1038/s41379-018-0120-9. PMID 30181563
  3. Agaram NP, Zhang L, Sung YS, et al. Extraskeletal myxoid chondrosarcoma with non-EWSR1-NR4A3 variant fusions correlate with rhabdoid phenotype and high-grade morphology. Hum Pathol. 2014;45(5):1084–1091. doi:10.1016/j.humpath.2014.01.007. PMID 24746215
  4. Al-Darwish AS, Alfaraj AM, El Darazi E, et al. Elastofibroma dorsi: a rare benign connective tissue tumor. J Surg Case Rep. 2026;2026(5):rjag347. doi:10.1093/jscr/rjag347. PMID 42145312
  5. Alaggio R, Zhang L, Sung YS, et al. A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases. Am J Surg Pathol. 2016;40(2):224–235. doi:10.1097/PAS.0000000000000538. PMID 26501226
  6. Amary F, Perez-Casanova L, Ye H, et al. Synovial chondromatosis and soft tissue chondroma: extraosseous cartilaginous tumor defined by FN1 gene rearrangement. Mod Pathol. 2019;32(12):1762–1771. doi:10.1038/s41379-019-0315-8. PMID 31273315
  7. American Joint Committee on Cancer. Version 9 of the AJCC Cancer Staging System. https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/ (accessed 2026-11-17) (cited as AJCC 2026)
  8. Anderson WJ, Jo VY. Diagnostic Immunohistochemistry of Soft Tissue and Bone Tumors: An Update on Biomarkers That Correlate with Molecular Alterations. Diagnostics (Basel). 2021;11(4):690. doi:10.3390/diagnostics11040690. PMID 33921435
  9. Angelico G, Marletta S, Broggi G, et al. Practical Approach to the Diagnosis of the Vulvo-Vaginal Stromal Tumors: An Overview. Diagnostics (Basel). 2022;12(2):357. doi:10.3390/diagnostics12020357. PMID 35204448
  10. Antonescu CR, Dal Cin P, Nafa K, et al. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2007;46(12):1051–1060. doi:10.1002/gcc.20491. PMID 17724745
  11. Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52(8):775–784. doi:10.1002/gcc.22073. PMID 23737213
  12. Antonescu CR, Owosho AA, Zhang L, et al. Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases. Am J Surg Pathol. 2017;41(7):941–949. doi:10.1097/PAS.0000000000000846. PMID 28346326
  13. Antonescu CR, Sung YS, Zhang L, et al. Recurrent SRF-RELA Fusions Define a Novel Subset of Cellular Myofibroma/Myopericytoma: A Potential Diagnostic Pitfall With Sarcomas With Myogenic Differentiation. Am J Surg Pathol. 2017;41(5):677–684. doi:10.1097/PAS.0000000000000811. PMID 28248815
  14. Antonescu CR, Suurmeijer AJ, Zhang L, et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol. 2015;39(7):957–967. doi:10.1097/PAS.0000000000000404. PMID 25723109 (abstract)
  15. Antonescu CR, Zhang L, Nielsen GP, et al. Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosomes Cancer. 2011;50(10):757–764. doi:10.1002/gcc.20897. PMID 21717526 (abstract)
  16. Arbajian E, Puls F, Magnusson L, et al. Recurrent EWSR1-CREB3L1 gene fusions in sclerosing epithelioid fibrosarcoma. Am J Surg Pathol. 2014;38(6):801–808. doi:10.1097/PAS.0000000000000158. PMID 24441665 (abstract)
  17. Arega G, Mohamedsaid A, Fikad G, et al. Histologically confirmed pediatric extracardiac rhabdomyoma: case series. Discov Oncol. 2025;16(1):17. doi:10.1007/s12672-025-01741-x. PMID 39775349
  18. Argani P, Aulmann S, Illei PB, et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010;34(10):1395–1406. doi:10.1097/PAS.0b013e3181f17ac0. PMID 20871214
  19. Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27(6):750–761. doi:10.1097/00000478-200306000-00005. PMID 12766578
  20. Baranov E, McBride MJ, Bellizzi AM, et al. A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. Am J Surg Pathol. 2020;44(7):922–933. doi:10.1097/PAS.0000000000001447. PMID 32141887
  21. Baumhoer D, Hench J, Amary F. Recent advances in molecular profiling of bone and soft tissue tumors. Skeletal Radiol. 2024;53(9):1925–1936. doi:10.1007/s00256-024-04584-9. PMID 38231260
  22. Beham A, Fletcher CD. Intramuscular angioma: a clinicopathological analysis of 74 cases. Histopathology. 1991;18(1):53–59. doi:10.1111/j.1365-2559.1991.tb00814.x. PMID 2013460 (abstract)
  23. Bekers EM, Eijkelenboom A, Rombout P, et al. Identification of novel GNAS mutations in intramuscular myxoma using next-generation sequencing with single-molecule tagged molecular inversion probes. Diagn Pathol. 2019;14(1):15. doi:10.1186/s13000-019-0787-3. PMID 30736805
  24. Billings SD, Folpe AL, Weiss SW. Do leiomyomas of deep soft tissue exist? An analysis of highly differentiated smooth muscle tumors of deep soft tissue supporting two distinct subtypes. Am J Surg Pathol. 2001;25(9):1134–1142. doi:10.1097/00000478-200109000-00003. PMID 11688572
  25. Bourgeois JM, Knezevich SR, Mathers JA, et al. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol. 2000;24(7):937–946. doi:10.1097/00000478-200007000-00005. PMID 10895816 (abstract)
  26. Calonje E, Fletcher CD, Wilson-Jones E, et al. Retiform hemangioendothelioma. A distinctive form of low-grade angiosarcoma delineated in a series of 15 cases. Am J Surg Pathol. 1994;18(2):115–125. PMID 8291650
  27. Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology. 2007;51(4):509–514. doi:10.1111/j.1365-2559.2007.02794.x. PMID 17711447 (abstract)
  28. Carter JE, Evans TN, Tucker JA. Cytologic diagnosis of alveolar soft part sarcoma of the lower extremity by fine needle aspiration and correlation with core biopsy: a case report. Acta Cytol. 2008;52(4):459–463. doi:10.1159/000325553. PMID 18702365 (abstract)
  29. Cates JMM. The AJCC 8th Edition Staging System for Soft Tissue Sarcoma of the Extremities or Trunk: A Cohort Study of the SEER Database. J Natl Compr Canc Netw. 2018;16(2):144–152. doi:10.6004/jnccn.2017.7042. PMID 29439175 (abstract)
  30. Chamberlain BK, McClain CM, Gonzalez RS, et al. Alveolar soft part sarcoma and granular cell tumor: an immunohistochemical comparison study. Hum Pathol. 2014;45(5):1039–1044. doi:10.1016/j.humpath.2013.12.021. PMID 24746209
  31. Chbani L, Guillou L, Terrier P, et al. Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. Am J Clin Pathol. 2009;131(2):222–227. doi:10.1309/AJCPU98ABIPVJAIV. PMID 19141382
  32. Chen BJ, Mariño-Enríquez A, Fletcher CD, et al. Loss of retinoblastoma protein expression in spindle cell/pleomorphic lipomas and cytogenetically related tumors: an immunohistochemical study with diagnostic implications. Am J Surg Pathol. 2012;36(8):1119–1128. doi:10.1097/PAS.0b013e31825d532d. PMID 22790852 (abstract)
  33. Chen QQ, Jiang Y, Guo JR, et al. Diagnostic pitfalls of morphological mimicry and CD34 heterogeneity in recurrent or fibrosarcomatous dermatofibrosarcoma protuberans: a clinicopathological analysis of three molecularly confirmed cases with literature review. J Cutan Pathol. 2026;53(12):1172–1179. doi:10.1111/cup.70172. PMID 42502207 (abstract)
  34. Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013;45(2):131–132. doi:10.1038/ng.2522. PMID 23313954 (abstract)
  35. Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007;31(4):509–520. doi:10.1097/01.pas.0000213393.57322.c7. PMID 17414097 (abstract)
  36. Coffin CM, Hornick JL, Zhou H, et al. Gardner fibroma: a clinicopathologic and immunohistochemical analysis of 45 patients with 57 fibromas. Am J Surg Pathol. 2007;31(3):410–416. doi:10.1097/01.pas.0000213348.65014.0a. PMID 17325483 (abstract)
  37. Coindre JM. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med. 2006;130(10):1448–1453. doi:10.5858/2006-130-1448-GOSTSR. PMID 17090186 (abstract)
  38. College of American Pathologists. Cancer protocol templates. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17) (cited as CAP 2026)
  39. College of American Pathologists. Protocol for the Examination of Biopsy Specimens from Patients with Soft Tissue Tumors (Soft.Tissue.Bx_4.2.0.0.REL_CAPCP), version 4.2.0.0. Posted June 2024. https://www.cap.org/wp-content/uploads/protocols/Soft.Tissue.Bx_4.2.0.0.REL_CAPCP.pdf (accessed 2026-11-17) (cited as CAP 2024b)
  40. College of American Pathologists. Protocol for the Examination of Resection Specimens from Patients with Soft Tissue Tumors (Soft.Tissue_4.2.0.0.REL_CAPCP), version 4.2.0.0. Posted June 2024. https://www.cap.org/wp-content/uploads/protocols/Soft.Tissue_4.2.0.0.REL_CAPCP.pdf (accessed 2026-11-17) (cited as CAP 2024a)
  41. College of American Pathologists. Protocol for the examination of resection specimens from pediatric patients with rhabdomyosarcoma, version 5.0.0.1. Posted June 2025. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). Cited as CAP 2025
  42. Cordier F, Kleijn TG, Mentzel T, et al. Atypical spindle cell/pleomorphic lipomatous tumour: a clinicopathologic, immunohistochemical and molecular study of 55 cases, highlighting TP53 gene alterations as a genetic hallmark of atypical pleomorphic lipomatous tumour. Histopathology. 2025;87(2):197–205. doi:10.1111/his.15474. PMID 40405626 (abstract)
  43. Creytens D, Folpe AL, Koelsche C, et al. Myxoid pleomorphic liposarcoma-a clinicopathologic, immunohistochemical, molecular genetic and epigenetic study of 12 cases, suggesting a possible relationship with conventional pleomorphic liposarcoma. Mod Pathol. 2021;34(11):2043–2049. doi:10.1038/s41379-021-00862-2. PMID 34168281 (abstract)
  44. Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr. 2013;162(1):142–147. doi:10.1016/j.jpeds.2012.06.044. PMID 22871490
  45. Dachy G, de Krijger RR, Fraitag S, et al. Association of PDGFRB Mutations With Pediatric Myofibroma and Myofibromatosis. JAMA Dermatol. 2019;155(8):946–950. doi:10.1001/jamadermatol.2019.0114. PMID 31017643
  46. De Noon S, Piggott R, Trotman J, et al. Recurrent FOSL1 rearrangements in desmoplastic fibroblastoma. J Pathol. 2023;259(2):119–124. doi:10.1002/path.6038. PMID 36426824 (abstract)
  47. Dei Tos AP, Webster F, Agaimy A, et al. Datasets for reporting of soft-tissue sarcoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. 2023;82(5):745–754. doi:10.1111/his.14862. PMID 36631406 (abstract)
  48. Del Baldo G, Carta R, Alessi I, et al. Rhabdoid Tumor Predisposition Syndrome: From Clinical Suspicion to General Management. Front Oncol. 2021;11:586288. doi:10.3389/fonc.2021.586288. PMID 33692948
  49. Delaney D, Diss TC, Presneau N, et al. GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Mod Pathol. 2009;22(5):718–724. doi:10.1038/modpathol.2009.32. PMID 19287459
  50. Demicco EG, Wagner MJ, Maki RG, et al. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. Mod Pathol. 2017;30(10):1433–1442. doi:10.1038/modpathol.2017.54. PMID 28731041 (abstract)
  51. Dermawan JK, Hwang S, Wexler L, et al. Myxoid pleomorphic liposarcoma is distinguished from other liposarcomas by widespread loss of heterozygosity and significantly worse overall survival: a genomic and clinicopathologic study. Mod Pathol. 2022;35(11):1644–1655. doi:10.1038/s41379-022-01107-6. PMID 35672466 (abstract)
  52. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96–107. doi:10.1016/j.ejca.2019.11.013. PMID 32004793 (abstract)
  53. Deyrup AT, Lee VK, Hill CE, et al. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol. 2006;30(1):75–82. doi:10.1097/01.pas.0000178088.69394.7b. PMID 16330945
  54. Deyrup AT, Tighiouart M, Montag AG, et al. Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. Am J Surg Pathol. 2008;32(6):924–927. doi:10.1097/pas.0b013e31815bf8e6. PMID 18551749
  55. Dickson BC, Antonescu CR, Demicco EG, et al. Hybrid schwannoma-perineurioma frequently harbors VGLL3 rearrangement. Mod Pathol. 2021;34(6):1116–1124. doi:10.1038/s41379-021-00783-0. PMID 33649458
  56. Doyle LA, Fletcher CD, Hornick JL. Nuclear Expression of CAMTA1 Distinguishes Epithelioid Hemangioendothelioma From Histologic Mimics. Am J Surg Pathol. 2016;40(1):94–102. doi:10.1097/PAS.0000000000000511. PMID 26414223
  57. Doyle LA, Möller E, Dal Cin P, et al. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am J Surg Pathol. 2011;35(5):733–741. doi:10.1097/PAS.0b013e318210c268. PMID 21415703 (abstract)
  58. Doyle LA, Vivero M, Fletcher CD, et al. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014;27(3):390–395. doi:10.1038/modpathol.2013.164. PMID 24030747 (abstract)
  59. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731–739. doi:10.1056/NEJMoa1714448. PMID 29466156 (abstract)
  60. Dwianingsih EK, Bawono RG, Saputri A, et al. Histomorphological and molecular characteristics of liposarcoma (Review). Oncol Lett. 2025;30(4):454. doi:10.3892/ol.2025.15200. PMID 40747377
  61. Erickson-Johnson MR, Chou MM, Evers BR, et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab Invest. 2011;91(10):1427–1433. doi:10.1038/labinvest.2011.118. PMID 21826056 (abstract)
  62. Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50(8):644–653. doi:10.1002/gcc.20886. PMID 21584898
  63. Fan P, Tao P, Wang Z, et al. Evaluation of AJCC staging system and proposal of a novel stage grouping system in retroperitoneal liposarcoma: the Fudan Zhongshan experience. Front Oncol. 2024;14:1373762. doi:10.3389/fonc.2024.1373762. PMID 38601763
  64. Fanburg-Smith JC, Meis-Kindblom JM, Fante R, et al. Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation. Am J Surg Pathol. 1998;22(7):779–794. doi:10.1097/00000478-199807000-00001. PMID 9669341
  65. Fanburg-Smith JC, Miettinen M, Folpe AL, et al. Lingual alveolar soft part sarcoma; 14 cases: novel clinical and morphological observations. Histopathology. 2004;45(5):526–537. doi:10.1111/j.1365-2559.2004.01966.x. PMID 15500657 (abstract)
  66. Fanburg-Smith JC, Miettinen M. Angiomatoid "malignant" fibrous histiocytoma: a clinicopathologic study of 158 cases and further exploration of the myoid phenotype. Hum Pathol. 1999;30(11):1336–1343. doi:10.1016/s0046-8177(99)90065-5. PMID 10571514 (abstract)
  67. Fetsch JF, Laskin WB, Lefkowitz M, et al. Aggressive angiomyxoma: a clinicopathologic study of 29 female patients. Cancer. 1996;78(1):79–90. doi:10.1002/(SICI)1097-0142(19960701)78:1<79::AID-CNCR13>3.0.CO;2-4. PMID 8646730
  68. Fetsch JF, Miettinen M, Laskin WB, et al. A clinicopathologic study of 45 pediatric soft tissue tumors with an admixture of adipose tissue and fibroblastic elements, and a proposal for classification as lipofibromatosis. Am J Surg Pathol. 2000;24(11):1491–1500. doi:10.1097/00000478-200011000-00004. PMID 11075850 (abstract)
  69. Fletcher CD, Beham A, Bekir S, et al. Epithelioid angiosarcoma of deep soft tissue: a distinctive tumor readily mistaken for an epithelial neoplasm. Am J Surg Pathol. 1991;15(10):915–924. doi:10.1097/00000478-199110000-00001. PMID 1718176
  70. Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol. 1992;16(3):213–228. PMID 1317996 (abstract)
  71. Folpe AL, Billings SD, McKenney JK, et al. Expression of claudin-1, a recently described tight junction-associated protein, distinguishes soft tissue perineurioma from potential mimics. Am J Surg Pathol. 2002;26(12):1620–1626. doi:10.1097/00000478-200212000-00010. PMID 12459629
  72. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1–30. doi:10.1097/00000478-200401000-00001. PMID 14707860
  73. Folpe AL, Fanburg-Smith JC, Miettinen M, et al. Atypical and malignant glomus tumors: analysis of 52 cases, with a proposal for the reclassification of glomus tumors. Am J Surg Pathol. 2001;25(1):1–12. doi:10.1097/00000478-200101000-00001. PMID 11145243
  74. Folpe AL, Lane KL, Paull G, et al. Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes: a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas. Am J Surg Pathol. 2000;24(10):1353–1360. doi:10.1097/00000478-200010000-00004. PMID 11023096 (abstract)
  75. Folpe AL, Mentzel T, Lehr HA, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol. 2005;29(12):1558–1575. doi:10.1097/01.pas.0000173232.22117.37. PMID 16327428
  76. Folpe AL, Weiss SW. Ossifying fibromyxoid tumor of soft parts: a clinicopathologic study of 70 cases with emphasis on atypical and malignant variants. Am J Surg Pathol. 2003;27(4):421–431. doi:10.1097/00000478-200304000-00001. PMID 12657926
  77. Folpe AL, Weiss SW. Pleomorphic hyalinizing angiectatic tumor: analysis of 41 cases supporting evolution from a distinctive precursor lesion. Am J Surg Pathol. 2004;28(11):1417–1425. doi:10.1097/01.pas.0000141406.02581.fb. PMID 15489645 (abstract)
  78. Fukushima M, Schaefer IM, Fletcher CD. Myolipoma of Soft Tissue: Clinicopathologic Analysis of 34 Cases. Am J Surg Pathol. 2017;41(2):153–160. doi:10.1097/PAS.0000000000000737. PMID 27635945 (abstract)
  79. Furlong MA, Fanburg-Smith JC, Miettinen M. The morphologic spectrum of hibernoma: a clinicopathologic study of 170 cases. Am J Surg Pathol. 2001;25(6):809–814. doi:10.1097/00000478-200106000-00014. PMID 11395560 (abstract)
  80. Furlong MA, Mentzel T, Fanburg-Smith JC. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. Mod Pathol. 2001;14(6):595–603. doi:10.1038/modpathol.3880357. PMID 11406662
  81. Gan S, Xie D, Dai H, et al. Proliferative myositis and nodular fasciitis: a retrospective study with clinicopathologic and radiologic correlation. Int J Clin Exp Pathol. 2019;12(12):4319–4328. PMID 31933833 (abstract)
  82. Gebhard S, Coindre JM, Michels JJ, et al. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2002;26(5):601–616. doi:10.1097/00000478-200205000-00006. PMID 11979090 (abstract)
  83. Gelderblom H, Bhadri V, Stacchiotti S, et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403(10445):2709–2719. doi:10.1016/S0140-6736(24)00885-7. PMID 38843860 (abstract)
  84. Giraldo-Roldan D, Louredo BVR, Penafort PVM, et al. Low-Grade Myofibroblastic Sarcoma of the Oral and Maxillofacial Region: An International Clinicopathologic Study of 13 Cases and Literature Review. Head Neck Pathol. 2023;17(3):832–850. doi:10.1007/s12105-023-01577-3. PMID 37540486 (abstract)
  85. Goldenberg DC, Vikkula M, Penington A, et al. Updated Classification of Vascular Anomalies. A living document from the International Society for the Study of Vascular Anomalies Classification Group. J Vasc Anom (Phila). 2025;6(2):e113. doi:10.1097/JOVA.0000000000000113. PMID 40636925
  86. Gonçales ES, Almeida AS, Soares S, et al. Silicone implant for chin augmentation mimicking a low-grade liposarcoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(4):e21–e23. doi:10.1016/j.tripleo.2008.12.044. PMID 19327631 (abstract)
  87. Gong LH, Liu WF, Niu XH, et al. Two cases of spindle cell tumors with S100 and CD34 co-expression showing novel RAF1 fusions. Diagn Pathol. 2022;17(1):80. doi:10.1186/s13000-022-01263-y. PMID 36229858 (abstract)
  88. Gounder M, Schöffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21(11):1423–1432. doi:10.1016/S1470-2045(20)30451-4. PMID 33035459
  89. Graham DS, Qorbani A, Eckardt MA, et al. Does "Low-Grade" Dedifferentiated Liposarcoma Exist? The Role of Mitotic Index in Separating Dedifferentiated Liposarcoma From Cellular Well-differentiated Liposarcoma. Am J Surg Pathol. 2023;47(6):649–660. doi:10.1097/PAS.0000000000002037. PMID 37057834 (abstract)
  90. Graham RP, Weiss SW, Sukov WR, et al. PHF1 rearrangements in ossifying fibromyxoid tumors of soft parts: A fluorescence in situ hybridization study of 41 cases with emphasis on the malignant variant. Am J Surg Pathol. 2013;37(11):1751–1755. doi:10.1097/PAS.0b013e31829644b4. PMID 23887158
  91. Gross JM, Fritchie KJ. Calcified chondroid mesenchymal neoplasm. Semin Diagn Pathol. 2026;43(1):150978. doi:10.1016/j.semdp.2025.150978. PMID 41412024 (abstract)
  92. Gross JM, Perret R, Coindre JM, et al. Lipoblastoma-Like Tumor and Fibrosarcoma-Like Lipomatous Neoplasm Represent the Same Entity: A Clinicopathologic and Molecular Genetic Study of 23 Cases Occurring in Both Men and Women at Diverse Locations. Mod Pathol. 2023;36(9):100246. doi:10.1016/j.modpat.2023.100246. PMID 37307874 (abstract)
  93. Guedes A, Oliveira MBDR, Costa FM, de Melo AS. Updating on Bone and Soft Tissue Sarcomas Staging. Rev Bras Ortop (Sao Paulo). 2021;56(4):411–418. doi:10.1055/s-0040-1710331. PMID 34483382 (reproduces the AJCC 8th edition trunk and extremity stage groups)
  94. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350–362. doi:10.1200/JCO.1997.15.1.350. PMID 8996162 (abstract)
  95. Gullì C, Ferrara G, Ferravante E, et al. Revisiting Myositis Ossificans: A Comprehensive Stage-by-Stage Imaging Review. Muscles. 2026;5(2):27. doi:10.3390/muscles5020027. PMID 42029569
  96. Gun BD, Bahadir B, Behzatoglu K, et al. Elastofibroma: a clinicopathologic and immunohistochemical study of seven cases and literature review. APMIS. 2007;115(2):115–119. doi:10.1111/j.1600-0463.2007.apm_525.x. PMID 17295677 (abstract)
  97. Haihua R, Xiaobing W, Jie P, et al. Retrospective analysis of 73 cases of elastofibroma. Ann R Coll Surg Engl. 2020;102(2):84–93. doi:10.1308/rcsann.2019.0089. PMID 31233334 (abstract)
  98. Hibbard MK, Kozakewich HP, Dal Cin P, et al. PLAG1 fusion oncogenes in lipoblastoma. Cancer Res. 2000;60(17):4869–4872. PMID 10987300 (abstract)
  99. Hibbitts E, Chi YY, Hawkins DS, et al. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group. Cancer Med. 2019;8(14):6437–6448. doi:10.1002/cam4.2504. PMID 31456361
  100. Hirose T, Chang HY, Saoud C, et al. A Clinicopathologic and Molecular Reappraisal of Myxoinflammatory Fibroblastic Sarcoma-A Controversial and Pathologically Challenging Low-Grade Sarcoma. Genes Chromosomes Cancer. 2025;64(1):e70018. doi:10.1002/gcc.70018. PMID 39822017 (abstract)
  101. Hisaoka M, Hashimoto H. Extraskeletal myxoid chondrosarcoma: updated clinicopathological and molecular genetic characteristics. Pathol Int. 2005;55(8):453–463. doi:10.1111/j.1440-1827.2005.01853.x. PMID 15998372
  102. Hisaoka M, Ishida T, Kuo TT, et al. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. Am J Surg Pathol. 2008;32(3):452–460. doi:10.1097/PAS.0b013e31814b18fb. PMID 18300804
  103. Hofvander J, Arbajian E, Stenkula KG, et al. Frequent low-level mutations of protein kinase D2 in angiolipoma. J Pathol. 2017;241(5):578–582. doi:10.1002/path.4865. PMID 28139834 (abstract)
  104. Hornick JL, Bovee JVMG, Antonescu CR, et al. The 2026 World Health Organization Classification of Tumors of Soft Tissue and Bone: 6th Edition. Am J Surg Pathol. 2026;50(12):e48–e64. doi:10.1097/PAS.0000000000002624. PMID 42839882 (summarizes the WHO Classification of Tumours of Soft Tissue and Bone, 6th edition)
  105. Hornick JL, Bundock EA, Fletcher CD. Hybrid schwannoma/perineurioma: clinicopathologic analysis of 42 distinctive benign nerve sheath tumors. Am J Surg Pathol. 2009;33(10):1554–1561. doi:10.1097/PAS.0b013e3181accc6c. PMID 19623031
  106. Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 2009;33(4):542–550. doi:10.1097/PAS.0b013e3181882c54. PMID 19033866
  107. Hornick JL, Fletcher CD. Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters. Am J Surg Pathol. 2003;27(9):1183–1196. doi:10.1097/00000478-200309000-00001. PMID 12960802
  108. Hornick JL, Fletcher CD. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol. 2011;35(2):190–201. doi:10.1097/PAS.0b013e3181ff0901. PMID 21263239
  109. Hornick JL, Fletcher CD. Soft tissue perineurioma: clinicopathologic analysis of 81 cases including those with atypical histologic features. Am J Surg Pathol. 2005;29(7):845–858. doi:10.1097/01.pas.0000155166.86409.d2. PMID 15958848
  110. Huang D, Sumegi J, Dal Cin P, et al. C11orf95-MKL2 is the resulting fusion oncogene of t(11;16)(q13;p13) in chondroid lipoma. Genes Chromosomes Cancer. 2010;49(9):810–818. doi:10.1002/gcc.20788. PMID 20607705 (abstract)
  111. Huang SC, Zhang L, Sung YS, et al. Frequent FOS gene rearrangements in epithelioid hemangioma: a molecular study of 58 cases with morphologic reappraisal. Am J Surg Pathol. 2015;39(10):1313–1321. doi:10.1097/PAS.0000000000000469. PMID 26135557
  112. Hung YP, Fletcher CD, Hornick JL. FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma. Am J Surg Pathol. 2017;41(5):596–606. doi:10.1097/PAS.0000000000000795. PMID 28009608
  113. Ji Y, Chen S, Yang K, et al. Kaposiform hemangioendothelioma: current knowledge and future perspectives. Orphanet J Rare Dis. 2020;15(1):39. doi:10.1186/s13023-020-1320-1. PMID 32014025
  114. Jo VY, Fletcher CD. Epithelioid malignant peripheral nerve sheath tumor: clinicopathologic analysis of 63 cases. Am J Surg Pathol. 2015;39(5):673–682. doi:10.1097/PAS.0000000000000379. PMID 25602794
  115. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15(4):434–440. doi:10.1038/modpathol.3880543. PMID 11950918
  116. Kao YC, Owosho AA, Sung YS, et al. BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas. Am J Surg Pathol. 2018;42(5):604–615. doi:10.1097/PAS.0000000000000965. PMID 29300189
  117. Karamzadeh Dashti N, Bahrami A, Lee SJ, et al. BRAF V600E mutations occur in a subset of glomus tumors, and are associated with malignant histologic characteristics. Am J Surg Pathol. 2017;41(11):1532–1541. doi:10.1097/PAS.0000000000000913. PMID 28834810
  118. Kaya M, Wada T, Nagoya S, et al. MRI and histological evaluation of the infiltrative growth pattern of myxofibrosarcoma. Skeletal Radiol. 2008;37(12):1085–1090. doi:10.1007/s00256-008-0542-4. PMID 18629459 (abstract)
  119. Kehrer-Sawatzki H, Farschtschi S, Mautner VF, et al. The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Hum Genet. 2017;136(2):129–148. doi:10.1007/s00439-016-1753-8. PMID 27921248
  120. Kinger M, Chakrabarti P, Varma A, Doshi B. Alveolar soft part sarcoma of tongue in 14-year-old boy. Ann Maxillofac Surg. 2014;4(2):240–242. doi:10.4103/2231-0746.147165. PMID 25593886 (abstract)
  121. Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18(2):184–187. doi:10.1038/ng0298-184. PMID 9462753 (abstract)
  122. Kojima N, Mori T, Motoi T, et al. Frequent CD30 Expression in an Emerging Group of Mesenchymal Tumors With NTRK, BRAF, RAF1, or RET Fusions. Mod Pathol. 2023;36(4):100083. doi:10.1016/j.modpat.2022.100083. PMID 36788089 (abstract)
  123. Kosemehmetoglu K, Vrana JA, Folpe AL. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol. 2009;22(7):872–878. doi:10.1038/modpathol.2009.47. PMID 19363472
  124. Kwak L, Hakim M, Ivey G, Brookmeyer C. Symptomatic presentation and imaging features of a chylous cystic lymphangioma. BMJ Case Rep. 2024;17(11):e261472. doi:10.1136/bcr-2024-261472. PMID 39532324 (abstract)
  125. Kwee RM, Kwee TC. Calcified or ossified benign soft tissue lesions that may simulate malignancy. Skeletal Radiol. 2019;48(12):1875–1890. doi:10.1007/s00256-019-03272-3. PMID 31297550
  126. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20(1):48–57. doi:10.1038/sj.onc.1204074. PMID 11244503
  127. Lae ME, Roche PC, Jin L, et al. Desmoplastic small round cell tumor: a clinicopathologic, immunohistochemical, and molecular study of 32 tumors. Am J Surg Pathol. 2002;26(7):823–835. doi:10.1097/00000478-200207000-00001. PMID 12131150
  128. Laskin WB, Miettinen M, Fetsch JF. Infantile digital fibroma/fibromatosis: a clinicopathologic and immunohistochemical study of 69 tumors from 57 patients with long-term follow-up. Am J Surg Pathol. 2009;33(1):1–13. doi:10.1097/PAS.0b013e3181788533. PMID 18830128 (abstract)
  129. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173(5):1518–1527. doi:10.2353/ajpath.2008.080475. PMID 18832571 (abstract)
  130. Le Guellec S, Velasco V, Pérot G, et al. ETV4 is a useful marker for the diagnosis of CIC-rearranged undifferentiated round-cell sarcomas: a study of 127 cases including mimicking lesions. Mod Pathol. 2016;29(12):1523–1531. doi:10.1038/modpathol.2016.155. PMID 27562494
  131. Lee JC, Jeng YM, Su SY, et al. Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol. 2015;235(4):539–545. doi:10.1002/path.4465. PMID 25319834
  132. Lee SA, Chung HW, Cho KJ, et al. Encapsulated fat necrosis mimicking subcutaneous liposarcoma: radiologic findings on MR, PET-CT, and US imaging. Skeletal Radiol. 2013;42(10):1465–1470. doi:10.1007/s00256-013-1647-y. PMID 23695807 (abstract)
  133. Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23(8):1506–1513. doi:10.1038/s41436-021-01170-5. PMID 34012067
  134. Li L, Xia Q, Rao Q, et al. [Molecular genetics and immunophenotype of INI1/SMARCB in epithelioid sarcoma]. Zhonghua Bing Li Xue Za Zhi. 2014;43(6):389–393. PMID 25208989 (English abstract)
  135. Libbrecht S, Van Dorpe J, Creytens D. The Rapidly Expanding Group of RB1-Deleted Soft Tissue Tumors: An Updated Review. Diagnostics (Basel). 2021;11(3):430. doi:10.3390/diagnostics11030430. PMID 33802620
  136. Liu H, Sukov WR, Ro JY. The t(1;10)(p22;q24) TGFBR3/MGEA5 Translocation in Pleomorphic Hyalinizing Angiectatic Tumor, Myxoinflammatory Fibroblastic Sarcoma, and Hemosiderotic Fibrolipomatous Tumor. Arch Pathol Lab Med. 2019;143(2):212–221. doi:10.5858/arpa.2017-0412-RA. PMID 29979612 (abstract)
  137. Longhi A, Bielack SS, Grimer R, et al. Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients. Eur J Cancer. 2017;74:9–16. doi:10.1016/j.ejca.2016.12.016. PMID 28167373
  138. Lucas CG, Gross AM, Romo CG, et al. Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1. Neuro Oncol. 2025;27(3):616–624. doi:10.1093/neuonc/noae235. PMID 39500722
  139. Machado I, Llombart-Bosch A, Charville GW, et al. Sarcomas with EWSR1::Non-ETS Fusion (EWSR1::NFATC2 and EWSR1::PATZ1). Surg Pathol Clin. 2024;17(1):31–55. doi:10.1016/j.path.2023.07.001. PMID 38278606
  140. Machado I, Nieto Morales MG, Cruz J, et al. Solitary Fibrous Tumor: Integration of Clinical, Morphologic, Immunohistochemical and Molecular Findings in Risk Stratification and Classification May Better Predict Patient outcome. Int J Mol Sci. 2021;22(17):9423. doi:10.3390/ijms22179423. PMID 34502329
  141. Makise N, Mori T, Motoi T, et al. Recurrent FOS rearrangement in proliferative fasciitis/proliferative myositis. Mod Pathol. 2021;34(5):942–950. doi:10.1038/s41379-020-00725-2. PMID 33318581 (abstract)
  142. Maly A, Regev E, Meir K, et al. Tissue reaction to liquid silicone simulating low-grade liposarcoma following lip augmentation. J Oral Pathol Med. 2004;33(5):314. doi:10.1111/j.0904-2512.2004.00059.x. PMID 15078494 (abstract)
  143. Manner J, Radlwimmer B, Hohenberger P, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol. 2010;176(1):34–39. doi:10.2353/ajpath.2010.090637. PMID 20008140
  144. Mariño-Enríquez A, Wang WL, Roy A, et al. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol. 2011;35(1):135–144. doi:10.1097/PAS.0b013e318200cfd5. PMID 21164297 (abstract)
  145. Martínez R, Niklander S, Deichler J, et al. Alveolar soft-part sarcoma of the masseter and mandibular ramus: report of a case and review of the literature. J Dent Sci. 2018;13(1):75–79. doi:10.1016/j.jds.2013.02.032. PMID 30895098 (abstract)
  146. McCluggage WG, Connolly L, McBride HA. HMGA2 is a sensitive but not specific immunohistochemical marker of vulvovaginal aggressive angiomyxoma. Am J Surg Pathol. 2010;34(7):1037–1042. doi:10.1097/PAS.0b013e3181e32a11. PMID 20551826
  147. Meis JM, Enzinger FM. Juxta-articular myxoma: a clinical and pathologic study of 65 cases. Hum Pathol. 1992;23(6):639–646. doi:10.1016/0046-8177(92)90319-x. PMID 1592386 (abstract)
  148. Mello CA, Campos FAB, Santos TG, et al. Desmoplastic Small Round Cell Tumor: A Review of Main Molecular Abnormalities and Emerging Therapy. Cancers (Basel). 2021;13(3):498. doi:10.3390/cancers13030498. PMID 33525546
  149. Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996;20(4):391–405. doi:10.1097/00000478-199604000-00001. PMID 8604805 (abstract)
  150. Michal M, Fetsch JF, Hes O, et al. Nuchal-type fibroma: a clinicopathologic study of 52 cases. Cancer. 1999;85(1):156–163. doi:10.1002/(sici)1097-0142(19990101)85:1<156::aid-cncr22>3.0.co;2-o. PMID 9921988 (abstract)
  151. Miettinen M, Fanburg-Smith JC, Virolainen M, et al. Epithelioid sarcoma: an immunohistochemical analysis of 112 classical and variant cases and a discussion of the differential diagnosis. Hum Pathol. 1999;30(8):934–942. doi:10.1016/s0046-8177(99)90247-2. PMID 10452506 (abstract)
  152. Miettinen M, Fetsch JF. Collagenous fibroma (desmoplastic fibroblastoma): a clinicopathologic analysis of 63 cases of a distinctive soft tissue lesion with stellate-shaped fibroblasts. Hum Pathol. 1998;29(7):676–682. doi:10.1016/s0046-8177(98)90275-1. PMID 9670823 (abstract)
  153. Miettinen M, Wang ZF, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol. 2011;35(3):432–441. doi:10.1097/PAS.0b013e318206b67b. PMID 21317715
  154. Miettinen M, Wang ZF. Prox1 transcription factor as a marker for vascular tumors-evaluation of 314 vascular endothelial and 1086 nonvascular tumors. Am J Surg Pathol. 2012;36(3):351–359. doi:10.1097/PAS.0b013e318236c312. PMID 22067331
  155. Miettinen M. Smooth muscle tumors of soft tissue and non-uterine viscera: biology and prognosis. Mod Pathol. 2014;27 Suppl 1:S17–S29. doi:10.1038/modpathol.2013.178. PMID 24384850 (abstract)
  156. Miettinen MM, Antonescu CR, Fletcher CDM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol. 2017;67:1–10. doi:10.1016/j.humpath.2017.05.010. PMID 28551330
  157. Mingoli A, Cavallaro A, Sapienza P, et al. International registry of inferior vena cava leiomyosarcoma: analysis of a world series on 218 patients. Anticancer Res. 1996;16(5B):3201–3205. PMID 8920790
  158. Mišánik M, Smolár M, Grajciar M, et al. Cystic lymphangioma of the lesser omentum in an adult patient. Rozhl Chir. 2024;103(6):224–227. doi:10.33699/pis.2024.103.6.224-227. PMID 38991786 (abstract)
  159. Moretti VM, Brooks JS, Ogilvie CM. Case report: hemosiderotic fibrohistiocytic lipomatous lesion: a clinicopathologic characterization. Clin Orthop Relat Res. 2010;468(10):2808–2813. doi:10.1007/s11999-010-1242-7. PMID 20127213 (abstract)
  160. Mosquera JM, Sboner A, Zhang L, et al. Novel MIR143-NOTCH fusions in benign and malignant glomus tumors. Genes Chromosomes Cancer. 2013;52(11):1075–1087. doi:10.1002/gcc.22102. PMID 23999936
  161. Nagasaka S, Phi JH. Genetic basis and clinical management of schwannomatosis. J Korean Neurosurg Soc. 2025;68(3):286–293. doi:10.3340/jkns.2025.0001. PMID 40049215
  162. Nahi SL, Dann AM. Systemic Therapies for Desmoid Tumors: A Review of Past, Present, and Future Treatments. Cancers (Basel). 2026;18(10):1521. doi:10.3390/cancers18101521. PMID 42192882
  163. Neuville A, Collin F, Bruneval P, et al. Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas. Am J Surg Pathol. 2014;38(4):461–469. doi:10.1097/PAS.0000000000000184. PMID 24625414
  164. Ng CS, Qin J, Gao GY. Intra-Abdominal Sporadic Desmoid Tumors with Canonical CTNNB1 and Uncommon Wnt/β-Catenin Pathway Somatic Mutations: A Clinicopathologic and Genetic Study of Five Cases. Int J Mol Sci. 2026;27(19):8655. doi:10.3390/ijms27198655. PMID 42883903
  165. Nishio J, Koga K, Aoki M. Plexiform Fibrohistiocytic Tumor: An Updated Review. In Vivo. 2026;40(5):2596–2603. doi:10.21873/invivo.14415. PMID 42665406 (abstract)
  166. Nishio J, Nakayama S, Koga K, et al. Giant Cell Tumor of Soft Tissue: An Updated Review. J Clin Med. 2024;13(10):2870. doi:10.3390/jcm13102870. PMID 38792412 (abstract)
  167. North PE, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000;31(1):11–22. doi:10.1016/s0046-8177(00)80192-6. PMID 10665907
  168. Oda Y, Tsuneyoshi M. Extrarenal rhabdoid tumors of soft tissue: clinicopathological and molecular genetic review and distinction from other soft-tissue sarcomas with rhabdoid features. Pathol Int. 2006;56(6):287–295. doi:10.1111/j.1440-1827.2006.01962.x. PMID 16704491
  169. Oide T, Yasufuku K, Shibuya K, et al. Primary pulmonary glomus tumor of uncertain malignant potential: a case report with literature review focusing on current concepts of malignancy grade estimation. Respir Med Case Rep. 2016;19:143–149. doi:10.1016/j.rmcr.2016.10.002. PMID 27752464
  170. Oliver-Perez R, Ortega M, Manzano A, et al. Malignant perivascular epithelioid cell tumor (PEComa) of the uterus: a rare type of mesenchymal tumors and a management challenge. Cancers (Basel). 2025;17(13):2185. doi:10.3390/cancers17132185. PMID 40647483
  171. Panagopoulos I, Gorunova L, Bjerkehagen B, et al. The recurrent chromosomal translocation t(12;18)(q1415;q1221) causes the fusion gene HMGA2-SETBP1 and HMGA2 expression in lipoma and osteochondrolipoma. Int J Oncol. 2015;47(3):884–890. doi:10.3892/ijo.2015.3099. PMID 26202160
  172. Park JY, Cohen C, Lopez D, et al. EGFR Exon 20 Insertion/Duplication Mutations Characterize Fibrous Hamartoma of Infancy. Am J Surg Pathol. 2016;40(12):1713–1718. doi:10.1097/PAS.0000000000000729. PMID 27631514 (abstract)
  173. Penning AJ, Al-Ibraheemi A, Michal M, et al. Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma. Mod Pathol. 2021;34(8):1530–1540. doi:10.1038/s41379-021-00806-w. PMID 33850302 (abstract)
  174. Perret R, Tallegas M, Velasco V, et al. Recurrent YAP1::MAML2 fusions in "nodular necrotizing" variants of myxoinflammatory fibroblastic sarcoma: a comprehensive study of 7 cases. Mod Pathol. 2022;35(10):1398–1404. doi:10.1038/s41379-022-01096-6. PMID 35546636 (abstract)
  175. Perry KD, Al-Lbraheemi A, Rubin BP, et al. Composite hemangioendothelioma with neuroendocrine marker expression: an aggressive variant. Mod Pathol. 2017;30(11):1589–1602. doi:10.1038/modpathol.2017.83. PMID 28731049
  176. Pižem J, Matjašič A, Zupan A, et al. Fibroma of tendon sheath is defined by a USP6 gene fusion-morphologic and molecular reappraisal of the entity. Mod Pathol. 2021;34(10):1876–1888. doi:10.1038/s41379-021-00836-4. PMID 34088995 (abstract)
  177. Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genet Med. 2022;24(9):1967–1977. doi:10.1016/j.gim.2022.05.007. PMID 35674741
  178. Prieto-Granada CN, Wiesner T, Messina JL, et al. Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST. Am J Surg Pathol. 2016;40(4):479–489. doi:10.1097/PAS.0000000000000564. PMID 26645727
  179. Puls F, Hofvander J, Magnusson L, et al. FN1-EGF gene fusions are recurrent in calcifying aponeurotic fibroma. J Pathol. 2016;238(4):502–507. doi:10.1002/path.4683. PMID 26691015 (abstract)
  180. Qiao YD, Tao J, Zhao M, et al. [Nodular fasciitis in children: a clinicopathological analysis of twenty-four cases]. Zhonghua Bing Li Xue Za Zhi. 2026;55(1):46–50. doi:10.3760/cma.j.cn112151-20250410-00264. PMID 41490638 (English abstract)
  181. Richman LP, Michaels PD, Nief C, et al. Defining Prognostic Markers and Clinical Outcomes in Epithelioid Malignant Peripheral Nerve Sheath Tumor. Mod Pathol. 2026;39(5):100993. doi:10.1016/j.modpat.2026.100993. PMID 41881192
  182. Robert M, Farese H, Miossec P. Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features. Front Immunol. 2022;13:820046. doi:10.3389/fimmu.2022.820046. PMID 35265077
  183. Rodriguez FJ, Folpe AL, Giannini C, et al. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012;123(3):295–319. doi:10.1007/s00401-012-0954-z. PMID 22327363
  184. Romo CG, Ahlawat S, Amrami KK, et al. Defining and managing NF1-related peripheral nerve sheath tumors at risk for malignant transformation: Consensus from the Atypical Neurofibroma Symposium. Neuro Oncol. Published online November 13, 2026. doi:10.1093/neuonc/noag275. PMID 43021633 (abstract)
  185. Rottmann D, Abdulfatah E, Pantanowitz L. Molecular testing of soft tissue tumors. Diagn Cytopathol. 2023;51(1):12–25. doi:10.1002/dc.25013. PMID 35808975
  186. Salminen SH, Sampo MM, Böhling TO, et al. Radiation-associated sarcoma after breast cancer in a nationwide population: Increasing risk of angiosarcoma. Cancer Med. 2018;7(9):4825–4835. doi:10.1002/cam4.1698. PMID 30044058 (abstract)
  187. Savarese LG, Papalexis N, Hernandes MA, et al. Fat-containing soft-tissue tumors: imaging findings and pathologic correlation. Skeletal Radiol. 2026;55(7):1437–1456. doi:10.1007/s00256-026-05160-z. PMID 41714734
  188. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021;113(2):70–84. doi:10.32074/1591-951X-213. PMID 33179614 (summarizes the WHO 5th edition)
  189. Schoolmeester JK, Xing D, Keeney GL, et al. Genital Rhabdomyoma of the Lower Female Genital Tract: A Study of 12 Cases With Molecular Cytogenetic Findings. Int J Gynecol Pathol. 2018;37(4):349–355. doi:10.1097/PGP.0000000000000428. PMID 28700439
  190. Schwartz RA, Powers CN, Wakely PE Jr, et al. Fibromatosis colli. The utility of fine-needle aspiration in diagnosis. Arch Otolaryngol Head Neck Surg. 1997;123(3):301–304. doi:10.1001/archotol.1997.01900030075010. PMID 9076237 (abstract)
  191. Shibuya R, Matsuyama A, Nakamoto M, et al. The combination of CD99 and NKX2.2, a transcriptional target of EWSR1-FLI1, is highly specific for the diagnosis of Ewing sarcoma. Virchows Arch. 2014;465(5):599–605. doi:10.1007/s00428-014-1627-1. PMID 25031013
  192. Simon AG, Mariño-Enríquez A, Hornick JL, et al. Dedifferentiated Solitary Fibrous Tumor: A Clinicopathologic, Immunohistochemical, and Molecular Characterization of 25 Cases. Am J Surg Pathol. 2025;49(10):1015–1027. doi:10.1097/PAS.0000000000002417. PMID 40420616 (abstract)
  193. Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007;31(10):1476–1489. doi:10.1097/PAS.0b013e3180581fff. PMID 17895748 (abstract)
  194. Stewart BD, Nascimento AF. Palmar and plantar fibromatosis: a review. J Pathol Transl Med. 2021;55(4):265–270. doi:10.4132/jptm.2021.06.14. PMID 34225446 (abstract)
  195. Suurmeijer AJH, Dickson BC, Swanson D, et al. A morphologic and molecular reappraisal of myoepithelial tumors of soft tissue, bone, and viscera with EWSR1 and FUS gene rearrangements. Genes Chromosomes Cancer. 2020;59(6):348–356. doi:10.1002/gcc.22835. PMID 31994243
  196. Švajdler M, Michal M, Martínek P, et al. Fibro-osseous pseudotumor of digits and myositis ossificans show consistent COL1A1-USP6 rearrangement: a clinicopathological and genetic study of 27 cases. Hum Pathol. 2019;88:39–47. doi:10.1016/j.humpath.2019.02.009. PMID 30946936 (abstract)
  197. Tanaka K, Ozaki T. New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin Oncol. 2019;49(2):103–107. doi:10.1093/jjco/hyy157. PMID 30423153 (abstract)
  198. Thway K, Fisher C. Angiomatoid fibrous histiocytoma: the current status of pathology and genetics. Arch Pathol Lab Med. 2015;139(5):674–682. doi:10.5858/arpa.2014-0234-RA. PMID 25927151
  199. Torres-Mora J, Dry S, Li X, et al. Malignant melanotic schwannian tumor: a clinicopathologic, immunohistochemical, and gene expression profiling study of 40 cases, with a proposal for the reclassification of "melanotic schwannoma". Am J Surg Pathol. 2014;38(1):94–105. doi:10.1097/PAS.0b013e3182a0a150. PMID 24145644
  200. Turbiville D, Zhang X. Calcifying fibrous tumor of the gastrointestinal tract: A clinicopathologic review and update. World J Gastroenterol. 2020;26(37):5597–5605. doi:10.3748/wjg.v26.i37.5597. PMID 33071524 (abstract)
  201. Vierra BM, Saadat LV, Hornick JL, et al. Distribution and Rate of Myxoid Liposarcoma Spine Metastases: Impact on Surveillance Imaging. Ann Surg Oncol. 2023;30(13):8647–8652. doi:10.1245/s10434-023-14309-2. PMID 37773566 (abstract)
  202. Wagner AJ, Tap WD, Bauer S, et al. Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study. Oncologist. 2025;30(7):oyae345. doi:10.1093/oncolo/oyae345. PMID 40613752 (abstract)
  203. Walker EA, Petscavage JM, Brian PL, et al. Imaging features of superficial and deep fibromatoses in the adult population. Sarcoma. 2012;2012:215810. doi:10.1155/2012/215810. PMID 22966216
  204. Walther C, Tayebwa J, Lilljebjörn H, et al. A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma. J Pathol. 2014;232(5):534–540. doi:10.1002/path.4322. PMID 24374978
  205. Warman ML, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A. 2011;155A(5):943–968. doi:10.1002/ajmg.a.33909. PMID 21438135
  206. Washing D, Zaher A. Pathologic quiz case: a 76-year-old debilitated woman with a right thigh mass. Ischemic fasciitis (atypical decubital fibroplasia). Arch Pathol Lab Med. 2004;128(10):e139–e140. doi:10.5858/2004-128-e139-PQCAYD. PMID 15387683 (title)
  207. Weiss SW. Smooth muscle tumors of soft tissue. Adv Anat Pathol. 2002;9(6):351–359. doi:10.1097/00125480-200211000-00004. PMID 12409644
  208. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103(3):690–695. doi:10.1073/pnas.0507321103. PMID 16407111 (abstract)
  209. Yamagata Y, Komiyama M, Iwata S. Clinical characteristics and management of primary retroperitoneal sarcoma: A literature review. Ann Gastroenterol Surg. 2024;8(1):21–29. doi:10.1002/ags3.12756. PMID 38250690 (reproduces the AJCC 8th edition stage groups)
  210. Yoshimoto M, Yamada Y, Ishihara S, et al. Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma: Histopathologic and Clinicopathologic Review. Am J Surg Pathol. 2020;44(1):87–97. doi:10.1097/PAS.0000000000001389. PMID 31651522 (abstract)
  211. Yu S, Cordier F, Baranov E, et al. FOS and FOSB Immunohistochemistry and Molecular Testing Reveal Novel Patterns in Proliferative Fasciitis and Myositis, FOSB Rearrangement in Proliferative Funiculitis, and FOSL1::RELA Fusion in Pediatric Proliferative Fasciitis. Am J Surg Pathol. 2026;50(7):726–738. doi:10.1097/PAS.0000000000002540. PMID 41882504 (abstract)
  212. Zhu G, Benayed R, Ho C, et al. Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol. 2019;32(5):609–620. doi:10.1038/s41379-018-0175-7. PMID 30459475
  213. Zilla ML, Naous R, John I. Lack of FOS/FOSB Gene Rearrangements in Ischemic Fasciitis Indicates Distinct Pathogenesis from Proliferative Fasciitis and Proliferative Myositis. Int J Surg Pathol. 2024;32(4):726–730. doi:10.1177/10668969231188893. PMID 37461273 (abstract)